OA16409A - Spiro-oxindole MDM2 antagonists. - Google Patents
Spiro-oxindole MDM2 antagonists. Download PDFInfo
- Publication number
- OA16409A OA16409A OA1201300198 OA16409A OA 16409 A OA16409 A OA 16409A OA 1201300198 OA1201300198 OA 1201300198 OA 16409 A OA16409 A OA 16409A
- Authority
- OA
- OAPI
- Prior art keywords
- group
- optionally substituted
- compound
- hydrogen
- pharmaceutically acceptable
- Prior art date
Links
- 101700032565 MDM2 Proteins 0.000 title abstract description 45
- 102100019155 MDM2 Human genes 0.000 title abstract description 45
- 230000003042 antagnostic Effects 0.000 title abstract description 6
- 239000005557 antagonist Substances 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 525
- 239000000203 mixture Substances 0.000 claims abstract description 123
- 201000011510 cancer Diseases 0.000 claims abstract description 78
- 201000010099 disease Diseases 0.000 claims abstract description 54
- 239000001257 hydrogen Substances 0.000 claims description 219
- 229910052739 hydrogen Inorganic materials 0.000 claims description 219
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 138
- 125000000217 alkyl group Chemical group 0.000 claims description 96
- 150000002431 hydrogen Chemical class 0.000 claims description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 79
- 229910001868 water Inorganic materials 0.000 claims description 73
- 239000002246 antineoplastic agent Substances 0.000 claims description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 69
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 67
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 67
- 239000002904 solvent Substances 0.000 claims description 66
- 125000003107 substituted aryl group Chemical group 0.000 claims description 61
- 125000001072 heteroaryl group Chemical group 0.000 claims description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 55
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- 230000000541 pulsatile Effects 0.000 claims description 45
- 125000001153 fluoro group Chemical group F* 0.000 claims description 39
- 230000003463 hyperproliferative Effects 0.000 claims description 38
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 37
- 206010025650 Malignant melanoma Diseases 0.000 claims description 36
- 238000006317 isomerization reaction Methods 0.000 claims description 35
- 201000001441 melanoma Diseases 0.000 claims description 35
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 206010024324 Leukaemias Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 6
- 206010017758 Gastric cancer Diseases 0.000 claims description 6
- 206010024627 Liposarcoma Diseases 0.000 claims description 6
- 206010025310 Other lymphomas Diseases 0.000 claims description 6
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 201000009251 multiple myeloma Diseases 0.000 claims description 6
- 201000000582 retinoblastoma Diseases 0.000 claims description 6
- 201000000498 stomach carcinoma Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 43
- 230000001225 therapeutic Effects 0.000 abstract description 19
- 230000003993 interaction Effects 0.000 abstract description 15
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 182
- 210000004027 cells Anatomy 0.000 description 142
- -1 solvatés Substances 0.000 description 142
- 239000000651 prodrug Substances 0.000 description 101
- 229940002612 prodrugs Drugs 0.000 description 101
- 238000005160 1H NMR spectroscopy Methods 0.000 description 71
- 102100019730 TP53 Human genes 0.000 description 68
- 101710026335 TP53 Proteins 0.000 description 68
- 230000006907 apoptotic process Effects 0.000 description 54
- 239000003795 chemical substances by application Substances 0.000 description 46
- 239000000243 solution Substances 0.000 description 44
- 206010059512 Apoptosis Diseases 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 40
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 38
- 150000003839 salts Chemical class 0.000 description 38
- 239000011780 sodium chloride Substances 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 30
- 230000027455 binding Effects 0.000 description 29
- 238000004128 high performance liquid chromatography Methods 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 24
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 23
- 238000004166 bioassay Methods 0.000 description 23
- 150000002829 nitrogen Chemical group 0.000 description 23
- 108090001123 antibodies Proteins 0.000 description 22
- 102000004965 antibodies Human genes 0.000 description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 22
- 102100003594 TP73 Human genes 0.000 description 21
- 101710026706 TP73 Proteins 0.000 description 21
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 21
- 238000004007 reversed phase HPLC Methods 0.000 description 20
- 230000000875 corresponding Effects 0.000 description 19
- 238000001959 radiotherapy Methods 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000002829 reduced Effects 0.000 description 17
- 229940079593 drugs Drugs 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000003647 oxidation Effects 0.000 description 16
- 238000007254 oxidation reaction Methods 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 108050005300 MDM4 Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 125000001188 haloalkyl group Chemical group 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 102000001309 Proto-Oncogene Proteins c-mdm2 Human genes 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- 230000025084 cell cycle arrest Effects 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 230000002194 synthesizing Effects 0.000 description 14
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
- 230000000259 anti-tumor Effects 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 230000010261 cell growth Effects 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 125000005518 carboxamido group Chemical group 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 125000005017 substituted alkenyl group Chemical group 0.000 description 11
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 201000009030 carcinoma Diseases 0.000 description 9
- 238000002875 fluorescence polarization Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 8
- SBDDQRQCHOSEHH-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxy-3-methylcyclobutan-1-amine Chemical compound CC(C)(C)[Si](C)(C)OC1(C)CC(N)C1 SBDDQRQCHOSEHH-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 8
- 229960002949 Fluorouracil Drugs 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000003211 malignant Effects 0.000 description 8
- 108010082117 matrigel Proteins 0.000 description 8
- 201000008968 osteosarcoma Diseases 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 125000004426 substituted alkynyl group Chemical group 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 210000001519 tissues Anatomy 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960004679 Doxorubicin Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
- 230000002730 additional Effects 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000005466 alkylenyl group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000411 inducer Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 7
- 210000004881 tumor cells Anatomy 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 229960000583 Acetic Acid Drugs 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- 101700079540 FAS Proteins 0.000 description 6
- 102100003082 FASLG Human genes 0.000 description 6
- 108010039471 Fas Ligand Protein Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 6
- 229960004857 Mitomycin Drugs 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 101710038569 TNFRSF25 Proteins 0.000 description 6
- 102100003107 TNFRSF25 Human genes 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000001640 apoptogenic Effects 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000001472 cytotoxic Effects 0.000 description 6
- 230000002354 daily Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000000051 modifying Effects 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229910000160 potassium phosphate Inorganic materials 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 6
- 235000019798 tripotassium phosphate Nutrition 0.000 description 6
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 5
- 206010003816 Autoimmune disease Diseases 0.000 description 5
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229960005420 Etoposide Drugs 0.000 description 5
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- MOWTXLISNVXVLN-UHFFFAOYSA-N OC1CCC(CC1)[NH-] Chemical compound OC1CCC(CC1)[NH-] MOWTXLISNVXVLN-UHFFFAOYSA-N 0.000 description 5
- 229960001592 Paclitaxel Drugs 0.000 description 5
- 229960003171 Plicamycin Drugs 0.000 description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
- 210000002307 Prostate Anatomy 0.000 description 5
- 229960001052 Streptozocin Drugs 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 description 5
- 102100012981 TNFRSF10A Human genes 0.000 description 5
- 101710030971 TNFRSF10A Proteins 0.000 description 5
- 102100012980 TNFRSF10B Human genes 0.000 description 5
- 101710030970 TNFRSF10B Proteins 0.000 description 5
- 102100002198 TNFSF10 Human genes 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000000692 anti-sense Effects 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 230000003115 biocidal Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atoms Chemical group C* 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000001575 pathological Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002633 protecting Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
- ZAMASFSDWVSMSY-UHFFFAOYSA-N 5-[[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy-2-methylphenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C(C)=CC=1OC1=NC=C(C(F)(F)F)C=C1Cl ZAMASFSDWVSMSY-UHFFFAOYSA-N 0.000 description 4
- 229960004562 Carboplatin Drugs 0.000 description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 4
- 101710011595 DPT Proteins 0.000 description 4
- 229960000640 Dactinomycin Drugs 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- 102100006425 GAPDH Human genes 0.000 description 4
- 101710008404 GAPDH Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 4
- 101000412293 MDM2 Proteins 0.000 description 4
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 4
- OGZVIYIMAOFJJG-UHFFFAOYSA-N OC1(CC(C1)[NH-])C Chemical compound OC1(CC(C1)[NH-])C OGZVIYIMAOFJJG-UHFFFAOYSA-N 0.000 description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 101700054742 TRAM1 Proteins 0.000 description 4
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 4
- 229960004528 Vincristine Drugs 0.000 description 4
- 206010047461 Viral infection Diseases 0.000 description 4
- 208000001756 Virus Disease Diseases 0.000 description 4
- 101700081164 ZBED1 Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- OPGPYIKNRCXNQY-UHFFFAOYSA-N benzyl 3-oxocyclobutane-1-carboxylate Chemical compound C1C(=O)CC1C(=O)OCC1=CC=CC=C1 OPGPYIKNRCXNQY-UHFFFAOYSA-N 0.000 description 4
- 229960002938 bexarotene Drugs 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000000973 chemotherapeutic Effects 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960000390 fludarabine Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 230000002496 gastric Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000005842 heteroatoms Chemical group 0.000 description 4
- 102000028165 human MDM2 protein Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 230000002503 metabolic Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- 125000004430 oxygen atoms Chemical group O* 0.000 description 4
- 230000003389 potentiating Effects 0.000 description 4
- 230000001235 sensitizing Effects 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229930003347 taxol Natural products 0.000 description 4
- 231100000224 toxic side effect Toxicity 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000017613 viral reproduction Effects 0.000 description 4
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 3
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 3
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 description 3
- 108060005293 AGA Proteins 0.000 description 3
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 3
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 3
- 102100004323 ASPG Human genes 0.000 description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- 102100013894 BCL2 Human genes 0.000 description 3
- 108060000885 BCL2 Proteins 0.000 description 3
- 229960001561 Bleomycin Drugs 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- 102100006435 CSF3 Human genes 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 229960004397 Cyclophosphamide Drugs 0.000 description 3
- 229960000684 Cytarabine Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229960000975 Daunorubicin Drugs 0.000 description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- 102100016439 FAS Human genes 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- JEHCHYAKAXDFKV-UHFFFAOYSA-J Lead(IV) acetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 3
- 229960004961 Mechlorethamine Drugs 0.000 description 3
- 229960000350 Mitotane Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 Mitoxantrone Drugs 0.000 description 3
- RSYYQCDERUOEFI-SNVBAGLBSA-N N-benzoyl-D-arginine zwitterion Chemical compound NC(=[NH2+])NCCC[C@H](C([O-])=O)NC(=O)C1=CC=CC=C1 RSYYQCDERUOEFI-SNVBAGLBSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 229960001603 Tamoxifen Drugs 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 229960005454 Thioguanine Drugs 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- QXKHYNVANLEOEG-UHFFFAOYSA-N XANTHOTOXIN Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 3
- 229960001445 alitretinoin Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229960000473 altretamine Drugs 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 229960001467 bortezomib Drugs 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 229960000590 celecoxib Drugs 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 230000029578 entry into host Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229960002411 imatinib Drugs 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 231100000202 sensitizing Toxicity 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 229960000653 valrubicin Drugs 0.000 description 3
- LTPOSIZJPSDSIL-JKSUJKDBSA-N (5S,6R)-5,6-diphenylmorpholin-2-one Chemical compound C1([C@@H]2[C@@H](NCC(O2)=O)C=2C=CC=CC=2)=CC=CC=C1 LTPOSIZJPSDSIL-JKSUJKDBSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004482 13C cross polarization magic angle spinning Methods 0.000 description 2
- PECYZEOJVXMISF-REOHCLBHSA-N 2,3-Diaminopropionic acid Chemical compound [NH3+]C[C@H](N)C([O-])=O PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2H-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 2
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- PLHJCIYEEKOWNM-HHHXNRCGSA-N 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 2
- IKWTVSLWAPBBKU-UHFFFAOYSA-N A1010_SIAL Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 2
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N AZOMYCIN Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 229960001097 Amifostine Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940046836 Anti-estrogens Drugs 0.000 description 2
- 102100019683 BAX Human genes 0.000 description 2
- 101700010813 BAX Proteins 0.000 description 2
- 108010005144 Bevacizumab Proteins 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- VHXNKPBCCMUMSW-HXUWFJFHSA-N Camptogen Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-HXUWFJFHSA-N 0.000 description 2
- 229940088954 Camptosar Drugs 0.000 description 2
- 229960004117 Capecitabine Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P Ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 229960004630 Chlorambucil Drugs 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 description 2
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 101710008039 DR3R Proteins 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 229960003957 Dexamethasone Drugs 0.000 description 2
- 229960000605 Dexrazoxane Drugs 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N Dirurol Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- 101700057458 Drice Proteins 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 229960001904 EPIRUBICIN Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 101710009915 FAD7 Proteins 0.000 description 2
- 102100007583 FADD Human genes 0.000 description 2
- 101700015998 FADD Proteins 0.000 description 2
- 102000027757 FGF receptors Human genes 0.000 description 2
- 108091008101 FGF receptors Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 229960004177 Filgrastim Drugs 0.000 description 2
- 229960000961 Floxuridine Drugs 0.000 description 2
- 229960002258 Fulvestrant Drugs 0.000 description 2
- 210000004051 Gastric Juice Anatomy 0.000 description 2
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 2
- 229940080856 Gleevec Drugs 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 206010018651 Graft versus host disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 229940022353 Herceptin Drugs 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 229960001101 Ifosfamide Drugs 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 231100000608 Immunotoxin Toxicity 0.000 description 2
- 108010004484 Immunotoxins Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 2
- 101700047455 KTI1 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 206010024190 Leiomyosarcomas Diseases 0.000 description 2
- 206010024218 Lentigo maligna Diseases 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229940008250 Leuprolide Drugs 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 229960004296 Megestrol Acetate Drugs 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N Mepacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 206010061289 Metastatic neoplasm Diseases 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 206010028417 Myasthenia gravis Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000007538 Neurilemmoma Diseases 0.000 description 2
- 229940085033 Nolvadex Drugs 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- CNDQSXOVEQXJOE-UHFFFAOYSA-N Oxyphenbutazone Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 2
- 108091007929 PDGF receptors Proteins 0.000 description 2
- 102100015381 PTGS2 Human genes 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 2
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- 229940068968 Polysorbate 80 Drugs 0.000 description 2
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 2
- 102100000883 RALBP1 Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 2
- 229940003641 Rituxan Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 208000003265 Stomatitis Diseases 0.000 description 2
- 101710040537 TNF Proteins 0.000 description 2
- 101710038526 TNFRSF1A Proteins 0.000 description 2
- 102100003106 TNFRSF21 Human genes 0.000 description 2
- 101710008042 TNFRSF21 Proteins 0.000 description 2
- 101710038599 TNFRSF21 Proteins 0.000 description 2
- 229940099419 Targretin Drugs 0.000 description 2
- 229940063683 Taxotere Drugs 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960000237 Vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- XLSYIXQNBQZOGW-LJGSYFOKSA-N [NH-]C[C@H]1CC[C@H](O)CC1 Chemical compound [NH-]C[C@H]1CC[C@H](O)CC1 XLSYIXQNBQZOGW-LJGSYFOKSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 201000004384 alopecia Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 230000002280 anti-androgenic Effects 0.000 description 2
- 230000001833 anti-estrogenic Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229960002594 arsenic trioxide Drugs 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 2
- 229940017743 dromostanolone propionate Drugs 0.000 description 2
- 229950004683 drostanolone propionate Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000003260 fluorescence intensity Methods 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 229940020899 hematological Enzymes Drugs 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 229910001411 inorganic cation Inorganic materials 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960002014 ixabepilone Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001394 metastastic Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 201000010927 mucositis Diseases 0.000 description 2
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 2
- 230000001613 neoplastic Effects 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 201000002674 obstructive nephropathy Diseases 0.000 description 2
- 230000000174 oncolytic Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 108010027841 pegademase bovine Proteins 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960000952 pipobroman Drugs 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000003537 radioprotector Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M sodium;2-sulfanylethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
- 229960000977 trabectedin Drugs 0.000 description 2
- 230000035916 transactivation Effects 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- FRPJXPJMRWBBIH-UHFFFAOYSA-N (17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl) N,N-bis(2-chloroethyl)carbamate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 FRPJXPJMRWBBIH-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- CPVLFAPAIXRGNV-DJJHDAFRSA-N (2'R,3R,3'S,5'S)-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-5,6-difluoro-N-(4-hydroxycyclohexyl)-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide Chemical compound C1([C@H]2[C@@H](N[C@H]([C@]22C3=CC(F)=C(F)C=C3NC2=O)CC(C)(C)C)C(=O)NC2CCC(O)CC2)=CC=CC(Cl)=C1F CPVLFAPAIXRGNV-DJJHDAFRSA-N 0.000 description 1
- RMDLCHAGVUSJTL-GDMDWKKYSA-N (2'S,3R,3'R,5'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-N-(4-hydroxycyclohexyl)-1'-[(1S,2R)-2-hydroxy-1,2-diphenylethyl]-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide Chemical compound C1([C@@H](O)[C@@H](N2[C@H]([C@]3(C4=CC=C(Cl)C=C4NC3=O)[C@H](C=3C(=C(Cl)C=CC=3)F)[C@H]2C(=O)NC2CCC(O)CC2)CC(C)(C)C)C=2C=CC=CC=2)=CC=CC=C1 RMDLCHAGVUSJTL-GDMDWKKYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JNSWIYCWZPFQQF-JGVFFNPUSA-N (2R,3S)-3-(carboxyamino)-2-hydroxy-3-phenylpropanoic acid Chemical compound OC(=O)[C@H](O)[C@@H](NC(O)=O)C1=CC=CC=C1 JNSWIYCWZPFQQF-JGVFFNPUSA-N 0.000 description 1
- MMHDBUJXLOFTLC-WOYTXXSLSA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide Chemical compound CC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O)CC1=CN=CN1 MMHDBUJXLOFTLC-WOYTXXSLSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- NECZZOFFLFZNHL-XVGZVFJZSA-N (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]-oxidophosphaniumyl]oxyethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 NECZZOFFLFZNHL-XVGZVFJZSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- QVXLODBTQQESRQ-UHFFFAOYSA-N (3-$l^{1}-oxidanyl-4,5-dioxopyran-1-ium-2-yl)methanolate Chemical group [O]C1=C(C[O-])[O+]=CC(=O)C1=O QVXLODBTQQESRQ-UHFFFAOYSA-N 0.000 description 1
- BLLDULGTZRWONK-IZZDOVSWSA-N (3E)-6-chloro-3-[(3-chloro-2-fluorophenyl)methylidene]-1H-indol-2-one Chemical compound FC1=C(Cl)C=CC=C1\C=C\1C2=CC=C(Cl)C=C2NC/1=O BLLDULGTZRWONK-IZZDOVSWSA-N 0.000 description 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- AZJYSALMGIGGDH-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one;sodium Chemical compound [Na].O=C1N=CN=C2NNC=C12 AZJYSALMGIGGDH-UHFFFAOYSA-N 0.000 description 1
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical class C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-N-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- GRPFZJNUYXIVSL-UHFFFAOYSA-N 2-[3-(cyanomethyl)phenyl]acetonitrile Chemical compound N#CCC1=CC=CC(CC#N)=C1 GRPFZJNUYXIVSL-UHFFFAOYSA-N 0.000 description 1
- FOMKFBXHAKRALK-UHFFFAOYSA-N 2-[4-[(2-bromoethylamino)methyl]-2-nitroimidazol-1-yl]ethanol Chemical compound OCCN1C=C(CNCCBr)N=C1[N+]([O-])=O FOMKFBXHAKRALK-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2S)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- PRARWMPSYXQMIX-ADKAHSJRSA-N 2-[[2-[[(4S)-4-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(=O)NC(CCC(O)=O)C(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C=C1 PRARWMPSYXQMIX-ADKAHSJRSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- ALHXTYGCVYTWIY-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione Chemical compound N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 ALHXTYGCVYTWIY-UHFFFAOYSA-N 0.000 description 1
- PJKVJJYMWOCLIJ-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1H-quinazolin-4-one;hydron;dichloride Chemical compound Cl.Cl.CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 PJKVJJYMWOCLIJ-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- FPQQSNUTBWFFLB-UHFFFAOYSA-N 2-chloro-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CCl FPQQSNUTBWFFLB-UHFFFAOYSA-N 0.000 description 1
- LIJLYNWYKULUHA-UHFFFAOYSA-N 2-chloroethyl carbamate Chemical compound NC(=O)OCCCl LIJLYNWYKULUHA-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1H-pyrrole Chemical compound [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LTNUSYNQZJZUSY-UHFFFAOYSA-N 3,3-dimethylbutanal Chemical compound CC(C)(C)CC=O LTNUSYNQZJZUSY-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-PATWWPTKSA-N 3-[[2-[2-[2-[[(2R,3R)-2-[[(2R,3R,4S)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2R)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2S,3R,4R,5R,6R)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan- Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-PATWWPTKSA-N 0.000 description 1
- SGKHACSKXNWDGI-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxy-3-methylcyclobutane-1-carboxylic acid Chemical class CC(C)(C)[Si](C)(C)OC1(C)CC(C(O)=O)C1 SGKHACSKXNWDGI-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CCRNCEKMSVYFLU-UHFFFAOYSA-N 4,5-dinitro-1H-imidazole Chemical compound [O-][N+](=O)C=1N=CNC=1[N+]([O-])=O CCRNCEKMSVYFLU-UHFFFAOYSA-N 0.000 description 1
- DWWWGZSFABKRSP-UHFFFAOYSA-N 4-(aminomethyl)cyclohexan-1-ol;hydrochloride Chemical compound Cl.NCC1CCC(O)CC1 DWWWGZSFABKRSP-UHFFFAOYSA-N 0.000 description 1
- SETFNECMODOHTO-UHFFFAOYSA-N 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- NBLHOLNNKJBEDC-XOGQCRKLSA-O 4-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCC[NH+]=C(N)N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C NBLHOLNNKJBEDC-XOGQCRKLSA-O 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- GAMOILWTJHUYFX-UHFFFAOYSA-N 4-methyl-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2N(C)C=NS(=O)(=O)C2=C1 GAMOILWTJHUYFX-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- ZCJXQWYMBJYJNB-LRDBBFHQSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZCJXQWYMBJYJNB-LRDBBFHQSA-N 0.000 description 1
- KUEFXPHXHHANKS-UHFFFAOYSA-N 5-nitro-1H-1,2,4-triazole Chemical compound [O-][N+](=O)C1=NC=NN1 KUEFXPHXHHANKS-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- VNSFICAUILKARD-UHFFFAOYSA-N 6-chloropyrimidine-4,5-diamine Chemical compound NC1=NC=NC(Cl)=C1N VNSFICAUILKARD-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- MLFKVJCWGUZWNV-REOHCLBHSA-N ALANOSINE Chemical compound OC(=O)[C@@H](N)CN(O)N=O MLFKVJCWGUZWNV-REOHCLBHSA-N 0.000 description 1
- 229950005033 ALANOSINE Drugs 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 206010000583 Acral lentiginous melanoma Diseases 0.000 description 1
- 229940060205 Adagen Drugs 0.000 description 1
- 210000004404 Adrenal Cortex Anatomy 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229940064305 Adrucil Drugs 0.000 description 1
- 229960003767 Alanine Drugs 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229940098174 Alkeran Drugs 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 208000006431 Amelanotic Melanoma Diseases 0.000 description 1
- DVARTQFDIMZBAA-UHFFFAOYSA-O Ammonium nitrate Chemical compound [NH4+].[O-][N+]([O-])=O DVARTQFDIMZBAA-UHFFFAOYSA-O 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 229950002465 Apaziquone Drugs 0.000 description 1
- 229940115115 Aranesp Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940078010 Arimidex Drugs 0.000 description 1
- 229940087620 Aromasin Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- SERHTTSLBVGRBY-UHFFFAOYSA-N Atiprimod Chemical compound C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 SERHTTSLBVGRBY-UHFFFAOYSA-N 0.000 description 1
- 229950003462 Atiprimod Drugs 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N BBR-2778 Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000024678 Bcl-2 family Human genes 0.000 description 1
- 108091011726 Bcl-2 family Proteins 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229940021459 Betaseron Drugs 0.000 description 1
- 229940108502 BiCNU Drugs 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N Bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- LQZGERFRLYQGET-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(NC1CC(C1)(C)O[Si](C)(C)C(C)(C)C)=O Chemical class C(C1=CC=CC=C1)OC(NC1CC(C1)(C)O[Si](C)(C)C(C)(C)C)=O LQZGERFRLYQGET-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229960005084 CALCITRIOL Drugs 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 102000013135 CD52 Antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 229960002129 CEFIXIME Drugs 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N CHEMBL118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
- ZPFVQKPWGDRLHL-WITOOOCMSA-N CHEMBL2074689 Chemical compound Cl.Cl.Cl.C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1[C@@H]1C2=CC=CC=C2[C@H]2C(F)(F)[C@H]2C2=CC=CC=C12 ZPFVQKPWGDRLHL-WITOOOCMSA-N 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229950000772 Canfosfamide Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229940047495 Celebrex Drugs 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 229940106189 Ceramides Drugs 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N Cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 229950009003 Cilengitide Drugs 0.000 description 1
- PHFDSUAPTIIQJT-UHFFFAOYSA-N Cl.OC1=C2C(C=3CCCC(C3C(C2=C(C2=CC=C(C=C12)O)O)=O)OC)=O Chemical compound Cl.OC1=C2C(C=3CCCC(C3C(C2=C(C2=CC=C(C=C12)O)O)=O)OC)=O PHFDSUAPTIIQJT-UHFFFAOYSA-N 0.000 description 1
- 229910020257 Cl2F2 Inorganic materials 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N Combretastatin A-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 229940088547 Cosmegen Drugs 0.000 description 1
- 229940109262 Curcumin Drugs 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229940119025 Cysteamine Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 229940041983 Daunorubicin Liposomal Drugs 0.000 description 1
- 102000010170 Death domain Human genes 0.000 description 1
- 108050001718 Death domain Proteins 0.000 description 1
- 229940026692 Decadron Drugs 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N Decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N Deforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 229940027008 Deltasone Drugs 0.000 description 1
- 229940070968 DepoCyt Drugs 0.000 description 1
- 206010072449 Desmoplastic melanoma Diseases 0.000 description 1
- 229960004833 Dexamethasone phosphate Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- HKXBNHCUPKIYDM-CGMHZMFXSA-N Doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
- 229940115080 Doxil Drugs 0.000 description 1
- 206010013781 Dry mouth Diseases 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- BNFRJXLZYUTIII-UHFFFAOYSA-N Efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940053603 Elitek Drugs 0.000 description 1
- 229940087477 Ellence Drugs 0.000 description 1
- 229940120655 Eloxatin Drugs 0.000 description 1
- 229940073038 Elspar Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940000733 Emcyt Drugs 0.000 description 1
- AXRCEOKUDYDWLF-UHFFFAOYSA-N Enzastaurin Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 1
- 229950002189 Enzastaurin Drugs 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 229960003388 Epoetin alfa Drugs 0.000 description 1
- 229940089118 Epogen Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000002047 Essential Thrombocythemia Diseases 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N Ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940098617 Ethyol Drugs 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 229940047887 Etopophos Drugs 0.000 description 1
- 241000320368 Eucryphia cordifolia Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- MVGSNCBCUWPVDA-MFOYZWKCSA-N Exisulind Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
- 229940043168 Fareston Drugs 0.000 description 1
- 229940087861 Faslodex Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940087476 Femara Drugs 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229950011423 Forodesine Drugs 0.000 description 1
- IWKXDMQDITUYRK-KUBHLMPHSA-N Forodesine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)N[C@H]1C1=CNC2=C1N=CNC2=O IWKXDMQDITUYRK-KUBHLMPHSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HDVBZDRIUHRXAV-UHFFFAOYSA-N GTI2040 Chemical compound O=C1N=C(N)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 HDVBZDRIUHRXAV-UHFFFAOYSA-N 0.000 description 1
- 229950001109 Galiximab Drugs 0.000 description 1
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 description 1
- 229940020967 Gemzar Drugs 0.000 description 1
- 229940045109 Genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N Genistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229950011595 Glufosfamide Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- QBKSWRVVCFFDOT-UHFFFAOYSA-N Gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 229940003183 Hexalen Drugs 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N Homoharringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 208000003671 Hutchinson's Melanotic Freckle Diseases 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- 229940096120 Hydrea Drugs 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101700046422 IFNA Proteins 0.000 description 1
- 229940099279 Idamycin Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- 229940090411 Ifex Drugs 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 108010027440 Immunoconjugates Proteins 0.000 description 1
- 102000018748 Immunoconjugates Human genes 0.000 description 1
- 108010053490 Infliximab Proteins 0.000 description 1
- 206010022498 Insulinoma Diseases 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 229950000038 Interferon alfa Drugs 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- NICJCIQSJJKZAH-AWEZNQCLSA-N Irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 1
- 229950005254 Irofulven Drugs 0.000 description 1
- 108010078354 J591 monoclonal antibody Proteins 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229950001845 Lestaurtinib Drugs 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N Lestaurtinib Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 229940063725 Leukeran Drugs 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940100029 Lysodren Drugs 0.000 description 1
- 102000017274 MDM4 Human genes 0.000 description 1
- PBUUPFTVAPUWDE-HSLMEMBISA-N Mafosfamide Chemical compound OS(=O)(=O)CCS[C@@H]1CCOP(=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-HSLMEMBISA-N 0.000 description 1
- 229950000547 Mafosfamide Drugs 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940087732 Matulane Drugs 0.000 description 1
- 229940090004 Megace Drugs 0.000 description 1
- 229960003151 Mercaptamine Drugs 0.000 description 1
- 229960004635 Mesna Drugs 0.000 description 1
- 229940101533 Mesnex Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- XMYQHJDBLRZMLW-UHFFFAOYSA-N Methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 1
- 229960004469 Methoxsalen Drugs 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 230000036095 Microsomal Stability Effects 0.000 description 1
- 210000001853 Microsomes, Liver Anatomy 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N Motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- JFOHFDSMPQIOES-UHFFFAOYSA-N Motexafin Chemical compound C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 JFOHFDSMPQIOES-UHFFFAOYSA-N 0.000 description 1
- 229950011637 Motexafin Drugs 0.000 description 1
- 229940087004 Mustargen Drugs 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 229940114179 Mycobacterium bovis Drugs 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 1
- LGGHDPFKSSRQNS-UHFFFAOYSA-N N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 description 1
- TUCSWKVJKUXHJV-UHFFFAOYSA-N N-butyl-2-methoxyacridin-1-amine Chemical compound C1=CC=C2C=C3C(NCCCC)=C(OC)C=CC3=NC2=C1 TUCSWKVJKUXHJV-UHFFFAOYSA-N 0.000 description 1
- UMJJGDUYVQCBMC-UHFFFAOYSA-N N-ethyl-N'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N N-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 229940086322 Navelbine Drugs 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229940071846 Neulasta Drugs 0.000 description 1
- 229940082926 Neumega Drugs 0.000 description 1
- 229940029345 Neupogen Drugs 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229940109551 Nipent Drugs 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 108010066154 Nuclear Export Signals Proteins 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O(6)-benzylguanine; Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- QWZRZYWLWTWVLF-UHFFFAOYSA-N O.OP(O)=O Chemical compound O.OP(O)=O QWZRZYWLWTWVLF-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- MOWTXLISNVXVLN-IZLXSQMJSA-N O[C@@H]1CC[C@H](CC1)[NH-] Chemical compound O[C@@H]1CC[C@H](CC1)[NH-] MOWTXLISNVXVLN-IZLXSQMJSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940099216 Oncaspar Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 229950007283 Oregovomab Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N Oxindole Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 description 1
- 239000009820 PHY 906 Substances 0.000 description 1
- 229940098901 POLIFEPROSAN 20 Drugs 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- 229940096763 Panretin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 208000003154 Papilloma Diseases 0.000 description 1
- 229940097097 Pediapred Drugs 0.000 description 1
- 229960001373 Pegfilgrastim Drugs 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 229940109328 Photofrin Drugs 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N Phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229960003073 Pirfenidone Drugs 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960004403 Pixantrone Drugs 0.000 description 1
- 229940072689 Plaquenil Drugs 0.000 description 1
- 229940063179 Platinol Drugs 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 208000008696 Polycythemia Vera Diseases 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229960004293 Porfimer Sodium Drugs 0.000 description 1
- 229940096111 Prelone Drugs 0.000 description 1
- 102000030002 Prion Proteins Human genes 0.000 description 1
- 108091000054 Prion Proteins Proteins 0.000 description 1
- YSQDQEOIFWWVHA-UHFFFAOYSA-A ProMune Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 YSQDQEOIFWWVHA-UHFFFAOYSA-A 0.000 description 1
- 229940087463 Proleukin Drugs 0.000 description 1
- 229940117820 Purinethol Drugs 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- 229940079923 Quinacrine Drugs 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229950007649 Ranpirnase Drugs 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N Rebeccamycin Chemical class O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- 229950009213 Rubitecan Drugs 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 101710012186 SLC7A1 Proteins 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940053186 Sclerosol Drugs 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000004927 Skin cells Anatomy 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001312734 Streptomyces parvulus Species 0.000 description 1
- 241000187412 Streptomyces plicatus Species 0.000 description 1
- 241001147844 Streptomyces verticillus Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- 101710002875 TYRO3 Proteins 0.000 description 1
- 229950010637 Talabostat Drugs 0.000 description 1
- 229950004608 Talampanel Drugs 0.000 description 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N Tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950005890 Tariquidar Drugs 0.000 description 1
- 229940061353 Temodar Drugs 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 229960001712 Testosterone Propionate Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 229950009158 Tipifarnib Drugs 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940086984 Trisenox Drugs 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229940001814 Uvadex Drugs 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N Valspodar Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- 229940054937 Valstar Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960003636 Vidarabine Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 229950001212 Volociximab Drugs 0.000 description 1
- 229940100445 WHEAT STARCH Drugs 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229940053890 Zanosar Drugs 0.000 description 1
- 229940099232 Zinecard Drugs 0.000 description 1
- 229940033942 Zoladex Drugs 0.000 description 1
- 229940002005 Zometa Drugs 0.000 description 1
- 229940088909 Zyloprim Drugs 0.000 description 1
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- PYDGNVZQEUTTKV-UHFFFAOYSA-O [Na+].COC1=CC([N+]([O-])=O)=CC=C1N1N(C=2C=CC(=CC=2)[N+]([O-])=O)N=C(C=2C(=CC(=CC=2)S(O)(=O)=O)S(O)(=O)=O)[NH2+]1 Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1N1N(C=2C=CC(=CC=2)[N+]([O-])=O)N=C(C=2C(=CC(=CC=2)S(O)(=O)=O)S(O)(=O)=O)[NH2+]1 PYDGNVZQEUTTKV-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 230000001780 adrenocortical Effects 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N arabinosyl adenine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001042 autoregulative Effects 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- PCCNIENXBRUYFK-UHFFFAOYSA-O azanium;cerium(4+);pentanitrate Chemical compound [NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PCCNIENXBRUYFK-UHFFFAOYSA-O 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- ASZMLLYVWJJPMZ-UHFFFAOYSA-N benzyl 3-[tert-butyl(dimethyl)silyl]oxy-3-methylcyclobutane-1-carboxylate Chemical class C1C(O[Si](C)(C)C(C)(C)C)(C)CC1C(=O)OCC1=CC=CC=C1 ASZMLLYVWJJPMZ-UHFFFAOYSA-N 0.000 description 1
- AFFVTFZFBYSFES-UHFFFAOYSA-N benzyl 3-hydroxy-3-methylcyclobutane-1-carboxylate Chemical class C1C(C)(O)CC1C(=O)OCC1=CC=CC=C1 AFFVTFZFBYSFES-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000001488 breeding Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- FDKXTQMXEQVLRF-UHFFFAOYSA-N dacarbazine Chemical compound CN(C)N=NC=1NC=NC=1C(N)=O FDKXTQMXEQVLRF-UHFFFAOYSA-N 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- DRXGWTUAIWQOKN-UHFFFAOYSA-L dihydroxy(dioxo)molybdenum;phosphonic acid Chemical compound OP(O)=O.O[Mo](O)(=O)=O DRXGWTUAIWQOKN-UHFFFAOYSA-L 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960000413 doxercalciferol Drugs 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical class CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229950000484 exisulind Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 108010012206 galiximab Proteins 0.000 description 1
- 201000002146 gastrointestinal system disease Diseases 0.000 description 1
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 108010061572 ibritumomab tiuxetan Proteins 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 201000010078 malignant spindle cell melanoma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- WFFQYWAAEWLHJC-UHFFFAOYSA-N mercaptopurine hydrate Chemical compound O.S=C1NC=NC2=C1NC=N2 WFFQYWAAEWLHJC-UHFFFAOYSA-N 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- BUTPBERGMJVRBM-UHFFFAOYSA-N methanol;methylsulfinylmethane Chemical compound OC.CS(C)=O BUTPBERGMJVRBM-UHFFFAOYSA-N 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- IKXILDNPCZPPRV-RFMGOVQKSA-N metholone Chemical compound C1C[C@@H]2[C@@]3(C)C[C@@H](C)C(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C IKXILDNPCZPPRV-RFMGOVQKSA-N 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical class [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- MAJTXTYGACTQGY-UHFFFAOYSA-N methylcyclobutane Chemical group [CH2+][C]1CCC1 MAJTXTYGACTQGY-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229950010514 misonidazole Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000003731 mucosal melanoma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 230000001338 necrotic Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- VOXZDWNPVJITMN-WKUFJEKOSA-N oestradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 108010060422 oregovomab Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 229940048111 pegademase bovine Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- OIRUWDYJGMHDHJ-AFXVCOSJSA-N retaspimycin hydrochloride Chemical compound Cl.N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OIRUWDYJGMHDHJ-AFXVCOSJSA-N 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 210000000242 supportive cell Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 108010009573 talabostat Proteins 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- LZPBKINTWROMEA-UHFFFAOYSA-N tetracene-5,12-dione Chemical compound C1=CC=C2C=C3C(=O)C4=CC=CC=C4C(=O)C3=CC2=C1 LZPBKINTWROMEA-UHFFFAOYSA-N 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 description 1
- 108010031272 volociximab Proteins 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N α-(methoxymethyl)-2-nitro-1H-Imidazole-1-ethanol Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
Abstract
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spirooxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Description
SPIRO-OXINDOLE MDM2 ANTAGONISTS
BACKGROUND
The aggressive cancer cell phenotype is the resuit of a variety of genetic and epigenetic alterations leading to deregulation of intracellular signaling pathways (Ponder, Nature 411:336 (2001)). Cancer cells typically fail to execute an apoptotic program, and lack of appropriate apoptosis due to defects in the normal apoptosis machinery is considered a hallmark of cancer (Lowe et al., Carcinogenesis 21:485 (2000)). The inability of cancer cells to execute an apoptotic program due to defects in the normal apoptotic machinery is often associated with an increase in résistance to chemotherapy, radiation, or immunotherapyinduced apoptosis. Prîmary or acquired résistance of human cancer of different origins to current treatment protocols due to apoptosis defects is a major problem in current cancer therapy (Lowe et al., Carcinogenesis 21:485 (2000); Nicholson, Nature 407:810 (2000)). Accordingly, current and future efforts towards designing and developing new molecular target-speclfic anticancer thérapies to improve survival and quality of life of cancer patients must include strategies that specîfically target cancer cell résistance to apoptosis.
The p53 tumor suppressor plays a central rôle in controlling cell cycle progression, senescence, and apoptosis (Vogelstein et al., Nature 408:307 (2000); Goberdhan, Cancer Cell 7:505 (2005)). MDM2 and p53 are part of an auto-regulatory feed-back loop (Wu et al., Genes Dev. 7:1126 (1993)). MDM2 is transcriptlonally activated by p53 and MDM2, in turn, inhibits p53 activity by at least three mechanisms (Wu et al., Genes Dev. 7:1126 (1993). First, MDM2 protein directly binds to the p53 transactivation domain and thereby inhibits p53-mediated transactivation. Second, MDM2 protein contains a nuclear export signal sequence, and upon binding to p53, induces the nuclear export of p53, preventing p53 from binding to the targeted DNAs. Third, MDM2 protein is an E3 ubiquitln ligase and upon binding to p53 is able to promote p53 dégradation.
Although high-affinity peptide-based inhibitors of MDM2 hâve been successfully designed in the past (Garcia-Echeverria ef al., Med. Chem. 43:3205 (2000)), these inhibitors are not suitable therapeutic molécules because of their poor cell permeability and in vivo bioavailability. Despite intensive efforts by the pharmaceutical industry, high throughput screening strategies hâve had very limited success in identifying potent, non-peptide small molécule inhibitors. Accordingly, there is a need for non-peptide, drug-like, small molécule inhibitors of the p53-MDM2 interaction.
The structural basis of the interaction p53 and MDM2 has been established by x-ray crystallography (Kussie et al., Science 274:948 (1996)).
Spiro-oxindole-based antagoniste of the p53-MDM2 interaction are described in U.S. Patent Nos. 7,759,383 B2 and 7,737,174 B2.
Skin cancer or melanoma is a commonly found type of cancer. Even though melanoma represents only a small fraction of the total number of cancer cases, it is responsible for many cancer deaths. According to statistics provided by the American Cancer Society, in contrast to many other types of cancers, the number of new cases of melanoma in the United States is still on the rise.
As with ail cancers, it is impérative to diagnose melanoma early. About 70% of melanomas are superfîcial spreading, meaning that they undergo a superficial, radial growth phase before they grow vertically and invade underlying tissue, a much more serious condition. Unfortunately, about 20% of cutaneous melanomas immediately start out with a vertical growth phase, which explains why these tumors are so dangerous. The 5-year survival rate for Stage 1 melanoma is very good. However, this drops off rapidly when cancer is allowed to progress and invade, first locally and then more distantly. Survival rate for Stage 2 disease is only 40-80%, Stage 3 10-70% and Stage 4 is almost invariably léthal within 5 years (<5-10% survives beyond 5 years) due to untreatable distant metastasis to especially lung and brain.
Melanoma originates from malignant transformation of mélanocytes, the pigment producing skin cells, via atypical and dysplastic premalignant intermediate stages to locally invasive and finally metastatic melanoma. A large number of genes hâve been implicated to play a rôle in these processes. Metastatic melanoma, the usual cause of death, is notoriously résistant to conventional therapy.
SUMMARY OF THE INVENTION
The présent disclosure contemplâtes that exposure of humans and animais to therapeutically effective amounts of drug(s) (e.g., small molécules) that increase the function(s) of p53 and p53-related proteins (e.g., p63, p73) inhibits the growth of p53 expressing cells. In some embodiments, the compounds provided herein inhibit the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins (e.g., MDMX). Inhibiting the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins inhibits the growth of cells. For example, inhibiting the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins can inhibit cancer cells or supporting cells and/or renders such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation thérapies. In 2 some embodiments, the inhibitors provided herein prolong the half-life of p53 by interfering with the p53-MDM2 interaction that would normally promote dégradation of p53. The compounds provided herein satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy to induce senescence, cell growth inhibition, apoptosis and/or cell cycle arrest in cancer ceils, or when administered in a temporal relationship with additional agent(s), such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation thérapies (combination thérapies), so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drug or radiation therapy alone.
In some embodiments, treatment of animais (including humans) with a therapeutically effective amount of one or more compounds provided herein and an anticancer agent produces a greater anti-tumor activity and clinical benefit in such animais compared to those treated with the compound or anticancer drugs/radiatîon alone. Put another way, because the compounds provided herein can lower the apoptotic threshold of cells that express p53 or p53-related protein, the proportion of cells that successfully execute the apoptosis program in response to the apoptosis inducing activity of anticancer drugs/radiation will be increased when used in combination with one or more of the compounds provided herein. Alternatively, the compounds provided herein can be used to allow administration of a lower, and therefore less toxic and more tolerable, dose of an anticancer drug and/or radiation to produce the same tumor response/clinical benefit as the conventional dose of the anticancer drug/radiation alone. Since the doses for ail approved anticancer drugs and radiation treatments are known, the présent compounds, compositions, and methods provided herein can be used with one or more approved anticancer drugs and/or radiation treatment. Also, since the compounds provided herein may act at least in part by stimulating the proapoptotic and/or cell cycle-inhibiting activities of p53 and p53-related proteins, the exposure of cancer cells and supporting cells to therapeutically effective amounts of the compounds can be temporally linked to coïncide with the attempts of cells to execute the apoptosis program in response to the anticancer drug or radiation therapy. Thus, in some embodiments, administering the compounds or compositions provided herein in combination with other known anticancer drugs provide especially efficacious therapeutic practices.
In other embodiments, the inhibitors of the interaction between p53 or p53-related proteins and MDM2 and MDM2-related proteins provided herein may protect normal (e.g., nonhyperproliferative) cells from the toxic effects of certain chemotherapeutic agents and radiation, possibly through the ability of the inhibitors to induce cell cycle arrest of normal cells. For example, the inhibitors provided herein may cause cell cycle arrest in cells comprising wild-type or functional p53 (and/or wild-type or functional p53-related proteins) while having no or less effect on cancer cells comprising mutated, deleted, or otherwise non- or less functional p53 (and/or mutated, deleted, or otherwise non-or less functional p53-related proteins). This différentiel protective effect may allow for more effective treatment of cancer by allowing the use of higher doses or longer treatments of chemotherapeutic agents or treatments without increasing the toxic side effects of such treatment when administered in combination with inhibitors provided herein.
Applicants hâve found that certain spiro-oxindoles provided herein display an unexpected combination of drug-like properties. The unexpected combinations include, e.g., two or more of in vitro efficacy, in vivo efficacy, in vitro liver microsome stability, désirable absorption, distribution, metabolism, and excrétion (ADME) properties. For example, certain spiro-oxindoles provided herein are more résistant to metabolic dégradation e.g., as measured by in vitro liver microsomal stability and/or in vivo pharmacokinetics, and/or display improved in vivo efficacy as compared to known antagonists of the p53-MDM2 interaction.
Applicants hâve also found that metabolically cleavable groups can be used to increase the aqueous solubility of the parent molécule. Thus, in some embodiments, the spiro-oxindoles provided herein are useful prodrugs with improved aqueous solubility relative to the parent molécule.
In some embodiments, the compounds provided herein are spiro-oxindoles having Formulae l-XXXV (see below under “Compounds), or pharmaceutically acceptable salts, solvatés, or prodrugs thereof. In some embodiments, the compounds provided herein inhibit the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins.
In some embodiments, the compounds provided herein contain a metabolically cleavable group. In particular, in some embodiments, the compounds provided herein contain a hydroxy group of a hydroxycycloalkyl side chain that can be used to attach a metabolically cleavable group. Suitable metabolically cleavable groups include, but are not limited to, amino acid esters or phosphate esters.
In some embodiments, the compounds provided herein can be used to induce senescence, cell cycle arrest and/or apoptosis in cells containing functional p53 or p53-related proteins. Also provided herein are methods of using the compounds provided herein for sensitizing cells to additional agent(s), such as inducers of senescence, apoptosis and/or cell cycle arrest. The compounds provided herein can also be used to provide chemoprotection of normal cells through the induction of cell cycle arrest prior to treatment with chemotherapeutic agents. In one embodiment, the methods of rendering a normal cell résistant to chemotherapeutic agents or treatments comprises contacting the cell with one or more compounds provided herein. In one embodiment, methods of protecting normal cells in an animal having a hyperproliferative disease from the toxic side effects of chemotherapeutic agents or treatments, comprises administering to the animal a compound provided herein. Provided herein are methods for the treatment, amelioration, or prévention of disorders, side effects, or conditions caused by the administration of chemotherapeutic agents to normal cells comprising administering to an animal undergoing chemotherapy a compound provided herein. Examples of such disorders and conditions caused by chemotherapy include, without limitation, mucositis, stomatitis, xerostomia, gastrointestinal disorders, and alopecia.
The compounds provided herein are useful for the treatment, amelioration, or prévention of disorders, such as those responsive to induction of apoptotic cell death, e.g., disorders characterized by dysrégulation of apoptosis, including hyperproliferative diseases such as cancer. In certain embodiments, the compounds can be used to treat, ameliorate, or prevent cancer that is characterized by résistance to cancer thérapies (e.g., those cancer cells which are chemoresistant, radiation résistant, hormone résistant, and the like). In other embodiments, the compounds can be used to treat hyperproliferative diseases characterized by expression of functional p53 or p53-related proteins. In other èmbodiments, the compounds provided herein can be used to protect normal (e.g., non-hyperproliferative) cells from the toxic side effects of chemotherapeutic agents and treatments by the induction of cell cycle arrest in those cells.
In one embodiment, pharmaceutical compositions are provided. The pharmaceutical compositions can comprise one of more of the compounds provided herein and a pharmaceutically acceptable carrier.
In one embodiment, kits are provided. The kits can comprise one or more of the compounds provided herein, or a pharmaceutically acceptable sait thereof, and instructions for administering the compound to an animal. The kits may optionally contain other therapeutic agents, e.g., anticancer agents or apoptosis-modulating agents.
In one embodiment, methods of treating, preventing, or ameliorating a hyperproliferative disease, e.g., cancer, in a patient comprising pulsatile administration to the patient a therapeutically effective amount of one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof are provided.
In one embodiment, methods of treating, preventing, or ameliorating a hyperproliferative disease, e.g., cancer, in a patient comprising pulsatile administration to the patient a therapeutically effective amount of one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, in combination with one or more additional therapeutic, e.g., anticancer, agents.
In one embodiment, kits comprising one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, and instructions for administering the compound(s) to a patient having a hyperproliferative disease by pulsatile dosing are provided. The kits can optionally contain one or more additional therapeutîc, e.g., anticancer, agents.
BRIEF DESCRIPTION OF DRAWINGS
Fig. 1 is a reverse phase HPLC chromatogram of MI-519-64 after isolation by column chromatography on silica gel.
Fig. 2 is reverse phase HPLC chromatogram of MI-519-64 after treatment with acetonitrile/water for 12 h. Three isomers are présent. MI-519-64 and MI-519-6401 correspond to RP-HPLC peaks at 30.578 minutes, and 31.787 minutes, respectively. The isomer eluting at 29.162 minutes is referred to as MI-519-6402.
Fig. 3 is reverse phase HPLC chromatogram of MI-519-64 after treatment with acetonitrile/water for 3 days.
Fig. 4 is a line graph showing the binding affinities of MI-519-64, MI-519-6401, and MI-5196402 to human MDM2 protein, as determined using a fluorescence-polarization binding assay. The purity of each isomer used in this experiment (as determined by RP-HPLC) are as follows: MI-519-6402: 90% (with 10% of MI-519-64); MI-519-64: 93% (with 3% of MI519-64 and 4% of MI-519-6401); and MI-519-6401: >99%. The log ICM values for MI-5196402, MI-519-64, and MI-519-6401 are 2.030 nM, 1.598 nM, and 0.8354 nM, respectively.
Fig. 5 is a line graph showing the binding affinities of MI-773 (TFA sait), MI-77301 (TFA sait), MI-77301 (free amine), and MI-77302 (TFA sait) to human MDM2 protein, as determined using a fluorescence-polarization binding assay.
Fig. 6 is a line graph showing the stability of MI-773 (TFA sait) at various time points in water/methanol = 1:1 with 0.1% of TFA, pH 2.1. The compound corresponding to peak 1 is MI-77302. The compound corresponding to peak 3 is MI-773. The compound corresponding to peak 4 is MI-77301.
Fig. 7 is a line graph showing the stability of MI-77301 (TFA sait) at various time points in water/methanol = 1:1 with 0.1% of TFA, pH 2.1. The compound corresponding to peak 1 is MI-77302. The compound corresponding to peak 3 is MI-773. The compound corresponding to peak 4 is MI-77301.
Fig. 8 is an illustration showing western blot analysis of p53 activation and apoptosis induced by MI-773 and MI-77301 in the SJSA-1 (osteosarcoma) cell line.
Fig. 9 is an illustration showing western blot analysis of p53 activation and apoptosis induced by MI-519-64 and MI-519-6401 in the SJSA-1 cell line.
Fig. 10 is a bar graph showing apoptosis induced by MI-773 and MI-77301 in the SJSA-1 cell line.
Fig. 11 is a bar graph showing cell death induced by MI-519-64 and MI-519-6401 in the SJSA-1 cell line.
Fig. 12 is a bar graph showing cell death induced by MI-519-64 and MI-519-6401 in the RS4;11 (human acute lymphoblastic leukemia (ALL)) cell line.
Fig. 13 is an illustration showing western blot analysis of in vivo activation of p53 and PARP cleavage induced by MI-519-64 and MI-519-6401 in SJSA-1 tumors in mice.
Fig. 14 is an illustration showing western blot analysis of in vivo activation of p53 and PARP cleavage induced by MI-519-64 and MI-519-6401 in RS4;11 tumors in mice.
Fig. 15 is an illustration showing western blot analysis of in vivo activation of p53 and PARP cleavage induced by MI-773 and MI-77301 in SJSA-1 tumors in mice.
Fig. 16 is an illustration showing three western blot analyses of p53 activation and apoptosis induced by MI-773 and MI-77301 in the RS4;11 cell line.
Fig. 17 is a line graph showing in vivo antitumor activity of MI-519-64, MI-519-6401, MI-773, and MI-77301 in the SJSA-1 osteosarcoma xenograft model in mice.
Fig. 18 is a line graph showing the animal weight following administration of MI-519-64, MI-519-6401, MI-773, and MI-77301 in mice.
Fig. 19 is a line graph showing in vivo antitumor activity of MI-519-6401 and MI-77301 in the 22Rv1 human prostate xenograft model in mice.
Fig. 20 is a line graph showing in vivo antitumor activity of MI-77301 in the SJSA-1 osteosarcoma xenograft model in mice (Cpd-B = MI-77301 ; treatment schedule = QD11 ).
Fig. 21 is a line graph showing the animal weight following administration of MI-77301 in mice (Cpd-B = MI-77301).
Fig. 22 is a line graph showing in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model in mice (Cpd-B = MI-77301).
Fig. 23 is a line graph showing in vivo antitumor activity of MI-77301 in the SJSA-1 osteosarcoma xenograft model in mice (Cpd-B = MI-77301 ). r
Fig. 24 is a line graph showing the cell growth inhibition activity of MI-77301 in melanoma cell lines.
Fig. 25 is an illustration showing western blot analysis of p53 activation induced by MI77301 in SK-Mel-103 (human melanoma) cells.
Fig. 26 is an illustration showing western blot analysis of p53 activation induced by MI77301 in UACC-62 (p53 wt melanoma) and SK-Mel-19 (human melanoma)cells.
Fig. 27 is a bar graph showing apoptosis induced by MI-77301 in the UACC-62 cell line.
Fig. 28 is an illustration showing western blot analysis of in vivo activation of p53 induced by MI-773001 in SK-Mel-103 melanoma xenografts in mice.
Fig. 29 is a line graph showing in vivo antitumor activity of MI-77301 in the SK-Mel-103 melanoma xenograft model in mice.
Fig. 30 is reverse phase HPLC chromatogram of substantially pure CB061-lsomer B.
Fig. 31 is a line graph showing in vivo antitumor activity of MI-77301 in the HCT-116 human colorectal tumor xenograft model in mice.
Fig. 32 is a line graph showing in vivo antitumor activity of MI-77301 in the LNCAP human prostate tumor xenograft model in mice.
Fig. 33 is a line graph showing in vivo antitumor activity of MI-77301 in the RS4;11 human acute lymphoblastic leukemia xenograft model in mice.
Fig. 34 is a sériés of three 13C CPMAS NMR spectrograms showing MI-77301 (top), MI-773 (middle), and MI-77302 (bottom).
Fig. 35 is a reverse phase HPLC chromatogram of substantially pure MI-773 (eluent: MeOH/water with 0.1% TFA).
Fig. 36 is a reverse phase HPLC chromatogram of substantially pure MI-77301 (eluent: MeOH/water with 0.1% TFA).
Fig. 37 is a line graph showing the stability of MI-773 (TFA sait) at various time points in water/methanol = 1:1 with 0.1% of TEA, pH 10.8. The compound corresponding to peak 3 is MI-773. The compound corresponding to peak 4 is Ml 77301,
Fig. 38 is a line graph showing the stability of MI-773 (TFA sait) at various time points in water/methanol = 1:1, pH 3.9. The compound corresponding to peak 3 is MI-773. The compound corresponding to peak 4 is MI-77301.
Fig. 39 is reverse phase HPLC chromatogram of substantially pure C027 (eluent: acetonitrile/H2O with 0.1% TFA).
Fig. 40 is reverse phase HPLC chromatogram of substantially pure C02701 (eluent: acetonitrile/H2O with 0.1% TFA).
Fig. 41 is reverse phase HPLC chromatogram of C029 substantially free of other stereoisomers (eluent: acetonitrile/H2O with 0.1% TFA).
Fig. 42 is reverse phase HPLC chromatogram of substantially pure C02901 (eluent: acetonitrile/H20 with 0.1% TFA).
DETAILED DESCRIPTION OF THE INVENTION
Provided herein are compounds that inhibit the interaction between p53 or p53-related proteins and MDM2 or MDM2-related proteins. By inhibiting the négative effect of MDM2 or MDM2-related proteins on p53 or p53-related proteins, these compounds sensitize cells to inducers of apoptosis and/or cell cycle arrest. In some embodiments, the compounds provided herein induce apoptosis and/or cell cycle arrest. Therefore, also provided herein are methods of sensitizing cells to inducers of apoptosis and/or cell cycle arrest and to methods of inducing apoptosis and/or cell cycle arrest in cells. In some embodiments, the methods comprise contacting the cells with one or more compounds provided herein alone or in combination with additional agent(s), e.g., an inducer of apoptosis or a cell cycle disrupter.
Also provided herein are methods of treating, ameliorating, or preventing disorders, e.g., a hyperproliferative disease, e.g., cancer, in an patient, comprising admînistering to the patient one or more compounds provided herein and additional agent(s), e.g., an inducer of apoptosis. Such disorders include those characterized by a dysrégulation of apoptosis and those characterized by the prolifération of cells expressing functional p53 or p53-related proteins. In other embodiments, methods of protecting normal (e.g., non-hyperproliferative) cells in an animal from the toxic side effects of chemotherapeutic agents and treatments are provided. The methods comprise admînistering to the animal one or more compounds provided herein. Also provided herein are methods of treating preventing, or ameliorating a hyperproliferative disease, e.g., cancer, in a patient comprising admînistering to the patient a therapeutically effective amount of one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, according to a pulsatile dosing regîmen.
Also provided herein are methods of treating preventing, or ameliorating a hyperproliferative disease, e.g., cancer, in a patient comprising admînistering to the patient a therapeutically effective amount of one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, according to a pulsatile dosing regîmen in combination with one or more additional therapeutic, e.g., anticancer, agents.
Also provided herein are kits comprising one or more of the compounds provided herein, and instructions for admînistering the compound(s) to a patient having a hyperproliferative disease by pulsatile dosing. The kits can optionally contain one or more additional therapeutic, e.g., anticancer, agents
Définitions
The terms pulsatile administration, pulsatile dose administration, or pulsatile dosing as used herein, refer to intermittent (i.e., not continuous) administration of one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, to a patient. Pulsatile dose administration regimens useful in the présent disclosure encompass any discontinuous administration regimen that provides a therapeutically effective amount of the compound(s) provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, to a patient in need thereof. Pulsatile dosing regimens can use équivalent, lower, or higher doses of compounds, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, than would be used in continuous dosing regimens. The compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, can be administered as a single agent under a pulsatile dosing regimen or can be administered under a pulsatile dosing regimen in combination with one or more additional anticancer agents (where the additional anticancer agents are administered either on a continuous or a pulsatile regimen). On the day that compounds, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are scheduled to be administered to the patient, administration can occur in a single or in divided doses, e.g., once-a-day, twice-aday, three times a day, four times a day or more. In one embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered once (QD) or twice (BID) on the day It is schedule to be administered. In one embodiment the compounds provided, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered orally to the patient according to a pulsatile dosing regimen. In one embodiment the compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered intravenously to the patient according to a pulsatile dosing regimen.
The therapeutic utility of drug administration can be offset by the number and severity of adverse events a patient expériences. Pulsatile dosing of compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, can resuit in a réduction in the number and/or severity of clinical adverse events coupled with a maintenance or enhancement in clinical efficacy, as compared to continuous daily dosing. The clinical benefits of pulsatile dose administration of compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, can be more prominent when combined with the administration of other therapeutic agents to the patient.
In one embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered to a patient no more frequently than one day out of every two days (e.g., administration occurs on day 1, day 3, day 5, day 7, day 9, etc.), 10 one ont of every three days (e.g., administration occurs on day 1, day 4, day 7, day 10, etc.), one out of every four days, one out of every five days, one ouf of every six days, one out of every seven days, one out of every eight days, one out of every nine days, one out of every ten days, one out of every two weeks, one out of every three weeks, one out of every four weeks, one out of every five weeks, or longer. The pulsatile dosing regimen can continue for one, two, three or four weeks, one, two, three or four months, one, two, three or four years or longer.
In another embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered to a patient one day a week, e.g., a compound of Formulae l-XXXV, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof, is administered to a patient on one day followed by six consecutive days wherein the compound is not administered. In another embodiment, compounds having Formulae IXXXV, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, administered to a patient one day every two weeks. In another embodiment, compounds having Formulae IXXXV, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered to a patient one day every three weeks. In another embodiment, compounds having Formulae l-XXXV, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered to a patient one day every four weeks.
In another embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered to a patient on a least two consecutive days, e.g., at least three, four, five, six or seven consecutive days, followed by at least one day, at least two consecutive days, at least three consecutive days, at least four consecutive days, at least five consecutive days, at least six consecutive days, at least seven consecutive days, at least eight consecutive days, at least nine consecutive days, at least ten consecutive days, at least eleven consecutive days, at least twelve consecutive days, at least thirteen consecutive days, at least two consecutive weeks, at least three consecutive weeks, or at least four consecutive weeks or longer wherein the compound disclosed herein is not administered.
In one embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, and one or more anticancer agents are administered to a patient on day 1 of an anticancer treatment cycle. Typically, the length of the treatment cycle is determined in accord with the approved dosing protocol(s) of the one or more anticancer agents that are to be administered to the patient in combination with the compounds having Formulae l-XXXV, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof. In one embodiment, the treatment cycle is about 14 days, about 21 days, or about 28 days. In a particular embodiment, the treatment cycle is 21 days. In one embodiment, the treatment cycle is repeated one or more times, e.g., 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,100, or more times.
In another embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered to the patient on day 1, on days 1 and 2, or on days 1, 2, and 3 of a treatment cycle and one or more anticancer agents are administered starting on day 1 of the treatment cycle in accord with the recommended dosing schedule of the anticancer agent In one embodiment, the anticancer agent is a chemotherapeutic agent. In another embodiment, the anticancer agent is radiation therapy.
In another embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered via the sequential use of a combination of two or more pulsatile dosing schedules. The combination may comprise the same pulsatile dosing schedules or different pulsatile dosing schedules. The sequential use of a combination of two or more pulsatile dosing regimens may be repeated as many times as necessary to achieve or maintain a therapeutic response, e.g., from one to about fifty times, e.g., from one to about twenty times, e.g., from about one to about ten times. With every répétition any additional therapeutic agents may be the same or different from that used in the previous répétition.
In another embodiment, compounds provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof, are administered according to a pulsatile dosing schedule and/or sequential combination of two or more pulsatile dosing schedules followed by a waiting period. The term waiting period, as used herein, refers to a period of time between dosing schedules when a compound disclosed herein is not administered to the patient The waiting period may be one, two, three, four, five or six days, one, two or three weeks, one, two, three or four months, one, two, three or four years or longer. In certain embodiments, the waiting period may be one to thirty days, e.g., seven, fourteen, twenty one or thirty days, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 days. After the waiting period, the same or a different pulsatile dosing schedule and/or sequential combination of one or more pulsatile dosing schedules of a compound disclosed herein can résumé. The pulsatile dosing/waiting period regimen may be repeated as many times as necessary to achieve or maintain a therapeutic response, e.g., from one to about fifty times, e.g., from one to about twenty times, e.g., from about one to about ten times. With every répétition any additional therapeutic agents may be the same or different from that used in the previous répétition.
The term “anticancer agent as used herein, refers to any therapeutic agent (e.g., chemotherapeutic compound and/or molecular therapeutic compound), antisense therapy, radiation therapy, or surgical intervention, used in the treatment of hyperproliferative diseases such as cancer (e.g., in mammals, e.g., in humans).
The term “prodrug” as used herein, refers to a pharmacologically inactive dérivative of a parent drug” molécule that requires biotransformation (e.g., either spontaneous or enzymatic) within the target physiological System to release, or to convert (e.g., enzymatically, physiologically, mechanically, electromagnetically) the prodrug into the active drug. Prodrugs are designed to overcome problems associated with stability, water solubility, toxicity, lack of specificity, or limited bioavailability. Exemplary prodrugs comprise an active drug molécule itself and a chemical masking group (e.g., a group that reversibly suppresses the activity of the drug). Some prodrugs are variations or dérivatives of compounds that hâve groups cleavable under metabolic conditions. Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: Design and Applications of Prodrugs; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academie Press, 1985, particularly pp. 309-396; Burgeris Médicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995, particularly Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; and Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987.
Exemplary prodrugs become pharmaceutically active in vivo or in vitro when they undergo solvolysis under physiological conditions or undergo enzymatic dégradation or other biochemical transformation (e.g., phosphorylation, hydrogénation, dehydrogenation, glycosylation). Prodrugs often offer advantages of water solubility, tissue compatibility, or delayed release in the mammalian organism. (See e.g., Bundgaard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam (1985); and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academie Press, San Diego, CA (1992)). Common prodrugs include acid dérivatives such as esters prepared by reaction of parent acids with a suitable alcohol (e.g., a lower alkanol) or esters prepared by reaction of parent alcohol with a suitable carboxylic acid, (e.g., an amino acid), amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base dérivative (e.g., a lower alkylamide), or phosphorus-containing dérivatives, e.g., phosphate, phosphonate, and phosphoramidate esters, including cyclic phosphate, phosphonate, and phosphoramidate, see, e.g., US 2007/0249564 A1.
The term metabolically cleavable group” as used herein, refers to groups which can be cleaved from the parent molécule by metabolic processes and be substituted with hydrogen. Certain compounds containing metabolically cleavable groups may be prodrugs, Le., they are pharmacologically inactive. Certain other compounds containing metabolically cleavable groups may be antagonists of the interaction between p53 and MDM2. In such cases, these compounds may hâve more, less, or équivalent activity of the parent molécule. Examples of metabolically cleavable groups include those derived from amino acids (see, e.g., US 2006/0241017 A1; US 2006/0287244 A1; and WO 2005/046575 A2) or phosphoruscontaining compounds (see, e.g., U.S. 2007/0249564 A1) as illustrated in Scheme 1.
Scheme 1
parent amino acid drug
O metabolic --------- R-OH cleavage amino acid ester parent drug
R-OH +
O
CI'f'0R OR”
O R-° orm | metabolic | R-OH |
cleavage |
phosphate ester parent drug parent drug phosphite
The term pharmaceutically acceptable sait as used herein, refers to any sait (e.g., obtained by reaction with an acid or a base) of a compound provided herein that is physiologically tolerated in the target animal (e.g., a mammal) or human. Salts of the compounds of provided herein may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p*sulfonic, tartane, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the préparation of salts useful as intermediates in obtaining the compounds provided herein and their pharmaceutically acceptable acid addition salts.
Examples of bases include, but are not limited to, alkalî métal (e.g., sodium) hydroxides, alkaline earth métal (e.g., magnésium) hydroxides, ammonia, and compounds of formula NW4 +, wherein W is Cm alkyl, and the like.
Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycérophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydroxyethanesulfonate, lactate, maleate, mesylate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds provided herein compounded with a suitable cation such as Na*. NH4 +, and NW4 + (wherein W is a Cm alkyl group), and the like. For therapeutic use, salts of the compounds provided herein are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the préparation or purification of a pharmaceutically acceptable compound.
The term solvaté as used herein, refers to the physical association of a compound provided herein with one or more solvent molécules, whether organic or inorganic. This physical association often includes hydrogen bonding. In certain instances, the solvaté is capable of isolation, for example, when one or more solvaté molécules are incorporated in the crystal lattice of the crystalline solid. Solvaté encompasses both solution-phase and isolable solvatés. Exemplary solvatés include hydrates, ethanolates, and methanolates.
The term monovalent pharmaceutically acceptable cation as used herein refers to inorganic cations such as, but not limited to, alkaline métal ions, e.g., Na* and K*, as well as organic cations such as, but not limited to, ammonium and substituted ammonium ions, e.g., ΝΗΛ NHMe3 +, NH2Mez+, NHMe3* and NMe4*.
The term divalent pharmaceutically acceptable cation as used herein refers to inorganic cations such as, but not limited to, alkaline earth métal cations, e.g., Ca2+ and Mg2*.
Examples of monovalent and divalent pharmaceutically acceptable cations are discussed, e.g., in Berge étal. J. Pharm. Sci., 66:1-19 (1997).
The term “therapeutically effective amount, as used herein, refers to that amount of the therapeutic agent (including the compounds, pharmaceutical compositions, and compositions of matter provided herein) sufficient to resuit in amelioration of one or more symptoms of a disorder, or prevent advancement of a disorder, or cause régression of the disorder. For example, with respect to the treatment of cancer, in one embodiment, a therapeutically effective amount can refer to the amount of a therapeutic agent that decreases the rate of tumor growth, decreases tumor mass, decreases the number of métastasés, increases time to tumor progression, increase tumor cell apoptosis, or increases survival time by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.
The terms sensitize” and “sensitizing, as used herein, refer to making, through the administration of a first therapeutic agent (e.g., a compound provided herein), an animal or a cell within an animal more susceptible, or more responsive, to the biological effects (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell division, cell growth, prolifération, invasion, angîogenesis, necrosis, or apoptosis) of a second therapeutic agent. The sensitizing effect of a first agent on a target cell can be measured as the différence in the intended biological effect (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, prolifération, invasion, angîogenesis, or apoptosis) observed upon the administration of a second agent with and without administration of the first agent. The response of the sensitized cell can be increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least 300%, at least about 350%, at least about 400%, at least about 450%, or at least about 500% over the response in the absence of the first agent.
The term dysrégulation of apoptosis, as used herein, refers to any aberration in the ability of (e.g., prédisposition) a cell to undergo cell death via apoptosis. Dysrégulation of apoptosis is associated with or induced by a variety of conditions, non-limiting examples of which include, autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, or Sjôgren's syndrome), chronic inflammatory conditions (e.g., psoriasis, asthma or Crohn's disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, or T cell lymphomas), viral infections (e.g., herpes, papilloma, or HIV), and other conditions such as osteoarthritis and atherosclerosis. It should be noted that when the dysrégulation is induced by or associated with a viral infection, the viral infection may or may not be détectable at the time dysrégulation occurs or is observed. That is, virai-induced dysrégulation can occur even after the disappearance of symptoms of viral infection.
The term functional p53, as used herein, refers to wild-type p53 expressed at normal, high, or low levels and mutant or allelic variants of p53 that retain(s) at least about 5% of the activity of wild-type p53, e.g., at least about 10%, about 20%, about 30%, about 40%, about
50%, or more of wild-type activity.
The term p53-related protein, as used herein, refers to proteins that hâve at least 25% sequence homology with p53, hâve tumor suppressor activity, and are înhibited by 5 interaction with MDM2 or MDM2-related proteins. Examples of p53-related proteins include, but are not limited to, p63 and p73.
The term MDM2-related protein, as used herein, refers to proteins that hâve at least 25% sequence homology with MDM2, and interact with and inhibit p53 or p53-related proteins. Examples of MDM2-related proteins include, but are not limited to, MDMX and MDM4.
The term senescence as used herein, refers to the phenomenon whereby non-cancerous diploid cells lose the ability to divide, and characterized in part by telomeric dysfunction or shortening.
The term “hyperproliferative disease, as used herein, refers to any condition in which a localized population of proliferating cells in an animal is not governed by the usual limitations 15 of normal growth. Examples of hyperproliferative disorders include tumors, neoplasms, lymphomas, leukemias and the like. A neoplasm is said to be benign if it does not undergo invasion or metastasis and malignant if it does either of these. A “metastatic cell means that the cell can invade neighboring body structures. Hyperplasia is a form of cell prolifération învolving an încrease in cell number in a tissue or organ without significant 20 alteration in structure or function. Metaplasîa is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell.
The pathological growth of activated lymphoid cells often results in an autoimmune disorder or a chronic inflammatory condition. As used herein, the term “autoimmune disorder” refers to any condition in which an organism produces antibodies or immune cells which recognize 25 the organism's own molécules, cells or tissues. Non-limiting examples of autoimmune disorders include autoimmune hemolytic anémia, autoimmune hepatitis, Berger’s disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave’s disease, Hashimoto’s thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, 30 rheumatic fever, rheumatic arthritis, scleroderma, SjÔgren’s syndrome, systemic lupus erythematosus, type 1 diabètes, ulcerative colitis, vitiligo, and the like.
The term “neoplastic disease, as used herein, refers to any abnormal growth of cells being either benign (non-cancerous) or malignant (cancerous).
The term melanoma as used herein refers to any form of cancer that begins in 35 mélanocytes. Melanoma includes, but is not limited to, the following subtypes: lentigo maligna, lentigo maligna melanoma, superficiel spreading melanoma, acral lentiginous melanoma, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, amelanotic melanoma, soft-tissue melanoma, and metastatic melanoma. Melanoma, as used herein also includes metastatic melanoma.
The term normal cell, as used herein, refers to a cell that is not undergoing abnormal growth or division. Normal cells are non-cancerous and are not part of any hyperproliferative disease or disorder.
The term “anti-neoplastic agent,” as used herein, refers to any compound that retards the prolifération, growth, or spread of a targeted (e.g., malignant) neoplasm.
The terms “prevent, “preventing,” and “prévention,” as used herein, refer to a decrease in the occurrence of pathological cells (e.g., hyperproliferative or neoplastic cells) in an animal. The prévention may be complété, e.g., the total absence of pathological cells in a subject. The prévention may also be partial, such that the occurrence of pathological cells in a subject is less than that which would hâve occurred without treatment with one or more compounds provided herein.
The terms a and an refer to one or more.
The term apoptosis-modulating agents, as used herein, refers to agents which are involved in modulating (e.g., inhibiting, decreasing, increasing, promoting) apoptosis. Examples of apoptosis-modulating agents include proteins which comprise a death domain such as, but not limited to, Fas/CD95, TRAMP, TNF RI, DR1, DR2, DR3, DR4, DR5, DR6, FADD, and RIP. Other examples of apoptosis-modulating agents include, but are not limited to, TNFa, Fas ligand, antibodies to Fas/CD95 and other TNF family receptors, TRAIL (also known as Apo2 Ligand or Apo2L/TRAIL), antibodies to TRAIL-R1 or TRAIL-R2, Bcl-2, p53, BAX, BAD, Akt, CAD, PI3 kinase, PP1, and caspase proteins. Modulating agents broadly include agonists and antagonists of TNF family receptors and TNF family ligands. Apoptosis-modulating agents may be soluble or membrane bound (e.g. ligand or receptor). Apoptosis-modulating agents include those which are inducers of apoptosis, such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-1 ligand, or TRAIL.
The term pharmaceutically acceptable carrier or pharmaceutically acceptable vehicle encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Suitable pharmaceutically acceptable vehicles include aqueous vehicles and nonaqueous vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995.
The term '‘alkyl” as used herein by itself or part of another group refers to a straight-chain or branched saturated aliphatic hydrocarbon having from one to eighteen carbons or the number of carbons designated (e.g., CrC1B means 1 to 18 carbons). In one embodiment, the alkyl is a Ci-C^ alkyl. In another embodiment, the alkyl is a C4-C8 alkyl. In another embodiment, the alkyl is a CrC6 alkyl. In another embodiment, the alkyl is a CrC4 alkyl. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, isohexyl, n-heptyl, 4,4-dimethylpentyl, n-octyl, 2,2,4-trimethylpentyl, nonyl, decyl and the like.
The term optionally substituted alkyl as used herein by itself or part of another group means that the alkyl as defined above is either unsubstituted or substituted with one, two or three substituents independently selected from hydroxy (i.e., -OH), nitro (/.e., -NO2), cyano (i.e., -CN), optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido. In one embodiment, the optionally substituted alkyl is substituted with two substituents. In another embodiment, the optionally substituted alkyl is substituted with one substituent. In another embodiment, the substituents are selected from hydroxyl (i.e., a hydroxyalkyl), optionally substituted cycloalkyl (i.e., a (cycloalkyl)alkyl), or amino (i.e., an aminoalkyl). Exemplary optionally substituted alkyl groups include -CH2OCH31 -CH2CH2NH2, CH2CH2NH(CH3), -CH2CH2CN, -CH2SO2CH3, hydroxymethyl, hydroxyethyl, hydroxypropyl, and the like.
The term alkylenyl” as used herein by itself or part of another group refers to a divalent alkyl radical containing one, two, three, four, or more joined methylene groups. Exemplary alkylenyl groups include -(CH2)-, -(CH2)2-, -(CH2)3-, -(CH2)4-, and the like.
The term optionally substituted alkylenyl as used herein by itself or part of another group means the alkylenyl as defined above is either unsubstituted or substituted with one, two, three, or four substituents independently selected from the group consisting of optionally substituted Ci-C8 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In one embodiment, the optionally substituted Ci-C6 alkyl is methyl. In one embodiment, the optionally substituted aryl is a phenyl optionally substituted with one or two halo groups. Exemplary optionally substituted alkylenyl groups include -CH(CH3)-, -C(CH3)2-, -CH2CH(CH3)-, -CH2CH(CH3)CH2-, -CH2CH(Ph)CH2-, -CH(CH3)CH(CH3)-, and the like.
The term haloalkyl as used herein by itself or part of another group refers to an alkyl as defined above having one to six halo substituents. In one embodiment, the haloalkyl has one, two or three halo substituents. Exemplary haloalkyl groups include trifluoromethyl, -CH2CH2F and the like.
The term hydroxyalkyl as used herein by itself or part of another group refers to an alkyl as defined above having one hydroxy substituent Exemplary hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl, and the like.
The term dihydroxyalkyl as used herein by itself or part of another group refers to alkyl as defined above having two hydroxyl substituents. Exemplary dihydroxyalkyl groups include CH2CH2CCH3(OH)CH2OH, -CH2CH2CH(OH)CH(CH3)OH, -CH2CH(CH2OH)2, CH2CH2CH(OH)C(CH3)2OH -CH2CH2CCH3(OH)CH(CH3)OH, and the like, including stereoisomers thereof.
The term hydroxycycloalkyl as used herein by itself or part of another group refers to an optionally substituted cycloalkyl as defined below having a least one, e.g., one or two, hydroxy substituents. Exemplary hydroxycycloalkyl groups include:
and the like, including stereoisomers thereof.
The term optionally substituted (cycloalkyl)alkyl as used herein by itself or part of another group refers to an optionally substituted alkyl as defined above having an optionally substituted cycloalkyl (as defined below) substituent. Exemplary optionally substituted (cycloalkyl)alkyl groups include:
and the like, including stereoisomers thereof.
The term aralkyl as used herein by itself or part of another group refers to an optionally substituted alkyl as defined above having one, two or three optionally substituted aryl substituents. In one embodiment, the aralkyl has two optionally substituted aryl substituents. In another embodiment, the aralkyl has one optionally substituted aryl substituent. In another embodiment, the aralkyl is an aryl(Ci-C4 alkyl). In another embodiment, the arylfCrC^ alkyl) has two optionally substîtuted aryl substituents. In another embodiment, the arylfCrC^ alkyl) has one optionally substîtuted aryl substituent. Exemplary aralkyl groups include, for example, benzyl, phenylethyl, (4-fluorophenyl)ethyl, phenylpropyl, diphenylmethyl (Le., Ph2CH-), diphenylethyi (Ph2CHCH2-) and the like.
The term cycloalkyl as used herein by itself or part of another group refers to saturated and partially unsaturated (containing one or two double bonds) cyclic hydrocarbon groups containing one to three rings having from three to twelve carbon atoms (Le., C3-C12 cycloalkyl) or the number of carbons desîgnated. In one embodiment, the cycloalkyl has one ring. In another embodiment, the cycloalkyl is a C3-C6 cycloalkyl. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl and the like.
The term “optionally substîtuted cycloalkyl” as used herein by itself or part of another group means the cycloalkyl as defined above is either unsubstituted or substîtuted with one, two or three substituents independently selected from halo, nitro, cyano, hydroxy, amino, optionally substîtuted alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aralkyl, optionally substîtuted cycloalkyl, optionally substîtuted alkenyl, optionally substîtuted alkynyl, optionally substîtuted aryl, optionally substîtuted heteroaryl, optionally substîtuted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido. The term optionally substîtuted cycloalkyl also means the cycloalkyl as defined above may be fused to an optionally substîtuted aryl. Exemplary optionally substîtuted cycloalkyl groups include:
and the like.
The term alkenyl as used herein by itself or part of another group refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds. In one embodiment, the alkenyl has one carbon-to-carbon double bond. Exemplary alkenyl groups include -CH=CH2, -CH2CH=CH2, -CH2CH2CH=CH2, -CH2CH2CH=CHCH3 and the like.
The term optionally substîtuted alkenyl as used herein by itself or part of another group means the alkenyl as defined above is either unsubstituted or substîtuted with one, two or three substituents independently selected from halo, nitro, cyano, hydroxy, amino, optionally substîtuted alkyl, haloalkyl, hydroxyalkyl, aralkyl, optionally substîtuted cycloalkyl, optionally substîtuted alkenyl, optionally substîtuted alkynyl, optionally substîtuted aryl, optionally substîtuted heteroaryl, optionally substîtuted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido. Exemplary optionally substituted alkenyl groups include -CH=CHPh, -CHzCH=CHPh and the like.
The term cycloalkenyl as used herein by îtself or part of another group refers to a cycloalkyl group as defined above containing one, two or three carbon-to-carbon double bonds. In one embodiment, the cycloalkenyl has one carbon-to-carbon double bond. Exemplary cycloalkenyl groups include cyclopentene, cyclohexene and the like.
The term optionally substituted cycloalkenyl as used herein by îtself or part of another group means the cycloalkenyl as defined above is either unsubstituted or substituted with one, two or three substituents independently selected from halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, aralkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido.
The term alkynyl as used herein by îtself or part of another group refera to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-to-carbon triple bond. Exemplary alkynyl groups include -C=CH, -CeCCH3, -CH2C=CH, -ΟΗ2ΟΗ2ΟξΟΗ and -CH2CH2C=CCH3.
The term optionally substituted alkynyl as used herein by itself or part of another group means the alkynyl as defined above is either unsubstituted or substituted with one, two or three substituents independently selected from halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, aralkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido. Exemplary optionally substituted alkenyl groups include -C=CPh, -CH2C^CPh and the like.
The term aryl as used herein by itself or part of another group refera to monocyclic and bicyclic aromatic ring Systems having from six to fourteen carbon atoms (/.e., Ο6-Ο14 aryl) such as phenyl (abbreviated as Ph), 1-naphthyl and 2-naphthyl and the like.
The term “optionally substituted aryl as used herein by itself or part of another group means the aryl as defined above is either unsubstituted or substituted with one to five substituents independently selected from halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, aralkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido. In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent. Exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl and 3,5dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, 3-chloro-4-fluorophenyl and the like, The term optionally substituted aryl is meant to include groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Examples include:
and the like.
The term heteroaryl as used herein by itself or part of another group refers to monocyclîc and bicyclic aromatic ring Systems having from five to fourteen carbon atoms {i.e., C5-C14 heteroaryl) and one, two, three or four heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur. In one embodiment, the heteroaryl has three heteroatoms. In one embodiment, the heteroaryl has two heteroatoms. In one embodiment, the heteroaryl has one heteroatom. Exemplary heteroaryl groups include 1-pyrrolyl, 2pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, purinyl, 2benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 2-benzthiazolyl, 4-benzthiazolyl, 5benzthiazolyl, 5-indolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 1-isoquinolyl, 5-isoquinolyl, 2quinoxalinyl, 5-quinoxalinyl, 2-quinolyl 3-quinolyl, 6-quinolyl and the like. The term heteroaryl is meant to include possible N-oxides. Exemplary N-oxides include pyridyl Noxide and the like.
The term optionally substituted heteroaryl as used herein by itself or part of another group means the heteroaryl as defined above is either unsubstituted or substituted with one to four substituents, typically one or two substituents, independently selected from halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, aralkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido or sulfonamido. In one embodiment, the optionally substituted heteroaryl has one substituent In another embodiment, the substituent is an optionally substituted aryl, araîkyl, or optionally substituted alkyl. In another embodiment, the substituent is an optionally substituted phenyl. Any available carbon or nitrogen atom may be substituted. Exemplary optionally substituted heteroaryl groups include:
Ph Ph
and the like.
The term heterocyclo as used herein by itself or part of another group refers to saturated and partially unsaturated (containing one or two double bonds) cyclic groups containing one to three rings having from two to twelve carbon atoms (i.e., C2-Ci2 heterocyclo) and one or two oxygen, sulfur or nitrogen atoms. The heterocyclo can be optionally linked to the rest of the molécule through a carbon or nitrogen atom. Exemplary heterocyclo groups include:
and the like.
The term “optionally substituted heterocyclo as used herein by itself or part of another group means the heterocyclo as defined above is either unsubstituted or substituted with one to four substituents independently selected from halo, nitro, cyano, hydroxy, amino, optionally substituted alkyl, haloalkyl, hydroxyalkyl, aralkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, -CORC, -SO2Rd, -N(Re)CORf, -N(Re)SO2R9 or -N(Re)C=N(Rh)-amino, wherein Rc is hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl; Rd is optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R® is hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl; Rf is hydrogen, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R9 is optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and Rh is hydrogen, -CN, optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl. Substitution may occur on any available carbon or nitrogen atom. Exemplary substituted heterocyclo groups include:
and the like. An optionally substituted heterocyclo may be fused to an aryl group to provide an optionally substituted aryl as described above.
The term alkoxy as used herein by itself or part of another group refers to a haloalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom. Exemplary alkoxy groups include methoxy, tert-butoxy, -OCH2CH=CH2 and the like.
The term aryloxy as used herein by itself or part of another group refers to an optionally substituted aryl attached to a terminal oxygen atom. Exemplary aryloxy groups include phenoxy and the like.
The term aralkyloxy as used herein by itself or part of another group refers to an aralkyl attached to a terminal oxygen atom. Exemplary aralkyloxy groups include benzyloxy and the like.
The term alkylthio as used herein by itself or part of another group refers to a haloalkyl, aralkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal sulfur atom. Exemplary alkyl groups include -SCH3 and the like.
The term halo or halogen as used herein by itself or part of another group refers to fluoro, chloro, bromo or iodo. In one embodiment, the halo is fluoro or chloro.
The term amino as used herein by itself or part of another group refers to a radical of formula -NRaRb wherein Ra and Rb are independently hydrogen, haloalkyl, aralkyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl or optionally substituted heteroaryl; or Ra and Rb taken together with the nitrogen atom to which they are attached form a four to seven membered optionally substituted heterocyclo. Exemplary amino groups include -NH2, -N(H)CH3, -N(CH3)2, N(H)CH2CH3, N(CH2CH3), -N(H)CH2Ph and the like.
The term carboxamido as used herein by itself or part of another group refers to a radical of formula -CO-amino. Exemplary carboxamido groups include -CONH2, -CON(H)CH3, CON(H)Ph, -CON(H)CH2CH2Ph, -CON(CH3)2, CON(H)CHPh2 and the like.
The term sulfonamido as used herein by itself or part of another group refers to a radical of formula -S02-amino. Exemplary sulfonamido groups include -SO2NH2, -SO2N(H)CH3, SO2N(H)Ph and the like.
The term about, as used herein, includes the recited number ± 10%. Thus, about 10 means 9 to 11.
Certain of the compounds of the présent disclosure may exist as stereoisomers, Le., isomers that differ only in the spatial arrangement of atoms, încluding optîcal isomers and conformational isomers (or conformers). The disclosure includes ail stereoisomers, both as pure individual stereoisomer préparations and enriched préparations of each, and both the racemic mixtures of such stereoisomers as well as the individual diastereomers and enantiomers that may be separated according to methods that are well known to those of skill in the art.
The term substantially free of’ as used herein means that the compound comprises less than about 25% of other stereoisomers, e.g., diastereomers and/or enantiomers, as established using conventional analytical methods routinely used by those of skill in the art. In some embodiments, the amount of other stereoisomers is less than about 24%, less than about 23%, less than about 22%, less than about 21%, less than about 20%, less than about 19%, less than about 18%, less than about 17%, less than about 16%, less than about 15%, less than about 14%, less than about 13%, less than about 12%, less than about 11%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, iess than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, or less than about 0.5%.
Stereoisomerically enriched compounds that contain about 95% or more of a desired stereoisomer, for example, about 96% or more, about 97% or more, about 98% or more, or about 99% or more are referred to herein as substantially pure or substantially pure stereoisomers.
Stereoisomerically enriched compounds that contain about 99% or more of a desired stereoisomer are referred to herein as pure or pure stereoisomers. The purity of any stereoisomerically enriched compound can be determined using conventional analytical methods such as, for example, normal phase HPLC, reverse phase HPLC, chiral HPLC, and ’Hand 13C NMR.
Compounds
In certain embodiments, compounds of Formula I are provided:
wherein:
R1a, R1b, R1c, and R1d are independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, cyano, alkoxy, aryloxy, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, carboxamido, and sulfonamido;
R2 is selected from the group consisting of optionally substituted aryl, aralkyl, and optionally substituted heteroaryl;
R3 is selected from the group consisting of optionally substituted alkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl;
R4 is selected from the group consisting of hydrogen and optionally substituted alkyl;
R5 is selected from the group consisting of:
wherein:
each R6a and Reb is îndependently selected from the group consisting of hydrogen and optionally substituted Ci-C6 alkyl;
R7 is selected from the group consisting of hydrogen, optionally substituted Ci-C6 alkyl, and optionally substituted cycloalkyl;
R8a and R8b are each îndependently selected from the group consisting of hydrogen, optionally substituted CrC6 alkyl, and optionally substituted cycloalkyl; or
R8a and Rab taken together with the carbon that they are attached form a 3to 8-membered optionally substituted cycloalkyl;
W1 is selected from the group consisting of -OR9a and -NR9bR9c;
R9a is hydrogen;
R9b is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -SO2R9d, and -CONR9eR9f;
R9c is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R9b and R9c taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R9d is selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl;
R9e and R9i are each îndependently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; or zx
R9e and R9f taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
W2 is selected from the group consisting of -OR10 and -NR11aR11b;
with the proviso that when W1 is -OR9a and W2 is -OR10 then at least one of R7, R8a, and R8b is other than hydrogen;
R10 is hydrogen; or one of R9a and R10 is hydrogen and the other is a metabolically cleavable group;
R11a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -SO2R11c, and -CONR11dR11e;
R11b is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R11a and R11b taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R11c is selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl;
R11d and R11e are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; or
R11d and R11® together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
n is 1,2, 3, 4, or 5;
each R1Za, R12b, R12c and R12d is independently selected from the group consisting of hydrogen and optionally substituted C^Ce alkyl;
R13 is selected from the group consisting of hydrogen and optionally substituted CrC6 alkyl;
R14 is selected from the group consisting of hydrogen, optionally substituted CtCs alkyl, and optionally substituted cycloalkyl;
Z is selected from the group consisting of -OR15 and -NR16aR16b; or
Z and R14 taken together form a carbonyl, i.e., a C=O, group.
R15 is selected from the group consisting of hydrogen and metabolically cleavable group;
R16a is selected from the group consisting of -SO2Riec and -CONR16dR16e;
R16b is selected from the group consisting of hydrogen and optionally substituted alkyl;
R16c is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R10d and R16® are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R16d and R16® taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocyclo;
is 1, 2, or 3;
p is 0, 1, 2, or 3;
each R17a, R17b, R17c and R17d is independently selected from the group consisting of hydrogen and optionally substituted Cj-Ce alkyl;
R18 is selected from the group consisting of hydrogen and optionally substituted Ci-C6 alkyl;
R19 is selected from the group consisting of hydrogen, optionally substituted Ci-C6 alkyl, and optionally substituted cycloalkyl;
R20 is selected from the group consisting of hydrogen, optionally substituted Ci-C6 alkyl, and optionally substituted cycloalkyl;
R21® and R21b are each hydrogen; or one of R21a and R21b is hydrogen and the other is metabolically cleavable group;
q is 0,1,2, or 3;
r is 1, 2, or 3;
each R22a, R22b, R22c, and R22d is independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;
R23 is selected from the group consisting of hydrogen and optionally substituted CpCg alkyl;
R24 is selected from the group consisting of -SO2R24a and -CONR24bR24c;
R24a is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R24b and R24c are each independently selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R24b and R24c taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocyclo;
s and t are each independently 1, 2, or 3;
X is selected from the group consisting of O, S, and NR*;
Y is selected from the group consisting of O, S, and NR;
R' is selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, and optionally substituted cycloalkyl;
R is selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, optionally substituted cycloalkyl, and -COR31;
R31 is selected from the group consisting of hydrogen and optionally substituted alkyl; and ~ represents a single or a double bond, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, for the compounds of Formula I, ~ represents a single bond.
In certain embodiments, the compound of Formula I is a mixture of stereoisomers, e.g., a mixture of diastereomers and/or enantiomers, e.g., a racemic mixture. In another such embodiment, the compound is a mixture of diastereomers. In another such embodiment, the compound is a mixture of enantiomers. In particular embodiments, the compound is a single enantiomer.
In certain embodiments, R5 is selected from the group consisting of R5-1 and R5-2. In particular embodiments, R5 is R5-2 and Z is -OH. In particular embodiments, R5 is R5-2A and Z is OH.
In certain embodiments, compounds of Formula la are provided:
wherein R1a, R1b, R1c, R1d, R2, R3, R4, R5, X, and Y hâve the meanings as described above for Formula I, or pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, compounds of Formula Ib are provided:
wherein R1a, R1b, R1c, R1d, R2, R3, R4, R5, X, and Y hâve the meanings as described above for Formula I, or tautomer thereof, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, compounds of Formula ll-XVII are provided:
wherein R1a, R1b, R1c, R1d, R2, R3, R4, R5, X, and Y hâve the meanings as described above for Formula I, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula II are provided, wherein R1a, R1b, R1c, R1d, R2, R3, R4, R5, X, and Y hâve the meanings as described above in connection with Formula I, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula II are substantially free of one or more other stereoîsomers, i.e., compounds of Formulae lll-XVII. In some embodiments, compounds of
Formula II are substantially pure stereoisomers. In some embodiments, compounds of
Formula II are pure stereoisomers.
In some embodiments, compounds of Formula XIII are substantially free of one or more other stereoisomers. In some embodiments, compounds of Formula XIII are substantially pure stereoisomers. In some embodiments, compounds of Formula XIII are pure stereoisomers.
In some embodiments, compounds of Formula XIV are substantially free of one or more other stereoisomers. In some embodiments, compounds of Formula XIV are substantially pure stereoisomers. In some embodiments, compounds of Formula XIV are pure stereoisomers.
In some embodiments, compounds of Formula VI are provided, wherein R1a, R1b, R1c, R1d, R2, R3, R4, R5, X, and Y hâve the meanings as described above in connection with Formula I, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula VI are substantially free of one or more other stereoisomers, i.e., compounds of Formulae ll-V and VII-XVII. In some embodiments, compounds of Formula VI are substantially pure stereoisomers. In some embodiments, compounds of Formulae VI are pure stereoisomers.
In some embodiments, compounds of Formula X are provided, wherein R1a, R1b, R1c, R1d, R2, R3, R4, Rs, X, and Y hâve the meanings as described above in connection with Formula I, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula X are substantially free of one or more other stereoisomers, i.e., compounds of Formulae ll-IX and XI-XVII. In some embodiments, compounds of Formula X are substantially pure stereoisomers. In some embodiments, compounds of Formula X are pure stereoisomers.
In some embodiments, compounds of Formula XII are provided, wherein R1a, R1b, R1c, R1d, R2, R3, R4, R5, X, and Y hâve the meanings as described above in connection with Formula I, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula XII are substantially free of one or more other stereoisomers, i.e., compounds of Formulae ll-XI and XIII-XVII. In some embodiments, compounds of Formula XII are substantially pure stereoisomers. In some embodiments, compounds of XII are pure stereoisomers.
In some embodiments, compounds of Formula XII are unexpectedly more potent than compounds of Formulae ll-XI and XIII-XVII. For example, as demonstrated herein, compounds of Formula XII hâve lower IC50 values than compounds of Formulae ll-XI and XIII-XVII against MDM2. In some embodiments, compounds of Formula XII are about 2-fold or more, e.g., about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 834 fold, about 9-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, or more, more potent than compounds of Formula H in fluorescence polarization-based MDM2 binding assays. In some embodiments, compounds of Formula XII are unexpectedly more efficacious than compounds of Formulae ll-XI and XIII-XVII in xenograft tumor models in mice and/or in other in vivo efficacy models.
In certain embodiments, compounds of Formulae l-XVII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided. In some embodiments, compounds of Formulae II, VI, X, and XII, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein:
a) R1a, R1b, R1c, and R1d are independently selected from the group consisting of hydrogen, fluoro, and chloro;
b) R1a and R1d are hydrogen; R1b is selected from the group consisting of hydrogen and fluoro; and R1c is selected from the group consisting of fluoro and chloro;
c) R2 is optionally substituted phenyl;
d) R3 is selected from the group consisting of optionally substituted alkyl, optionally substituted (cycloalkyl)alkyl, and optionally substituted cycloalkyl;
e) R4 is hydrogen;
f) X is NH;
g) X is O;
h) X is S;
i) Y is O;
j) Y is S;
k) Yis NH;or
l) X and Y are NH;
or any combination thereof.
In certain embodiments, compounds of Formulae 11, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-1 ; R6a and R6b are hydrogen; R7 is C1-C4 alkyl; R8a and R8b are hydrogen; W is -OR10, R9 and R10 are hydrogen; and n is 2.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-1; R6a and R6b are hydrogen; R7 is CrC4 alkyl; R8a and R8b are hydrogen; W is -NR11aR11b, R9is hydrogen; and n is 2.
In certain embodiments, the compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein Rs is R5-1; R6a and R6b are hydrogen; R7 is C1-C4 alkyl; Rea and R8b are hydrogen; W is -OR10, one of R9 and R10 is hydrogen and the other is a metabolically cleavable group; and n is 2.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-2; R12a, R12b, R12c, and R1Zd are each hydrogen; R13 is hydrogen; Z is -OR15 and R15 is hydrogen; o is 1 or 2; and p is 1 or 2.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-2; R12a, R1Zb, R12c, and R12d are each hydrogen; R13 is hydrogen; Z is -NR16aR16b; o is 1 or 2; and p is 1 or 2.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-2; R12a, R12b, R12c, and R12d are each hydrogen; R13 is hydrogen; Z is -OR15 and R15 a metabolically cleavable group; o is 1 or 2; and p is 1 or 2.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-3; R17a, R17b, R17c, and R17d are each hydrogen; R18, R19, and R20 are hydrogen; R21a and R21b are hydrogen; and q and r are 1.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-3; R17a, R17b, R17c, and R17d are each hydrogen; R18, R19, and R20 are hydrogen; one of R21a and R21b is hydrogen and the other is a metabolically cleavable group; and q and r are 1.
In certain embodiments, compounds of Formulae 11, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is R5-2A.
In certain embodiments, compounds of Formulae 11, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R2 is selected from the group consisting of aralkyl and optionally substituted aryl having the Formula R2-1:
R2-1 and R2Sa, R25b, R25c, R25d, and R25e are each independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, amino, cyano, alkoxy, optionally substituted alkyl, haloalkyl, optionally substituted aryl, and optionally substituted heteroaryl. In particular embodiments, R25a is selected from the group consisting of hydrogen and fluoro; R25b is chloro; R25c is selected from the group consisting of hydrogen and fluoro; and R25d and R25e are hydrogen.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the 5 group consisting of:
R5-9
\ | |||
—NR16aR16b | |||
-OR15 | C | >14 | |
R14 | |||
R5-10 | R5-11 |
R14
—NR16aR16b . R14 4 | |
n R5-13 R5'14 |
R5-12
o19 0R£,d
R5-18
R5-17 including stereoisomers, e.g., enantiomers, thereof, wherein:
R7 is optionally substituted CrC4 alkyl;
R9a and R10 are each hydrogen; or one of R9a and R10 is hydrogen and the other is a metabolically cleavable group;
R9b is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -SO2R9d, and -CONR9eR9f;
R9c is selected from the group consisting of hydrogen, optionally substîtuted alkyl, optionally substîtuted cycloalkyl, optionally substîtuted aryl, and optionally substituted heteroaryl; or
R9b and R9c taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R9d is selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl;
R9® and R9f are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; or
R9® and R9f taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R11a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -SO2R11c, and -CONR11dR11®;
R11b is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R11a and R11b taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R11c is selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl;
R11d and R11® are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; or
R11d and R11® taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R14 is selected from the group consisting of hydrogen, CrC4 alkyl, or C3-C6 cycloalkyl;
R15 is hydrogen or a metabolically cleavable group;
R16a is selected from the group consisting of -SO2R16c and -CONRiedR16®;
R16b is selected from the group consisting of hydrogen and optionally substituted alkyl;
R16c is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R16d and R1Be are each îndependently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R16d and R16e taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocyclo;
R1S is selected from the group consisting of hydrogen, optionally substituted CrCe alkyl, and optionally substituted cycloalkyl;
R20 is selected from the group consisting of hydrogen, optionally substituted Ci-C6 alkyl, and optionally substituted cycloalkyl;
R21a and Rz1b are each hydrogen; or one of R21a and R21b is hydrogen and the other is metabolically cleavable group;
R24 is selected from the group consisting of -SO2R24a and -CONR24bR24c;
R24a is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
R24b and R24c are each îndependently selected from the group consisting of hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or
R24b and R24c taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocyclo.
In certain embodiments, Rs is selected from the group consisting of R5-5, R5-6, R5-10, R511, R5-12, R5-13, and R5-14.
In certain embodiments, R5 is selected from the group consisting of R5-10 and R5-12 and R14 is hydrogen or methyl and R15 is hydrogen.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the group consisting of:
wherein:
R7 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, and cyclopropyl; and
RSa and R8b are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and cyclopropyl.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the
group consisting of: | ||
OH j\^NHSO2R11c R7 | OH / x/—NHSO2R110 R7 | OH /\^^]\,nhso2r11c R7] R8a |
f
11c
NHSO2R
Reb R8a
I
and
11c
NHSO2R£ld
OH Reb R8a
R7 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, and cyclopropyl;
R8a and R8b are each independently is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and cyclopropyl;
R9d is selected from the group consisting of methyl, trifluoromethyl, ethyl, propyl, isopropyl, and cyclopropyl; and
R11c is selected from the group consisting of methyl, trifluoromethyl, ethyl, propyl, isopropyl, and cyclopropyl.
In certain embodiments, compounds of Formulae II, VI, X, and XII or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the group consisting of:
OH /jF,NHCONHR11d
R7
NHCONHR110
11d
OH | OH | OH | |
z-F NHCONHR11d | k,NHCONHR11d / X | —F, NHCONHR11d | |
R7 T | R7 | h3ô P’R0b | |
R0a | R8a | R8a |
NHCONHR9®
NHCONHR9®
R7
NHCONHR9®
NHCONHR9®
R8®
NHCONHR9®
OH
and
NHCONHR9®
R8a
R7 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, and cyclopropyl;
R0a and Reb are each independently is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and cyclopropyl;
RSe is selected from the group consisting of methyl, trifluoromethyl, ethyl, propyl, isopropyl, and cyclopropyl; and
R11d is selected from the group consisting of methyl, trifluoromethyl, ethyl, propyl, isopropyl, and cyclopropyl.
In certain embodiments, compounds of Formulae II, VI, X, and XII, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the group consisting of:
wherein:
R14 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, and cyclopropyl; and
R19 and R20are each independently is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and cyclopropyl.
In certain embodiments, compounds of Formulae II, VI, X, and XII, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the 10 group consisting of:
NHSO2R16c s
NHSO2R16c ^Ÿ^'R14
NHSO2R16c
vr14 | —L , | |
NHSO2R16c | NHSO2R16c | ''NHSO2R16c |
M—NHSO2R16c R14 | L—|,,,NHSQ2R16c , R14 | Y Xxx^knhso2r16c |
ΖΌ· nhso2r16c | <Y-nhso2r16c K'· | /xo , LJ'''Nhso2r16c R14 |
^^Y^ -'NHSOzR160 , | T Y’NHSO2R16c | |
r V-NHSO2R16c , | *Y^\j'NHSO2R16c | **LG\-NHSO2R16c ' Y 4 |
\ \>'NHSO2R16c LVV R14 | A \ >-NHSO2R16c , X__< Υ7Ύ4 *nhso2r16c | |
and ' F^A-NHSOjR 16c . k__/ W NHSO2R16c |
16c wherein:
R14 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, and cyclopropyl; and
R16c is selected from the group consisting of methyl, trifluoromethyl, ethyl, propyl, isopropyl, and cyclopropyl.
In certain embodiments, compounds of Formulae II, VI, X, and XII, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is selected from the group consisting of:
NHCONHR16d
NHC0NHRied
NHCONHR16d
NHCONHR16d ’
NHCONHR
16d
\hconhr1m
L4“NHC0NHRied '
R14
A.
I—rNHCQNHR16d r!4 '^/NHCONHR16d h, /γγ <^-NHCONHR16d
NHCONHRied R14 <J-NHCONHRied ,
R14 ^*S^2/t '‘NHCONHR16d , ^'^^/-‘NHCONHR1611
Γ \->'NHCONHR16d , ^*\^\-NHCONHR16d
t. Λ.
Qr N.HC0NHR'“ ^NHCONHR''^^-nhconhr160 t^xY2S:^4HCONHRl6d
NHCONHR16d
wherein:
R14 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, and cyclopropyl; and
R16d is selected from the group consisting of methyl, trifluoromethyl, ethyl, propyl, isopropyl, and cyclopropyl.
In certain embodiments, compounds of Formulae II, VI, X, and XII, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof are provided, wherein R5 is:
In another embodiment, compounds of Formula XVIIIa are provided:
XVIIIa ιο wherein:
R1b and R1c are independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is selected from the group consisting of optionally substituted alkyl, optionally substituted (cycloalkyl)alkyl, and, optionally substituted aryl, optionally substituted cycloalkyl;
R26a, R26b, and R26c are independently selected from the group consisting of hydrogen, fluoro, and chloro; and
R27 is selected from the group consisting of:
OR0a
R7
R27-3
R14
R27-4
Z
I
R14
R14
R14
OR21b
21a
»
R27-6
R27-7 »
R27-20 ' OR21b .
R27-24
R27-22
K /
i pis' OR21b
R27-27
R27-25
R27-26
R20 Î-OR21a
R
A>or210
R i-0R21a
R20
R14
R27-9
R27-19
R27-23
R27-18
R14
R14
R27-21
R10'' 0R21b
_ Z R14
R27-28
R27-29
R27-31
R27-32
R27-30 wherein:
R7 is optionally substituted 0ν04 alkyl;
W2 is selected from the group consisting of-OR10 and -NR11aR11b;
R9a and R10 are each hydrogen; or one of R9a and Rw is hydrogen and the other is a metabolically cleavable group;
R11a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -SO2R11c, and -CONR11dR11e;
R11b is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R11a and R11b taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R11c is selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl;
R11d and R11e are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; or
R11d and R11e taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R14 is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, and optionally substituted cycloalkyl;
Z is selected from the group consisting of -OR15 and -NR16aR16b;
R1S is selected from the group consisting of hydrogen and metabolically cleavable group;
R16a is selected from the group consisting of -SO2R16c and -CONR16dR16e;
R16b is selected from the group consisting of hydrogen and optionally substituted alkyl;
R16c is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R16d and R16b are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R16d and R16® taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocyclo;
R19 is selected from the group consisting of hydrogen, optionally substituted CrCe alkyl, and optionally substituted cycloalkyl;
R20 is selected from the group consisting of hydrogen, optionally substituted CrC6 alkyl, and optionally substituted cycloalkyl;
R21a and R21b are each hydrogen; or one of R21a and R21b is hydrogen and the other is metabolically cleavable group;
or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In another embodiment, compounds of Formula XVIIIb are provided:
r2Y | |
H ^N'r27 | |
R26a | NH |
R1£ | |
υυλ | ?R3 |
*0 XVIIIb |
wherein R1b, R1b, R3, R26a, R26b, R26c, and R27 hâve the meanings as described above for Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In another embodiment, compounds of Formula XVIIIc are provided:
XVIIIc wherein R1b, R1b, R3, R26a, R26b, R26c, and R27 hâve the meanings as described above for Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, R27 is selected from the group consisting of R27-2, R27-3, R27-5, R27-6, R27-8, R27-9, R27-11, R27-12, R27-14, R27-15, R27-16, R27-17, R27-19, R27-20, R27-21, R27-22, R27-24, R27-25, R27-27, R27-29, R27-30, R27-31, and R27-32. In certain embodiments, R27 is selected from the group consisting of R27-2, R27-3, R27-5, and R27-6, R27-8, R27-9, R27-14, R27-15, R27-16, and R27-17. In certain embodiments, R27 is a hydroxycycloalkyl group.
In certain embodiments, R9a is hydrogen; W2 is OH; Z is OH; R7 is CrC4 alkyl, e.g., methyl, ethyl, propyl, or isopropyl, or cyclopropyl; R14, R19, and R20 are each independently hydrogen, CrC4 alkyl, e.g., methyl, ethyl, propyl, or isopropyl, or cyclopropyl; and R21a and
R21b are each hydrogen.
In certain embodiments, R9a is hydrogen, R7 is hydrogen, CrC4 alkyl, or cyclopropyl; W2 is NHR11a; R11a is CrC4 alkyl, e.g., methyl, trifluoromethyl, ethyl, propyl, or isopropyl, or 5 cyclopropyl; R14 is hydrogen, Ci-C4 alkyl, e.g., methyl, ethyl, propyl, or isopropyl, or cyclopropyl; Z is -NHSO2R16c or -NHC0NHR16d; and R16c and R16d are each independently optionally substituted CrC4 alkyl, e.g., methyl, trifluoromethyl, ethyl, propyl, or isopropyl, or cyclopropyl.
In certain embodiments, compounds of Formulae XIX-XXXIV are provided:
XXIII
XXIV
XXV
XXVI
XXVIII XXIX
XXVII
XXX
XXXI
XXXII
XXXI 11
XXXIV wherein R1b, R1c, R3, RZ6a, R26b, R26c, and R27 hâve the meanings as described above in connection with Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, compounds of Formula XIX are provided, wherein R1b, R1c, R3, R26a, R26b, R26c, and R27 hâve the meanings as described above in connection with Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula XIX are substantially free of one or more other stereoisomers, i.e., compounds of Formulae XX-XXXIV. In some embodiments, compounds of Formula XIX are substantially pure stereoisomers. In some embodiments, compounds of Formula XIX are pure stereoisomers.
In certain embodiments, compounds of Formula XXIII are provided, wherein R1b, R1c, R3, R26a, RZ6b, R26c, and R27 hâve the meanings as described above in connection with Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula XXIII are substantially free of one or more other stereoisomers, i.e., compounds of Formulae XIX-XXII and XXIV-XXXIV. In some embodiments, compounds of Formula XXIII are substantially pure stereoisomers. In some embodiments, compounds of Formula XXIII are pure stereoisomers.
In certain embodiments, compounds of Formula XXVII are provided, wherein R1b, R1c, R3, R26a, RZ6b, R26c, and R27 hâve the meanings as described above in connection with Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula XXVII are substantially free of one or more other stereoisomers, i.e., compounds of Formulae XIX-XXVI and XXVIII-XXXIV. In some embodiments, compounds of Formula XXVII are substantially pure stereoisomers. In some embodiments, compounds of Formula XXVII are pure stereoisomers.
In certain embodiments, compounds of Formula XXIX are provided, wherein R1b, R1c, R3, R26a, R26b, R26c, and R27 hâve the meanings as described above in connection with Formula XVIIIa, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds of Formula XXIX are substantially free of one or more other stereoisomers, i.e., compounds of Formulae XIX-XXVIII and XXX-XXIV. In some embodiments, compounds of Formula XXIX are substantially pure stereoisomers. In some embodiments, compounds of Formula XXIX are pure stereoisomers.
In certain embodiments, compounds of Formulae XIX, XXIII, XXVII, and XXIX are provided, wherein R27 is selected from the group consisting of:
0R9a
R7
R27-34 >
NR11aR11b
0R9a ^n-T^NR11aR11b
R7
R27-36
R14
OR15
R14
R14
•OR15 »
R27-37
R27-38
R14
R27-40
Vx^-NHR168 r’14
R14 »
R27-41
R27-42
R27-39
16a
'NHR16®
R14
R27-44
R27-45 R 27 -46
R27-47
R27-48
R27-49 R27-50 R27-51
R27-52
y or15 | i OR15 'V'R . | y or15 | y or15 * f'*t F VS14 |
R27-55 | R27-56 | ||
R27-53 | R27-54 | ||
/ NHR16a M- . | i NHRiea >/'-R» . | J NHR10a | J NHR1Sa and VV4 |
R27-57 | R27-58 | R27-59 | R27-60 |
wherein:
R7is C1-C4 alkyl;
R9a and R10 are hydrogen; or one of R9a and R10 is hydrogen and the other is metabolically cleavable group;
R11a and R11b are each independently selected from the group consisting of hydrogen, optionally substituted CrC4 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
or
R11a and R11b taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R14 is selected from the group consisting of hydrogen and Ci-C4 alkyl;
R15 is hydrogen or a metabolically cleavable group; and
R16a is selected from the group consisting of -SC^R160 and -CONR16dR16e;
R16c is selected from the group consisting of optionally substituted Ci-C4 alkyl or cyclopropyl;
R16d and R16e are each independently selected from the group consisting of hydrogen, optionally substituted CrC4 alkyl or cyclopropyl; or
R16d and R16® taken together with the nitrogen atom to which they are attached form a 4- to 8-membered heterocyclo, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, compounds of Formulae XIX, XXIII, XXVII, and XXIX are provided, wherein R27 is selected from the group consisting of:
OR0a
OR0a
W2
OR0a
R27-63
I
OR0a
X Ni2
R7 ~
R27-65
I
R27-66
R7 =
R27-68
OR0a
wherein:
R7 is optionally substituted 0^04 alkyl;
W2 is selected from the group consisting of-OR10 and -NR11aR11b;
R0aand R10 are each hydrogen; or one of R9a and R10 is hydrogen and the other is a metabolically cleavable group;
R11a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -S02R11c, and -CONR11dR11e;
R11b is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; or
R11a and R11b taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
R11c is selected from the group consisting of optionally substituted alkyl and optionally substituted cycloalkyl;
R11d and R11e are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted cycloalkyl; or
R11d and R11e taken together with the nitrogen atom to which they are attached form a 4- to 8-membered optionally substituted heterocyclo;
or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, compounds of Formulae XIX, XXIII, XXVII, and XXIX are provided, wherein R27 is selected from the group consisting of:
OH
OH ^d“0H
H3C
OH
OH
OH ch3 ch3 ν^2/’··ΌΗ , Λ'Χ> ° /.....Q-0H
/vQ\OH 1 ch3 | /sQr0H ^οη3 |
zVoh | . zV'oh |
Λ.
V0H ch3
ΟΗ
In certain embodiments, compounds of Formulae XIX, XXIII, XXVII, and XXIX are provided, wherein R27 is selected from the group consisting of;
wherein R11a and R116 taken together with the nitrogen to which they are attached form a 5- or 6-membered optionally substituted heterocyclo.
In certain embodiments, compounds of Formulae XIX, XXIII, XXVII, and XXIX are provided, 10 wherein R27 is selected from the group consisting of;
R14 is selected from the group consisting of hydrogen and Ci-C4 alkyl; and
R15 is a metabolically cleavable group.
In certain embodiments, compounds of Formulae II, VI, X, XII, XIX, XXIII, XXVII, and XXIX are provided, wherein R15 is a metabolically cleavable group selected from the group consisting of:
O R29a o ^x^vS)'N'R29b and s XR—OR30a R28a1’ R2eb OR30b wherein:
each Rzea and R28b is îndependently selected from the group consisting of hydrogen, optionally substituted alkyl, and aralkyl;
RZ9a and R29b are each selected from the group consisting of hydrogen and optionally substituted alkyl;
vis 1, 2, 3, or4; and
R30a and R30b are each selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, optionally substituted aryl, and monovalent pharmaceutically acceptable cation; or taken together R30a and R30b represent a divalent pharmaceutically acceptable cation or an optionally substituted alkylenyl.
In certain embodiments, R15 is the residue of a natural or unnatural amino acid. In other embodiments, R15 is the residue of glycine, îsoleucine alanine, leucine, asparagine, lysine, aspartic acid, méthionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, valine, proline, serine, tyrosine, arginine, and histidine.
In certain embodiments, compounds of Formulae II, VI, X, XII, XIX, XXIII, XXVII, and XXIX are provided, wherein R3 is CrC10 alkyl.
In certain embodiments, compounds of Formulae II, VI, X, XII, XIX, XXIII, XXVII, and XXIX are provided, wherein R3 is selected from the group consisting of -CH2C(CH3)3, CH2C(CH3)2CH2CH3, -CH2C(CH3)2CH2CH2CH3, -CH2C(CH3)2CH2CH2CH2CH31 -CH2C(CH2CH3)2CH3, and -CH2C(CH3)2CH2CH(CH3)2. In certain embodiments, R3 is -CH2C(CH3)3.
In certain embodiments, compounds of Formulae II, VI, X, XII, XIX, XXIII, XXVII, and XXIX are provided, wherein R3 is optionally substituted aryl.
In certain embodiments, compounds of Formulae II, VI, X, XII, XIX, XXIII, XXVII, and XXIX are provided, wherein R3 is optionally substituted phenyl.
In some embodiments, compounds of Formulae XIX, XXIII, XXVII, and XXIX are provided wherein R1b, R1c, R26a, R26b, and R26c are each independently selected from the group consisting of hydrogen and halogen, e.g., chloro or fluoro, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In certain embodiments, compounds having Formulae VI, X, and XII are provided, wherein: R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro:
R2 is selected from the group consisting of aralkyl and:
wherein:
R25a, R25b, RZ5c, R25d, and R25e are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is selected from the group consisting of optionally substituted CrCa alkyl and optionally substituted aryl;
R4 is selected from the group consisting of hydrogen and optionally substituted CrCe alkyl;
R5 is selected from the group consisting of:
and
wherein:
R14 is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl;
X is selected from the group consisting of O, S, and NR’;
Y is selected from the group consisting of O, S, and NR;
R' is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl; and
R is selected from the group consisting of hydrogen, optionally substituted Ci-04 alkyl, and -COCH31 wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, R4 is hydrogen. In some embodiments, X is NH. In some embodiments, Y is NH. In some embodiments, R3 is -CH2C(CH3)3. In some embodiments, R5 is selected from the group consisting of:
OH
OH
4-OH
Me
-OH
Me
Me
In certain embodiments, compounds having Formula XII are provided, wherein:
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is selected from the group consisting of benzyl and:
wherein:
R25a, R25b, R25c, R25d, and R25® are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is selected from the group consisting of optionally substituted Ci-Ce alkyl and phenyl;
R4 is selected from the group consisting of hydrogen and optionally substituted Ci-C6 alkyl;
R5 is selected from the group consisting of:
-4-O H
R14
xl-OH
RÎ4
wherein:
R14 is selected from the group consisting of hydrogen and optionally substituted CrC.t alkyl;
X is selected from the group consisting of O, S, and NR;
Y is selected from the group consisting of O, S, and NR';
R is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl; and
R is selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, and -COCH3, wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, R4 is hydrogen. In some embodiments, X is NH. In some embodiments, Y is NH. In some embodiments, R3 is -CH2C(CH3)3. In some embodiments,
R5 is selected from the group consisting of:
,νοΗ | Y LLOh | |
OH ''ΌΗ | Me | I Me |
Υ'Ό·, | <x4-oh Me | and Me |
In certain embodiments, compounds having Formula XII are provided, wherein:
R1a is hydrogen;
R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is:
wherein:
R25a, R25b, RZ5c, RZ5d, and R25e are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is C4-Ca alkyl;
R4 is hydrogen;
R5 is selected from the group consisting of:
A. 1 k i | v . M-oh | A. I—L,Oh |
0H ''OH | Me | 1 Me |
\^OH ΌΗ | Me | and Me |
; and
X and Y are NH, wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, R5 is selected from the group consisting of:
In some embodiments, compounds having Formula XXXV:
XXXV are provided, wherein:
R1b and R1c are independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is C4-C8 alkyl; and
R25a, R25b, and R25c are each independently selected from the group consisting of hydrogen, fluoro, and chloro, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
In some embodiments, compounds having Formula XXXV are substantially free of one or more other stereoisomers. In some embodiments, compounds having Formula XXXV are substantially pure stereoisomers. In some embodiments, compounds having Formula XXXV are pure stereoisomers.
In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided. In some embodiments, compounds having the following structure:
H H or a pharmaceutically acceptable sait or solvaté thereof are provided.
In some embodiments, compounds having the following structure:
In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided.
In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided. In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided.
In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided.
In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided, werein the compound is substantially free of one or more other stereoisomers.
In certain embodiments, compounds having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof are provided, werein the compound is substantially free of one or more other stereoisomers.
In certain embodiments, a compound having the following structure:
werein the compound is a substantially pure stereoisomer.
In certain embodiments, a compound having the following structure:
or a pharmaceutically acceptable sait or solvaté thereof is provided, werein the compound is a pure stereoisomer.
In certain embodiments, methods of preparing a compound having Formula XXXVII:
are provided, wherein:
R32 is selected from the group consisting of -OR33 and -NR34aR34b;
R33 is selected from the group consisting of hydrogen, alkyl, and aralkyl;
R34a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, aralkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R34b is selected from the group consisting of hydrogen and alkyl;
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is selected from the group consisting of aralkyl and:
R259
R25a, R25b, RZSe, R25d, and R25e are each independently selected from the group consisting of hydrogen, fluoro, and chloro; and
R3 is selected from the group consisting of optionally substituted C^Ca alkyl and optionally substituted aryl.
In one embodiment, the method of preparing a compound having Formula XXXVII comprises allowing a compound having Formula XXXVI:
to isomerize to a compound having Formula XXXVII:
XXXVI
XXXVII
wherein R1a, R1b, R1c, R1d, R2, R3, and R32 hâve the meanings as described above in connection with Formula XXXVII.
In one embodiment, the method of preparing a compound having Formula XXXVII comprises dissolving a compound having Formula XXXVI:
XXXVI in a solvent or a mixture of solvents, wherein R1a, R1b, R1c, R1d, R2, R3, and R32 hâve the meanings as described above in connection with Formula XXXVII.
In one embodiment, the method of preparing a compound having Formula XXXVII comprises:
dissolving a compound having Formula XXXVI:
XXXVI in a solvent or a mixture of solvents; and
b) allowing the compound having Formula XXXVI to isomerize to a compound having Formula XXXVII, wherein R1a, R1b, R1d, R1d, R2, R3, and R32 hâve the meanings as described above in connection with Formula XXXVII.
In one embodiment, the method of preparing a compound having Formula XXXVII:
comprises:
allowing the compound having Formula XXXVI:
XXXVI to isomerize to a compound having Formula XXXVII; and
b) isolating the compound having Formula XXXVII substantially free from the compound having Formula XXXVI, and one or more other stereoisomers, wherein R1a, R1b, R1c, R1d, R2, R3, and R32 hâve the meanings as described above in connection with Formula XXXVII.
In one embodiment, the method of preparing a compound having Formula XXXVII:
comprises:
dissolving a compound having Formula XXXVI:
in a solvent or a mixture of solvents;
b) allowing the compound having Formula XXXVI to isomerize to a compound having Formula XXXVII; and
XXXVI
c) isolating the compound having Formula XXXVII substantially free from the compound having Formula XXXVI, and one or more other stereoisomers, wherein R1a, R1b, R1e, R1d, R2, R3, and R32 hâve the meanings as described above in connection with Formula XXXVII.
In one embodiment, the solvent is selected from the group consisting of acetonitrile, methanol, ethyl acetate, and water, or a mixture thereof.
In one embodiment, the isomerization is carried out at a pH of less than 7, e.g., at a pH of about 6, about 5, about 4, about 3, about 2, or about 1. In one embodiment, the isomerization is carried out at a pH of about 7. In one embodiment, the isomerization is carried out at a pH of greater than 7, e.g., at a pH of about 8, about 9, about 10, about 11, about 12, or about 13.
In one embodiment, the isomerization is carried out in the presence of an acid, e.g., trifluoroacetic acid or acetic acid.
In one embodiment, the isomerization is carried out in the presence of a base, e.g., NaHCO3.
In one embodiment, isomerization is carried out at a température of about 20°C to about 100°C, e.g., at a température of about 25°C to about 70°C, e.g., at a température of about 45°C to about 65°C. In one embodiment the isomerization is carried out at about room température, e.g., at about 25°C. In one embodiment the isomerization is carried out above room température, e.g., at about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, about 70°C, about 75°C, about 80°C, about 85°C, about 90°C, about 95°C, or about 100°C.
In one embodiment, the isomerization is carried about for a period of time between about 0.5 hours and about 2 weeks, e.g., for about 1 hour, about 3 hours, about 6 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 1 week. The period of time needed for isomerization to occur may dépend on a variety of factors including the chemical structure of Formula XXXVI, the solvent(s), the température, and/or the pH.
In one embodiment, R32 is -OR33.
In one embodiment, R32 is -NR34aR34b.
In one embodiment, R34b is hydrogen and R34a is selected from the group consisting of alkyl, hydroxyalkyl, hydroxycycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
In one embodiment, R34b is hydrogen and R34a is selected from the group consisting of:
In one embodiment, the compound having Formula XXXVII is isolated as a substantially pure stereoisomer. In one embodiment, the compound having Formula XXXVII is isolated as a pure stereoisomer.
In one embodiment,
R32 is -NR34aR34b;
R34a is:
R34b is hydrogen;
R2 is:
R3 is Ci-C8 alkyl.
In one embodiment, a method of preparing MI-77301 comprising allowing MI-773 to isomerize to MI-77301 is provided.
In one embodiment, a method of preparing MI-77301 comprising:
allowing MI-773 to isomerize to MI-77301; and isolating MI-77301 substantially free from one or more other stereoisomers, is provided.
In one embodiment, a method of preparing MI-77301 comprising:
dissolving MI-773 in a solvent or a mixture of solvents;
allowing MI-773 to isomerize to MI-77301; and isolating MI-77301 substantially free from one or more other stereoisomers,
S.
is provided.
The compounds and processes provided herein will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds provided herein may be prepared. Starting materials can be obtained from commercial 5 sources or prepared by well-established literature methods known to those of ordinary skill in the art. It will be readily apparent to one of ordinary skill in the art that the compounds defined above can be synthesized by substitution of the appropriate reagents and agents in the synthèses shown below.
Compounds of Formula la wherein Y is NH can be synthesized as described in Schemes 2 10 and 3.
Scheme 2
CAN 2.5 equiv
THF/H2O or Pb(OAc)4
Formula la (wherein Y is NH)
Scheme 3
tfa/ch2ci2
R2 k | |
NBS, THF/H2O | R1a NH R1b k 3 R = p-OMeBn-, Bn-, Me-or other alkyl group |
or DDQ, THF/HjO | |
JL JL ρΐο-χγ-χ | |
RKJ | |
Formula la (wherein Y is NH) |
Compounds of Formula la can be separated by chiral resolution methods well known in the art, e.g., chiral column chromatography, to give compounds of Formulae ll-XVII. Suitable chiral columns for use in chiral resolutions include, for example, Daicel CHIRALCEL® OD-H, 5 Daicel CHIRAKPAK® AD-H and Regis Technologies ULMO chiral columns. Other chiral resolution methods are also possible. Compounds of Formulae ll-XVil can also be prepared by asymmetric synthetic methods. For example, compounds of Formula II, wherein Y is NH, can be synthesized by using a asymmetric 1,3-dipolar cycloaddition as the key step as previously described (See U.S. Patent Nos. 7,759,383 B2 and 7,737,174 B2, and Ding et 10 al., J. Am. Chem. Soc. 127:10130-10131 (2005)) (Scheme 4).
Scheme 4
A
B
F
Formula II (wherein Y = NH)
Reagents and conditions: a) CH2CI2-CH3CN, KF-AI2O3, microwave, or methanol, piperidine reflux; b) 4A molecular sieves, toluene, 70°C; c) HNR4R6, r.t.; d) Pb(OAc)4, CH2CI2-MeOH (1:1), 0“C, or ammonium cerium(IV) nitrate (CAN), CH3CN, K2CO3l r.t.
Briefly, compound A reacts with aldéhyde B to give C. Compound C reacts with aldéhyde E and compound D to give F (a compound of Formula I wherein R is aralkyl). Treatment of F 5 with Pb(OAc)4 or CAN gives the compound of Formula II wherein Y is NH,
Compounds of Formula XII can be prepared via isomerization of compounds of Formula II. Without intending to be bound by theory, the isomerization of a compound having Formula II to a compound having Formula XII (and other isomers, including compounds having Formula VI) may involve formation of the imine intermediate shown in Scheme 5. 10 Compounds of Formula XII may be less likely to isomerize, Le., they may be chemically more stable, than compounds of Formula II.
Scheme 5
(wherein Y = NH) isomerization
other isomers
X Formula XII / (wherein Y = NH)
imine intermediate
Methods
In some embodiments, compounds provided herein induce cell cycle arrest and/or apoptosis and also potentiate the induction of cell cycle arrest and/or apoptosis either alone or in response to additional apoptosis induction signais. Therefore, it is contemplated that these compounds sensitize cells to induction of cell cycle arrest and/or apoptosis, including cells that are résistant to such inducing stimuli. By inhibiting the interaction between p53 or p53related proteins and MDM2 or MDM2-realted proteins, the compounds provided herein can be used to induce apoptosis in any disorder that can be treated, ameliorated, or prevented by the induction of apoptosis. In one embodiment, the inhibitors can be used to induce apoptosis in cells comprising functional p53 or p53-related proteins.
In another embodiment, the disclosure pertains to modulating apoptosis with compounds provided herein in combination with one or more additional apoptosis-modulating agents. Examples of apoptosis-modulating agents include, but are not limited to, Fas/CD95, TRAMP, TNF RI, DR1, DR2, DR3, DR4, DR5, DR6, FADD, RIP, TNFa, Fas ligand, TRAIL, antibodies to TRAIL-R1 or TRAIL-R2, Bcl-2, p53, BAX, BAD, Akt, CAD, PI3 kinase, PP1, and caspase proteins. Other agents involved in the initiation, decision and dégradation phase of apoptosis are also included. Examples of apoptosis-modulating agents include agents, the activity, presence, or change in concentration of which, can modulate apoptosis in a subject. Apoptosis-modulating agents include those which are inducers of apoptosis, such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a
TNFR-1 ligand, orTRAIL.
In some embodiments, the compounds, compositions, and methods provided herein, încluding the methods comprising pulsatile dose administration, are used to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (e.g., a mammalian patient încluding, but not limited to, humans and veterinary animais). In this regard, various diseases and pathologies are amenable to treatment or prophylaxis using the présent methods and compositions. A non-limiting exemplary list of these diseases and conditions includes, but is not limited to, breast cancer, prostate cancer, lymphoma, skin cancer, pancreatic cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms’ tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourînary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, rénal cell carcinoma, endométrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperpiasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL) încluding B-CLL, acute myelogenous leukemia, chronic myeiogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, sarcoma such as liposarcoma, malignant fibrous histiocytoma, osteosarcoma, Ewing’s sarcoma, leiomyosarcoma, and rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, nonHodgkin's lymphoma, soft-tissue sarcomas such as lipoma, and malignant Schwannoma, ostéogénie sarcoma, primary macroglobulinemia, and retinoblastoma, and the like, T and B cell mediated autoimmune diseases; inflammatory diseases; infections; hyperproliferative diseases; AIDS; degenerative conditions, vascular diseases, and the like. In some embodiments, the cancer cells being treated are metastatic. In other embodiments, the cancer cells being treated are résistant to other anticancer agents.
In some embodiments, the compounds, compositions, and methods provided herein, încluding the methods comprising pulsatile dose administration, are used to treat, ameliorate, or prevent a cancer selected from the group consisting of melanoma, lung cancer, a sarcoma, colon cancer, prostate cancer, choriocarcinoma, breast cancer, retinoblastoma, stomach carcinoma, acute myeloid leukemia, a lymphoma, multiple myeloma, and a leukemia in a patient.
In some embodiments, the compounds, compositions, and methods provided herein, including the methods comprising pulsatile dose administration, are used to treat, ameliorate, or prevent melanoma in a patient.
In some embodiments, the compounds, compositions, and methods provided herein, including the methods comprising pulsatile dose administration, are used to treat, ameliorate, or prevent liposarcoma in a patient.
In some embodiments, the compounds, compositions, and methods provided herein, including the methods comprising pulsatile dose administration, are used to treat cancers that express functional or wild type p53 or p53-related proteins. In some embodiments, the compounds, compositions, and methods provided herein are used to treat cancers that express elevated levels of MDM2 or MDM2-related proteins.
In some embodiments, the methods, compounds, and compositions provided herein, including the methods comprising pulsatile dose administration, can be used to treat a patient having a sarcoma, including, for example, liposarcoma, malignant fibrous histiocytoma, osteosarcoma, and rhabdomyosarcoma. In some embodiments, the methods, compounds, and compositions provided herein, including the methods comprising pulsatile dose administration, can be used to treat a patient having a soft tissue tumor, including, for example, Ewing’s sarcoma, leiomyosarcoma, lipoma, and malignant Schwannomas. In some embodiments, the methods, compounds, and compositions provided herein, including the methods comprising pulsatile dose administration, can be used to treat a patient having lung, breast, liver, or colon cancer. In some embodiments, the methods, compounds, and compositions provided herein, including the methods comprising pulsatile dose administration, can be used to treat a patient having B-cell chronic lymphocytic leukemia and acute myeloid leukemia.
In some embodiments, infections suitable for treatment with the compounds, compositions, and methods provided herein include, but are not limited to, infections caused by viruses, bacteria, fungi, mycoplasma, prions, and the like.
In some embodiments, methods are provided, including the methods comprising pulsatile dose administration, for administering an effective amount of a compound or composition provided herein and at least one additional therapeutic agent (including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobiais, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, and/or radiothérapies). In a particular embodiment, the additional therapeutic agent(s) is an anticancer agent.
A number of suitable therapeutic or anticancer agents are contemplated for use in the methods provided herein, including the methods comprising pulsatile dose administration.
Indeed, the methods provided herein can include but are not limited to, administration of numerous therapeutic agents such as: agents that induce apoptosis; polynucleotides (e.g., anti-sense, ribozymes, siRNA); polypeptides (e.g., enzymes and antibodies); biological mimetics (e.g., gossypol or BH3 mimetics); agents that bind (e.g., oligomerize or complex) with a Bcl-2 family protein such as Bax; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal or polyclonal antibodies (e.g., antibodies conjugated with anticancer drugs, toxins, defensins), toxins; radionuclides; biological response modifiers (e.g., interferons (e.g., IFN-α) and interleukine (e.g., IL-2)); adoptive immunotherapy agents; hematopoietic growth factors; agents that induce tumor cell différentiation (e.g., all-trans-retinoic acid); gene therapy reagents (e.g., antisense therapy reagents and nucléotides); tumor vaccines; angiogenesis inhibitors; proteosome inhibitors: NF-KB modulators; anti-CDK compounds; HDAC inhibitors; and the like. Numerous other examples of therapeutic agents such as chemotherapeutic compounds and anticancer thérapies suitable for co-administration with the disclosed compounds are known to those skilled in the art.
In certain embodiments, anticancer agents comprise agents that induce or stimulate apoptosis. Agents that induce or stimulate apoptosis include, for example, agents that interact with or modify DNA, such as by intercalating, cross-linking, alkylating, or otherwise damaging or chemically modifying DNA. Agents that induce apoptosis include, but are not limited to, radiation (e.g., X-rays, gamma rays, UV); tumor necrosis factor (TNF)-related factors (e.g., TNF family receptor proteins, TNF family ligands, TRAIL, antibodies to TRAILR1 or TRAIL-R2); kinase inhibitors (e.g., epidermal growth factor receptor (EGFR) kinase inhibitor. Additional anticancer agents include: vascular growth factor receptor (VGFR) kinase inhibitor, fibroblast growth factor receptor (FGFR) kinase inhibitor, platelet-derived growth factor receptor (PDGFR) kinase inhibitor, and Bcr-Abl kinase inhibitors (such as GLEEVEC)); antisense molécules; antibodies (e.g., HERCEPTIN, RITUXAN, ZEVALIN, and AVASTIN); anti-estrogens (e.g., raloxifene and tamoxifen); anti-androgens (e.g., flutamide, bicalutamide, finasteride, amînoglutethamide, kétoconazole, and corticosteroids); cyclooxygenase 2 (COX-2) inhibitors (e.g., celecoxib, meloxicam, NS-398, and non-steroidal anti-inflammatory drugs (NSAIDs)); anti-inflammatory drugs (e.g., butazolidin, DECADRON, DELTASONE, dexamethasone, dexamethasone intensol, DEXONE, HEXADROL, hydroxychloroquine, METICORTEN, ORADEXON, ORASONE, oxyphenbutazone, PEDIAPRED, phenylbutazone, PLAQUENIL, prednisolone, prednisone, PRELONE, and TANDEARIL); and cancer chemotherapeutic drugs (e.g., irinotecan (CAMPTOSAR), CPT11, fludarabine (FLUDARA), dacarbazine (DTIC), dexamethasone, mitoxantrone, MYLOTARG, VP-16, cisplatin, carboplatin, oxaliplatin, 5-FU, doxorubicin, gemcitabine, bortezomib, gefitinib, bevacizumab, TAXOTERE or TAXOL); cellular signalîng molécules;
ceramides and cytokines; staurosporine, and the like.
In still other embodiments, the compositions and methods provided herein, including the methods comprising pulsatile dose administration, include one or more compounds provided herein and at least one anti-hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
Alkylating agents suitable for use in the présent compositions and methods include, but are not limited to: 1) nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin); and chlorambucil); 2) ethylenimines and methylmelamines (e.g., hexamethylmelamine and thiotepa); 3) alkyl sulfonates (e.g., busulfan); 4) nitrosoureas (e.g., carmustine (BCNU); lomustine (CCNU); semustine (methyl-CCNU); and streptozocin (streptozotocin)); and 5) triazenes (e.g., dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide).
In some embodiments, antimetabolites suitable for use in the présent compositions and methods include, but are not limited to: 1) folie acid analogs (e.g., methotrexate (amethopterin)); 2) pyrimidine analogs (e.g., fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and cytarabine (cytosine arabinoside)); and 3) purine analogs (e.g., mercaptopurîne (6-mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG), and pentostatin (2’-deoxycoformycin)).
In still further embodiments, chemotherapeutic agents suitable for use in the compositions and methods of the présent disclosure include, but are not limited to: 1) vinca alkaloids (e.g., Vinblastine (VLB), vincristine); 2) epipodophyllotoxins (e.g., etoposide and teniposide); 3) antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes (e.g., L-asparaginase); 5) biological response modifiers (e.g., interferon-alfa); 6) platinum coordinating complexes (e.g., cisplatin (cis-DDP) and carboplatin); 7) anthracenediones (e.g., mitoxantrone); 8) substituted ureas (e.g., hydroxyurea); 9) methylhydrazine dérivatives (e.g., procarbazine (N-methylhydrazine; MIH)); 10) adrenocortical suppressants (e.g., mitotane (ο,ρ’-DDD) and aminoglutéthimide); 11) adrenocorticosteroids (e.g., prednisone); 12) progestins (e.g., hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate); 13) estrogens (e.g., diethylstilbestrol and ethinyl estradiol); 14) antiestrogens (e.g., tamoxifen); 15) androgens (e.g., testosterone propionate and fluoxymesterone); 16) antiandrogens (e.g., flutamide): and 17)gonadotropin-releasing hormone analogs (e.g., leuprolide).
Any oncolytic agent that is routinely used in a cancer therapy context finds use in the compositions and methods of the présent disclosure. For example, the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States. International counterpart agencies to the U.S.F.D.A. maintain similar formularies.
Table 1 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the product labels required on ail U.S. approved chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents.
Table 1
Aldesleukin (des-alanyl-1, serine-125 human interleukin- 2) | Proleukin |
Alemtuzumab (IgG 1k anti CD52 antibody) | Campath |
Alitretinoin (9-cis-retinoic acid) | Panretin |
Allopurinol (1,5-dihydro-4 H -pyrazolo[3,4-d]pyrimidin-4one monosodium sait) | Zyloprim |
Altretamine (N,N,N,,N'1N,NI- hexamethyl-1,3,5-triazine- 2, 4, 6-triamine) | Hexalen |
Amifostine (ethanethiol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester)) | Ethyol |
Anastrozole (1,3-Benzenediacetonitrile, a, a, a', a'tetramethyl-5“(1H-1,2,4-triazol-1-ylmethyl)) | Arimidex |
Arsenic trioxide | Trisenox |
Asparaginase (L-asparagine amidohydrolase, type EC-2) | Elspar |
BCG Live (lyophilized préparation of an attenuated strain of Mycobacterium bovis (Bacillus | TICE BCG |
Calmette-Gukin [BCG], substrain Montreal) | |
bexarotene capsules (4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8pentamethyl-2-napthalenyl) ethenyl] benzoic acid) | Targretin |
bexarotene gel | Targretin |
Bleomycin (cytotoxic glycopeptide antibiotics produced by Streptomyces verticillus·, bleomycin A2 and bleomycin B2) | Blenoxane |
Capecitabine (5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine) | Xeloda |
Carboplatin (platinum, diammine [1,1- cyclobutanedicarboxylato(2-)-0, O']-,(SP-4-2)) | Paraplatin |
Carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea) | BCNU, BiCNU |
Carmustine with Polifeprosan 20 Implant | Gliadel Wafer |
Celecoxib (as 4-[5-(4-methylphenyl)-3- (trifluoromethyl)- 1 H-pyrazol-1-yl] benzenesulfonamide) | Celebrex |
Chlorambucil (4-[bis(2chlorethyl)amino]benzenebutanoic acid) | Leukeran |
Cisplatin (PtCI2H6N2) | Platinol |
Cladribine (2-chloro-2'-deoxy-b-D-adenosine) | Leustatin, 2-CdA |
Cyclophosphamide (2-[bis(2-chloroethyl)amino] tetrahydro-2H13,2-oxazaphosphorine 2-oxide monohydrate) | Cytoxan, Neosar |
Cytarabine | Cytosar-U |
( 1 -b-D-Arabinofuranosylcytosine, CgHi3N3O5) | |
cytarabine liposomal | DepoCyt |
Dacarbazine (5-(3,3-dimethyl-l-triazeno)-imidazole-4carboxamide (DTIC)) | DTIC-Dome |
Dactinomycin, actinomycin D (actinomycin produced by Streptomyces parvullus, CeïHaeNiîOie) | Cosmegen |
Darbepoetin alfa (recombinant peptide) | Aranesp |
daunorubicin liposomal ((8S-cis)-8-acetyl-10-[(3-amino-2,3,6trideoxy-â-L-lyxo-hexopyranosyl)oxy]7,8,9,10-tetrahydro-6,8,11-tri hydroxy-1methoxy-5,12-naphthacenedione hydrochloride) | DanuoXome |
Daunorubicin HCl, daunomycin ((1 S ,3 S )-3-Acetyl-1,2,3,4,6,11-hexahydro3,5,12-trihydroxy-10-methoxy-6,11 -dioxo-1 naphthacenyl 3-amino-2,3,6-trideoxy-(alpha)L- lyxo -hexopyranoside hydrochloride) | Cerubidine |
Denileukin diftitox (recombinant peptide) | Ontak |
Dexrazoxane ((S)-4,4'-(1 -methyl-1,2-ethanediyl)bis-2,6- piperazinedione) | Zinecard |
Docetaxel ((2R,3S)-N-carboxy-3-phenylisoserine, N-tertbutyl ester, 13-ester with 5b-20-epoxy12a,4,7b,10b,13a-hexahydroxytax-11-en-9one 4-acetate 2-benzoate, trihydrate) | Taxotere |
Doxorubicin HCl (8S, 10S)-10-[(3-amino-2,3,6-trideoxy-a-Llyxo-hexopyranosyl)oxy] -8-glycolyl-7,8,9,10- | Adriamycin, Rubex |
tetrahydro-6,8,11- trihydroxy-1-methoxy-5,12naphthacenedione hydrochloride) | |
doxorubicin | Adriamyctn PFS Intravenous injection |
doxorubicin liposomal | Doxil |
dromostanolone propionate (17b-Hydroxy-2a-methyl-5a-androstan-3-one propionate) | Dromostanolone |
dromostanolone propionate | Masterone injection |
Elliott's B Solution | Elliott's B Solution |
Epirubicin ((8S-cis)-10-[(3-amino-2,3,6-trideoxy-a-Larabino- hexopyranosyl)oxy]-7,8,9,10tetrahydro-6,8,11-trihydroxy-8(hydroxyacetyl)-l -methoxy-5,12naphthacenedione hydrochloride) | Ellence |
Epoetin alfa (recombinant peptide) | Epogen |
Estramustine (estra-1,3,5( 10)-triene-3,17-diol( 17(beta))-, 3[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium sait, monohydrate, or estradiol 3-[bis(2-chloroethyl)carbamate] 17(dihydrogen phosphate), disodium sait, monohydrate) | Emcyt |
Etoposide phosphate (4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)ethylidene-(beta)-D-glucopyranoside], 4'(dihydrogen phosphate)) | Etopophos |
etoposide, VP-16 (4'-demethylepipodophyllotoxin 9-(4,6-0-( R)ethylidene-(beta)-D-glucopyranoside]) | Vepesid |
Exemestane | Aromasin |
(6-methylenandrosta-1,4-diene-3, 17-dione) | |
Filgrastim (r-metHuG-CSF) | Neupogen |
floxuridine (intraarterial) (2'-deoxy-5-fluorouridine) | FUDR |
Fludarabine (fluorinated nucléotide analog of the antiviral agent vidarabine, 9-b -Darabinofuranosyladenine (ara-A)) | Fludara |
Fluorouracil, 5-FU (5-fluoro-2,4(1H,3H)-pyrimidinedione) | Adrucil |
Fulvestrant (7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-( 10)triene-3,17-beta-diol) | Faslodex |
Gemcitabine (2’-deoxy-2', 2'-difluorocytidine monohydrochloride (b-isomer)) | Gemzar |
Gemtuzumab Ozogamicin (anti-CD33 hP67.6) | Mylotarg |
Goserelin acetate | Zoladex Implant |
Hydroxy u rea | Hydrea |
Ibritumomab Tiuxetan (immunoconjugate resulting from a thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)- propyl]-[N-[2bis(carboxymethyl)amino]-2-(methyl) ethyljglycine) | Zevalin |
Idarubicin (5, 12-Naphthacenedione, 9-acetyl-7-[(3amino-2,316-trideoxy-(alpha)-L- lyxo hexopyranosyl)oxy]-7,8,9,10-tetrahydro- 6,9,11-trihydroxyhydrochloride, (7S- cis )) | Idamycin |
Ifosfamide (3-(2-chloroethyl)-2-[(2chloroethyl)amino]tetrahydro-2H-1,3,2oxazaphosphorine 2-oxide) | IFEX |
Imatinib Mesilate (4- [(4- Methyl-1 -piperazin yl )meth yl]- N- [4methyl-3-[[4-(3-pyridinyl)-2pyrimidinyl]amino]-phenyl]benzamide methanesulfonate) | Gleevec |
Interferon alfa-2a (recombinant peptide) | Roferon-A |
Interferon alfa-2b (recombinant peptide) | Intron A (Lyophïlized Betaseron) |
Irinotecan HCl ((4S)-4,11-diethyl-4-hydroxy-9-[(4- piperidinopiperidino)carbonyloxy]-1 H-pyrano[3', 4': 6,7] indolizino[1,2-b] quinoline-3,14(4H, 12H) dione hydrochloride trïhydrate) | Camptosar |
Letrozole (4,4'-( 1H-1,2,4 -T rïazol-1-ylmethylene) dibenzonitrile) | Femara |
Leucovorîn (L-Glutamic acid, N[4[[(2amino-5-formyl- 1,4,5,6,7,8 hexahydro4oxo6- pteridinyl)methyl]amino]benzoyl], calcium sait (1:1)) | Wellcovorin, Leucovorîn |
Levamisole HCl ((-)-( 3)-2,3,5, 6-tetrahydro-6-phenylimidazo [2,1-b] thiazole monohydrochloride CnH^NïS-HCI) | Ergamisol |
Lomustine (1 -(2-chloro-ethyl)-3-cyclohexyl-1 - nitrosourea) | CeeNU |
Meclorethamine, nitrogen mustard | Mustargen |
(2-chloro-N-(2-chloroethyl)-Nmethylethanamine hydrochloride) | |
Megestrol acetate 17a( acetyloxy)- 6- methylpregna- 4,6- diene- 3,20- dione | Megace |
Melphalan, L-PAM (4-[bis(2-chloroethyl) amino]-L-phenylalanine) | Alkeran |
Mercaptopurine, 6-MP (1,7-dihydro-6 H -purine-6-thione monohydrate) | Purinethol |
Mesna (sodium 2-mercaptoethane sulfonate) | Mesnex |
Methotrexate (N-[4-[[(2,4-diamino-6pteridinyl)methyl]methylamino]benzoyl]-Lglutamic acid) | Methotrexate |
Methoxsalen (9-methoxy-7H-furo[3,2-g][1]-benzopyran-7one) | Uvadex |
Mitomycin C | Mutamycin |
mitomycin C | Mitozytrex |
Mitotane (1,1-dichloro-2-(o-chlorophenyl)-2-(p- chlorophenyl) ethane) | Lysodren |
Mitoxantrone (1,4-dihydroxy-5,8-bis[[2- [(2hydroxyethyl)amino]ethyl]amino]-9,10anthracenedione dihydrochloride) | Novantrone |
Nandrolone phenpropionate | Durabolin-50 |
Nofetumomab | Verluma |
Oprelvekîn (IL-11) | Neumega |
Oxaliplatin (cis-[(1 R,2R)-1,2-cyclohexanediamine-N,N’] [oxalato(2-)-0,0'] platinum) | Eloxatin |
Paclitaxel (5β, 20-Epoxy-1,2a, 4,7β, 10β, 13ahexahydroxytax-11-en-9-one 4,10-dîacetate 2- benzoate 13-ester with (2R, 3 S)- Nbenzoyl-3-phenylisoserine) | TAXOL |
Pamidronate (phosphonic acid (3-amino-1hydroxypropylidene) bis-, disodium sait, pentahydrate, (APD)) | Aredia |
Pegademase ((monomethoxypolyethylene glycol succinimidyl) 11-17 -adenosine deaminase) | Adagen (Pegademase Bovine) |
Pegaspargase (monomethoxypolyethylene glycol succinimidyl L-asparaginase) | Oncaspar |
Pegfilgrastim (covalent conjugate of recombinant methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene glycol) | Neulasta |
Pentostatin | Nipent |
Pipobroman | Vercyte |
Plicamycin, Mithramycin (antibiotic produced by Streptomyces plicatus) | Mithracin |
Porfimer sodium | Photofrin |
Procarbazine (N-isopropyl-p-(2-methylhydrazino)-ptoluamide monohydrochloride) | Matulane |
Quinacrine (6-chloro-9-( 1 -methyl-4-diethyl-amine) butylamino-2-methoxyacridine) | Atabrine |
Rasburicase (recombinant peptide) | Elitek |
Rituximab (recombinant anti-CD20 antibody) | Rituxan |
Sargramostim (recombinant peptide) | Prokine |
Streptozocin (streptozocin 2 -deoxy - 2 [[(methylnitrosoamino)carbonyl]amino] a(and b ) - D - glucopyranose and 220 mg citric acid anhydrous) | Zanosar |
Talc (Mg3Si4O10 (OH)2) | Sclerosol |
Tamoxifen ((Z)2-[4-( 1 t2-diphenyl-1 -butenyl) phenoxy]-N, N-dimethylethanamine 2-hydroxy-1,2,3propanetricarboxylate (1:1)) | Nolvadex |
Temozolomide (3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]as-tetrazine-8-carboxamide) | Temodar |
teniposide, VM-26 (4'-demethylepipodophyllotoxin 9-[4,6-0-(R)- 2- thenylidene-(beta)-D-glucopyranoside]) | Vumon |
T estolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4dien-17-oic acid [dgr ]-lactone) | Teslac |
Thioguanine, 6-TG (2-amino-1,7-dihydro-6 H - purine-6-thione) | Thioguanine |
Thiotepa (Aziridine, Ι,Τ,Γ'-phosphinothioylidynetris-, or Tris (1-aziridinyl) phosphine sulfide) | Thioplex |
Topotecan HCl ((S)-10-[(dimethylamino) methyl]-4-ethyl-4,9dihydroxy-1H-pyrano[3', 4': 6,7] indolizino [1,2-b] quinolîne-3,14-(4H, 12H)-dione | Hycamtin |
monohydrochloride) | |
Toremifene (2-(p-[(Z)-4-chloro-1,2-d i pheny 1-1 -butenyl]phenoxy)-N,N-dimethylethylamine citrate (1:1)) | Fareston |
Tositumomab, 1131 Tositumomab (recombinant murine immunotherapeutic monoclonal lgG2a lambda anti-CD20 antibody (I 131 is a radioimmunotherapeutic antibody)) | Bexxar |
Trastuzumab (recombinant monoclonal IgGi kappa anti- HER2 antibody) | Herceptin |
Tretinoin, ATRA (all-trans retinoic acid) | Vesanoid |
Uracil Mustard | Uracil Mustard Capsules |
Valrubicin, N-trifluoroacetyladriamycin-14valerate ((2S-cis)-2- [1,2,3,4,6,11-hexahydro-2,5,12trihydroxy-7 methoxy-6,11-dioxo-[[4 2,3,6trideoxy-3- [(trifluoroacetyl)-amino-a-L-/yxohexopyranosyl]oxyl]-2-naphthacenyl]-2oxoethyl pentanoate) | Valstar |
Vinblastine, Leurocristine (C46H56N4O10-H2SO4) | Velban |
Vincristine (Ο46Η5ΘΝ4Οι0·Η25Ο4) | Oncovin |
Vinorelbine (3’ ,4'-didehydro-4’-deoxy-C’norvincaleukoblastine [R-(R*,R*)-2,3dihydroxybutanedioate (1:2)(salt)]) | Navelbine |
Zolédronate, Zoledronic acid ((1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) | Zometa |
phosphonic acid monohydrate) |
Anticancer agents further include compounds which hâve been identîfied to hâve anticancer activity. Examples include, but are not limited to, 3-AP, 12-0-tetradecanoylphorbol-13acetate, 17AAG, 852A, ABI-007, ABR-217620, ABT-751, ADI-PEG 20, AE-941, AG-013736, AGR0100, alanosine, AMG 706, antibody G250, antineoplastons, AP23573, apaziquone, APC8015, atiprimod, ATN-161, atrasenten, azacitidine, BB-10901, BCX-1777, bevacizumab, BG00001, bicalutamide, BMS 247550, bortezomib, bryostatin-1, buserelin, calcitriol, CCI-779, CDB-2914, cefixime, cetuximab, CG0070, cilengitide, clofarabine, combretastatin A4 phosphate, CP-675,206, CP-724,714, CpG 7909, curcumin, decitabine, DENSPM, doxercalciferol, E7070, E7389, ecteinascidin 743, efaproxiral, eflornithine, EKB569, enzastaurin, erlotinib, exisulind, fenretinide, flavopiridol, fludarabine, flutamide, fotemustine, FR901228, G17DT, galiximab, gefitinib, genistein, glufosfamide, GTI-2040, histrelin, HKI-272, homoharringtonine, HSPPC-96, hu14.18-interleukin-2 fusion protein, HuMax-CD4, iloprost, imiquimod, infliximab, interleukîn-12, IPI-504, irofulven, ixabepilone, lapatinib, lenalidomide, lestaurtinib, leuprolide, LMB-9 immunotoxin, lonafarnîb, luniliximab, mafosfamide, MB07133, MDX-010, MLN2704, monoclonal antibody 3F8, monoclonal antibody J591, motexafin, MS-275, MVA-MUC1-IL2, nilutamide, nitrocamptothecin, nolatrexed dihydrochloride, nolvadex, NS-9, O6-benzylguanine, oblimersen sodium, ONYX015, oregovomab, OSI-774, panitumumab, paraplatin, PD-0325901, pemetrexed, PHY906, pioglitazone, pirfenidone, pixantrone, PS-341, PSC 833, PXD101, pyrazoloacridine, R115777, RAD001, ranpirnase, rebeccamycin analogue, rhuAngiostatin protein, rhuMab 2C4, rosiglitazone, rubitecan, S-1, S-8184, satraplatin, SB-, 15992, SGN-0010, SGN-40, sorafenib, SR31747A, ST1571, SU011248, suberoylanilide hydroxamic acid, suramin, talabostat, talampanel, tariquidar, temsirolimus, TGFa-PE38 immunotoxin, thalidomide, thymalfasin, tipifarnib, tirapazamine, TLK286, trabectedin, trimetrexate glucuronate, TroVax, UCN-1, valprotc acid, vinflunine, VNP40101M, volociximab, vorinostat, VX-680, ZD1839, ZD6474, zileuton, and zosuquidar trihydrochloride.
For a more detailed description of anticancer agents and other therapeutic agents, those skilled in the art are referred to any number of instructive manuals including, but not limited to, the Physician's Desk Reference and to Goodman and Gilman’s Pharmaceutical Basis of Therapeutics tenth édition, Eds. Hardman étal., 2002.
In some embodiments, methods provided herein, including the methods comprising pulsatile dose administration, comprise administering one or more compounds provided herein with radiation therapy. The methods provided herein are not limited by the types, amounts, or delivery and administration Systems used to deliver the therapeutic dose of radiation to an animal. For example, the animal may receive photon radiotherapy, particle beam radiation therapy, other types of radiothérapies, and combinations thereof. In some embodiments, the radiation is delivered to the animal using a linear accelerator. In still other embodiments, the radiation is delivered using a gamma knife.
The source of radiation can be external or internai to the animal. External radiation therapy is most common and involves directing a beam of high-energy radiation to a tumor site through the skin using, for instance, a linear accelerator. While the beam of radiation is localized to the tumor site, it is nearly impossible to avoid exposure of normal, healthy tissue. However, external radiation is usually well tolerated by animais. Internai radiation therapy involves implanting a radiation-emitting source, such as beads, wires, pellets, capsules, particles, and the like, inside the body at or near the tumor site including the use of delivery Systems that specifically target cancer cells (e.g., using particles attached to cancer cell binding ligands). Such implants can be removed following treatment, or left in the body inactive. Types of internai radiation therapy include, but are not limited to, brachytherapy, interstitial irradiation, intracavity irradiation, radioimmunotherapy, and the like.
The animal may optionally receive radiosensitizers (e.g., metronidazole, misonidazole, intraarterial Budr, intravenous iododeoxyuridine (ludR), nitroimidazole, 5-substituted-4nitroimidazoles, 2H-isoindolediones, [[(2-bromoethyl)-amino]methyl]-nitro-1 H-imidazole-1ethanol, nitroaniline dérivatives, DNA-affinic hypoxia sélective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine oxides, 2-nitroimidazole dérivatives, fluorine-containing nitroazole dérivatives, benzamide, nicotinamide, acridine-intercalator, 5-thiotretrazole dérivative, 3nitro-1,2,4-triazole, 4,5-dinitroimidazole dérivative, hydroxylated texaphrins, cisplatin, mitomycin, tiripazamine, nitrosourea, mercaptopurine, methotrexate, fluorouracil, bleomycin, vincristine, carboplatin, epirubicin, doxorubicin, cyclophosphamide, vindesine, etoposide, paclitaxel, heat (hyperthermia), and the like), radioprotectors (e.g., cysteamine, aminoalkyl dihydrogen phosphorothioates, amifostine (WR 2721), IL-1, IL-6, and the like). Radiosensitizers enhance the killing of tumor cells. Radioprotectors protect healthy tissue from the harmful effects of radiation.
Any type of radiation can be administered to an animal, so long as the dose of radiation is tolerated by the animal without unacceptable négative side-effects. Suitable types of radiotherapy include, for example, ionizing (electromagnetic) radiotherapy (e.g., X-rays or gamma rays) or particle beam radiation therapy (e.g., high linear energy radiation). Ionizing radiation is defined as radiation comprising particles or photons that hâve sufficient energy to produce ionization, r.e., gain or loss of électrons (as described in, for example, U.S. 5,770,581 incorporated herein by reference in its entirety). The effects of radiation can be at least partially controlled by the clinician. In one embodiment, the dose of radiation is fractionated for maximal target cell exposure and reduced toxicity.
In one embodiment, the total dose of radiation administered to an animal is about .01 Gray (Gy) to about 100 Gy. In another embodiment, about 10 Gy to about 65 Gy (e.g., about 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, or 60 Gy) are administered over the course of treatment. While in some embodiments a complété dose of radiation can be administered over the course of one day, the total dose is ideally fractionated and administered over several days. Desirably, radiotherapy is administered over the course of at least about 3 days, e.g., at least 5, 7, 10, 14, 17, 21, 25, 28, 32, 35, 38, 42, 46, 52, or 56 days (about 1-8 weeks). Accordingly, a daily dose of radiation will comprise approximately 1-5 Gy (e.g., about 1 Gy, 1.5 Gy, 1.8 Gy, 2 Gy, 2.5 Gy, 2.8 Gy, 3 Gy, 3.2 Gy, 3.5 Gy, 3.8 Gy,
Gy, 4.2 Gy, or 4.5 Gy), or 1-2 Gy (e.g., 1.5-2 Gy). The daily dose of radiation should be sufficient to induce destruction of the targeted cells. If stretched over a period, in one embodiment, radiation is not administered every day, thereby allowing the animal to rest and the effects of the therapy to be realized. For example, radiation desirably is administered on consecutive days, and not administered on 2 days, for each week of treatment, thereby allowing 2 days of rest per week. However, radiation can be administered 1 day/week, 2 days/week, 3 days/week, 4 days/week, 5 days/week, 6 days/week, or ail 7 days/week, depending on the animal’s responsiveness and any potential side effects. Radiation therapy can be initiated at any time in the therapeutic period. In one embodiment, radiation is initiated in week 1 or week 2, and is administered for the remaining duration of the therapeutic period. For example, radiation is administered in weeks 1-6 or in weeks 2-6 of a therapeutic period comprising 6 weeks for treating, for instance, a solid tumor. Alternative^, radiation is administered in weeks 1-5 or weeks 2-5 of a therapeutic period comprising 5 weeks. These exemplary radiotherapy administration schedules are not intended, however, to limit the methods provided herein.
Antimicrobial therapeutic agents may also be used as therapeutic agents in combination with the compounds provided herein. Any agent that can kill, inhibit, or otherwise attenuate the function of microbial organisms may be used, as well as any agent contemplated to hâve such activities. Antimicrobial agents include, but are not limited to, natural and synthetic antibiotics, antibodies, inhibitory proteins (e.g., defensins), antisense nucleic acids, membrane disruptive agents and the like, used alone or in combination. Indeed, any type of antibiotic may be used including, but not limited to, antibacterial agents, antiviral agents, antifungal agents, and the like.
In some embodiments of the methods provided herein, one or more compounds provided herein and one or more therapeutic agents or anticancer agents are administered to an animal under one or more of the following conditions: at different periodicities, at different durations, at different concentrations, by different administration routes, etc. In some embodiments, the compound is administered prior to the therapeutic or anticancer agent, e.g., 0.5, 1,2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1,2, 3, or 4 weeks prior to the administration of the therapeutic or anticancer agent. In some embodiments, the compound is administered after the therapeutic or anticancer agent, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1,2, 3, or 4 weeks after the administration of the anticancer agent. In some embodiments, the compound and the therapeutic or anticancer agent are administered concurrently but on different schedules, e.g., the compound is administered daily while the therapeutic or anticancer agent is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the compound is administered once a week while the therapeutic or anticancer agent is administered daily, once a week, once every two weeks, once every three weeks, or once every four weeks.
In some embodiments, compositions provided herein comprise one or more of the compounds provided herein in an amount which is effective to achieve its intended purpose. While individual needs vary, détermination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, the compounds may be administered to mammals, e.g. humans, orally at a dose of 0.0025 to 50 mg/kg, or an équivalent amount of the pharmaceutically acceptable sait thereof, per day of the body weight of the mammal being treated for disorders responsive to induction of apoptosis. In one embodiment, about 0.01 to about 25 mg/kg is orally administered to treat, ameliorate, or prevent such disorders. For intramuscular injection, the dose is generally about one-half of the oral dose. For example, a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, or from about 0.01 to about 5 mg/kg.
The unit oral dose may comprise from about 0.01 to about 1000 mg, for example, about 0.1 to about 100 mg of the compound. The unit dose may be administered one or more times daily as one or more tablets or capsules each containing from about 0.1 to about 10 mg, conveniently about 0.25 to 50 mg of the compound or its solvatés.
In a topical formulation, the compound may be présent at a concentration of about 0.01 to 100 mg per gram of carrier. In a one embodiment, the compound is présent at a concentration of about 0.07-1.0 mg/ml, for example, about 0.1-0.5 mg/ml, and in one embodiment, about 0.4 mg/ml.
In addition to administering the compound as a raw chemical, the compounds provided herein may be administered as part of a pharmaceutical préparation or composition. In some embodiments, the pharmaceutical préparation or composition can include one or more pharmaceutically acceptable carriers, excipients, and/or auxiliaries. In some embodiments, the one or more carriers, excipients, and auxiliaries facilitate processing of the compound into a préparation or composition which can be used pharmaceutically. The préparations, particularly those préparations which can be administered orally or topically and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, haïr rinses, hair gels, shampoos and also préparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound(s), together with the one or more carriers, excipients, and/or auxiliaries.
The pharmaceutical compositions of provided herein may be administered to any patient which may expérience the bénéficiai effects of the compounds provided herein. Foremost among such patients are mammals, e.g., humans, although the methods and compositions provided herein are not intended to be so limited. Other patients include veterinary animais (cows, sheep, pigs, horses, dogs, cats and the like).
The compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose. For example, administration may be by patenterai, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dépendent upon the âge, health, and weight of the récipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
The pharmaceutical préparations provided herein are manufactured by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical préparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose préparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a sait thereof, such as sodium alginate. Auxiliaries can be suitable flow-regulating agents and lubricants. Suitable auxiliaries include, for example, silica, talc, stearic acid or salts thereof, such as magnésium stéarate or calcium stéarate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are résistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arable, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings résistant to gastric juices, solutions of suitable cellulose préparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
Other pharmaceutical préparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnésium stéarate and, optionally, stabilizers. In soft capsules, the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
Possible pharmaceutical préparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycérides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycérides, polyethylene glycols, or paraffin hydrocarbons.
Suitable formulations for parentéral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilie solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycérides or polyethylene glycol-400. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. The topical compositions provided herein are formulated in one embodiment as oils, creams, lotions, ointments and the like by choice of appropriate carriers. Suitable carriers include vegetable or minerai oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C12). The carriers may be those in which the active ingrédient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Additionally, transdermal pénétration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat Nos. 3,989,816 and 4,444,762.
Ointments may be formulated by mixing a solution of the active ingrédient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool. A typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight. Lotions may be conveniently prepared by dissolving the active ingrédient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.
In one embodiment, the présent disclosure relates to methods of treating a patient with a hyperproliferative disease, e.g., cancer, the methods comprising pulsatile administration to the patient one or more compounds or compositions provided herein, or pharmaceutically acceptable salts, solvatés, or prodrugs thereof.
The following examples are illustrative, but not limiting, of the compounds, compositions, and methods provided herein. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the methods, compounds, and compositions provided herein.
In certain aspects, the following embodiments are provided:
Embodiment I: A method of treating, preventing, or ameliorating cancer in a patient, wherein the method comprises pulsatile administration to the patient a therapeutically effective amount of a compound having Formula XII:
or a pharmaceutically acceptable sait thereof, wherein:
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is:
wherein:
R0a, R6b, R6c, R6d, and Ree are each independently selected from the group consisting of hydrogen, fluoro, and chloro; R3 is optionally substituted CrCa alkyl;
R4 is selected from the group consisting of hydrogen and optionally substituted
Ci-C6 alkyl;
R5 is selected from the group consisting of:
wherein:
R7 is selected from the group consisting of hydrogen and optionally substituted
CrC4 alkyl;
X is selected from the group consisting of O, S, and NR ;
Y is selected from the group consisting of O, S, and NR’;
R' is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl; and
R is selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl, wherein the compound is substantially free of one or more other stereoisomers. Embodiment II: The method of Embodiment I, wherein R4 is hydrogen, or a pharmaceutically acceptable sait thereof.
Embodiment lll: The method of Embodiment I, wherein X is NH, or a pharmaceutically acceptable sait thereof.
Embodiment IV: The method of Embodiment I, wherein Y is NH, or a pharmaceutically acceptable sait thereof.
Embodiment V: The method of Embodiment I, wherein R3 is -CH2C(CH3)3, or a pharmaceutically acceptable sait thereof.
Embodiment VI: The method of Embodiment I, wherein R5 is selected from the group consisting of:
or a pharmaceutically acceptable sait thereof. Embodiment VII. The method of Embodiment I, wherein:
R1a is hydrogen;
R1b, R1c, and R1d are each independently selected hydrogen, fluoro, and chloro;
R3 is C4-C8 alkyl;
R4 is hydrogen;
R5 is selected from the group consisting of:
from the group consisting of
X and Y are NH;
or a pharmaceutically acceptable sait thereof.
Embodiment VIII: The method of Embodiments VI or VII, wherein R5 is selected from the group consisting of:
'OH or a pharmaceutically acceptable sait thereof.
Embodiment IX: The method of Embodiment I, wherein the compound of Formula XII is selected from the group consisting of:
ιοο
or a pharmaceutically acceptable sait thereof.
Embodiment X: The method of Embodiment I, wherein the compound of Formula XII is:
or a pharmaceutically acceptable sait thereof.
Embodiment XI: The method of Embodiment I, wherein the compound of Formula XII is:
ΙΟΙ or a pharmaceutically acceptable sait thereof.
Embodiment XII: The method of any one of Embodiments ΙΧ-ΧΙ, wherein the compound is substantially free of other stereoisomers, or a pharmaceutically acceptable sait thereof.
Embodiment XIII: The method of Embodiment XII, wherein the compound is a substantially pure stereoisomer, or a pharmaceutically acceptable sait thereof.
Embodiment XIV: The method of any one of Embodiments l-XIII, wherein the compound is administered to the patient one day a week, one day every two weeks, one day every three weeks, or one day every four weeks.
Embodiment XV: The method of any one of Embodiments l-XIV, wherein cells of the hyperproliferative disease express functional p53.
Embodiment XVI: The method of any one of Embodiments l-XV, wherein the hyperproliferative disease is cancer.
Embodiment XVII.The method of Embodiment XVI, further comprising administering to the patient one or more anticancer agents.
Embodiment XVIII. The method of Embodiment XVII, wherein the anticancer agent is a chemotherapeutic agent.
Embodiment XIX: The method of Embodiment XVIII, wherein the anticancer agent is radiation therapy.
Embodiment XX: A kit comprising a compound having Formula XII:
or a pharmaceutically acceptable sait thereof, wherein:
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is:
wherein:
R6a, R6b R6c. Red, anc| R6e are egch jn(jependentiy selected from the group consisting of hydrogen, fluoro, and chloro;
102
R3 is optionally substituted C^Ca alkyl;
R4 is selected from the group consisting of hydrogen and optionally substituted
CrCe alkyl;
R5 is selected from the group consisting of:
wherein:
R7 is selected from the group consisting of hydrogen and optionally substituted
0,-04 alkyl;
X is selected from the group consisting of O, S, and NR ;
Y is selected from the group consisting of O, S, and NR;
R’ is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl; and
R is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl, wherein the compound is substantially free of one or more other stereoisomers, and instructions for pulsatile administration of the compound to a patient having a hyperproliferative disease.
Embodiment XXI: The kit of Embodiment XX, wherein the hyperproliferative disease is cancer.
EmbodimentXXII:The kit of Embodiment XXI, further comprising one or more anticancer agents.
Embodiment XXIII: The kit of Embodiment XXII, wherein the instructions direct co administration of the compound together with the one or more anticancer agents.
In certain aspects, the following particular embodiments are provided herein:
Embodiment XXIV: A method of treating, ameliorating, or preventing melanoma in a patient comprising admînistering to the patient a therapeutically effective amount of a compound having Formula XII:
wherein:
103
XII
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is:
R6b
wherein:
R6a, R6b, R6c, R6d, and R6e are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is optionally substituted CrC8 alkyl;
R4 is selected from the group consisting of hydrogen and optionally substituted
Ci-C8 alkyl;
R5 is selected from the group consisting of:
wherein:
R7 is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl;
X is selected from the group consisting of O, S, and NR';
Y is selected from the group consisting of O, S, and NR;
R' is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl; and
R is selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl, wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait thereof.
Embodiment XXV:The method of Embodiment XXIV, further comprising administering to the patient one or more additional anticancer agents.
Embodiment XXVI: | The method of Embodiment XXV, wherein the anticancer agent is |
a chemotherapeutic agent.
Embodiment XXVII: | The method of Embodiment XXVI, wherein the anticancer agent is |
radiation therapy.
Embodiment XXVIII: The method of any one of Embodiments XXIV-XXVII, wherein the melanoma is characterized by résistance to conventional cancer therapy.
104
Embodiment XXIX: The method of any one of Embodiments XXIV-XXVIII, wherein the melanoma expresses wild-type p53 protein.
Embodiment XXX:The method of any one of Embodiments XXIV-XXIX, wherein the compound of Formula XII is:
A kit comprising a compound having Formula XII:
Embodiment XXXI:
XII wherein:
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is:
wherein:
R6a, R6b, R6c, R6d, and R6® are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R3 is optionally substituted CrCa alkyl;
R4 is selected from the group consisting of hydrogen and optionally substituted
CrC6 alkyl;
R5 is selected from the group consisting of:
105 wherein:
R7 is selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl;
X is selected from the group consisting of O, S, and NR;
Y is selected from the group consisting of O, S, and NR;
R is selected from the group consisting of hydrogen and optionally substituted 0,-0^ alkyl; and
R’ is selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl, wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait thereof, and instructions for admînistering the compound to a patient having melanoma. Embodiment XXXII: The kit of Embodiment XXXI, further comprising one or more additional anticancer agents.
Embodiment XXXIII: The kit of Embodiment XXXI, wherein the instructions direct coadministration of the compound together with an additional anticancer agent.
In certain aspects, the following particular embodiments are provided herein: Embodiment XXXIV: A compound having Formulae XII:
XII wherein:
R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
R2 is:
wherein:
R25a, R2Sb, R25c, R25d, and R25® are each independently selected from the group consisting of hydrogen, fluoro, and chloro;
106
R3 is optionally substituted CrCa alkyl;
R4 is selected from the group consisting of hydrogen and optionally substituted
Ci-C6 alkyl;
R5 is selected from the group consisting of:
wherein:
R14 is selected from the group consisting of hydrogen and optionally substituted Ci-C4 alkyl;
X is selected from the group consisting of O, S, and NR';
Y is selected from the group consisting of O, S, and NR”;
R is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl; and
R” is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl, wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XXXV: The compound of Embodiment XXXIV, wherein R4 is hydrogen, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XXXVI: The compound of Embodiment XXXIV, wherein X is NH, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XXXVII: The compound of Embodiment XXXIV, wherein Y is NH, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XXXVIII: The compound of Embodiment XXXIV, wherein R3 is ΟΗ2Ο(ΟΗ3)3, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XXXIX: The compound of Embodiment XXXIV, wherein R5 is selected from the group consisting of:
—1 | /XU0H | L-I-oh | |
OH | Oh | Me | 1 Me |
'Xi | ZO | Me | Λ-Π and Ιχχί-ΟΗ Me |
107 or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XL: The compound of Embodiment XXXVIII, wherein:
R1a is hydrogen;
R1b, R1c, and R1d are each independently selected from the group consisting of
hydrogen, fluoro, and chloro; | |||
R3 is C4-Ce alkyl; R4 is hydrogen; R5 is selected from the group consisting of: | |||
A^ | VoH | A LL oh | |
''OH | Me | 1 Me | |
O- ΌΗ | ru | and Q..oh | |
Me | Me ;and |
XandYareNH;
or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLI: The compound of Embodiments XXXIX or XL, wherein Rs is selected from the group consisting of:
or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLII: The compound of Embodiment XXXIV selected from the group consisting of:
108
109
or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLIII: A compound having the structure:
or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLIV: A compound having the structure:
UO or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLV:The compound of any one of Embodiments XLII-XLIV, wherein the compound is substantially free of other stereoisomers, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLVI: The compound of Embodiment XLV, wherein the compound is a substantially pure stereoisomer, or a pharmaceutically acceptable sait, solvaté, or prodrug thereof.
Embodiment XLVII: A pharmaceutical composition comprising the compound of any one of Embodiments XXXIV-XLVI and a pharmaceutically acceptable carrier.
Embodiment XLVIII: A method of treating a patient comprising administering to the patient a therapeutïcally effective amount of the compound or a pharmaceutically acceptable sait thereof of any one of Embodiments XXXIV-XLVI, wherein the patient has a hyperproliferative disease.
Embodiment XLIX: A method of treating a patient comprising administering to the patient a therapeutïcally effective amount of the pharmaceutical composition of Embodiment XLVII, wherein the patient has a hyperproliferative disease.
Embodiment L: The method of Embodiments XLVIII or XLIX, wherein the hyperproliferative disease is cancer.
Embodiment Ll; The method of daims Embodiments XLVIII or XLIX, wherein cells of the hyperproliferative disease express functional p53.
Embodiment LII: The method of Embodiment L, further comprising administering to the patient one or more anticancer agents.
Embodiment LUI: The method of Embodiment LII, wherein the anticancer agent is a chemotherapeutic agent.
Embodiment LIV: The method of Embodiment LII, wherein the anticancer agent is radiation therapy.
Embodiment LV: A method of treating a patient, wherein the patient has a hyperproliferative disorder and is being treated with an anticancer agent, comprising administering to the patient a compound or pharmaceutically acceptable sait thereof of any one of Embodiments XXXIV-XLVI.
Embodiment LVI: The method of Embodiment LV, wherein the patient is experiencing sideeffects of the anticancer agent treatment selected from the group consisting of mucositis, stomatitis, xerostoma, alopecia, and gastrointestinal disorder.
Embodiment LVII: The method of Embodiment LVI, wherein cells of the hyperproliferative disorder express functional p53.
lll
Embodiment LVIII: A kit comprising a compound of any one of Embodiments XXXIVXLVI and instructions for administering the compound to a patient having a hyperproliferative disease.
Embodiment LIX: The kit of Embodiment LVIII, wherein the hyperproliferative disease is cancer.
Embodiment LX: The kit of Embodiment LIX, further comprising one or more anticancer agents.
Embodiment LXI: The kit of Embodiment LX, wherein the instructions direct coadministration of the compound together with the one or more anticancer agents.
EXAMPLE 1
Analytical Data for compounds
General Information
NMR spectra were recorded on a BRUKER AVANCE 250, BRUKER AVANCE 300, BRUKER AVANCE DRX-400, or BRUKER AVANCE DPX-500, or similar instrument Unless otherwise indicated all NMR chemical shifts reported herein are denoted by the delta (□) scale.
Liquid chromatography-mass spectrometry (denoted LC-MS) analysis was performed using method A, method B, or method C:
Method A: WATERS UPLC-SQD apparatus; lonization: electrospray in positive mode and/or négative mode (ES+/-); Chromatographie conditions: Column: ACQUITY BEH C18
1.7 pm - 2.1 x 50 mm; Solvents: A: H2O (0.1 % formic acid) B: CH3CN (0.1 % formic acid); Column température: 50 °C; Flow: 1 ml/min; Gradient (2 min): from 5 to 50 % of B in 0.8 min; 1.2 min: 100 % of B; 1.85 min: 100 % of B; 1.95 : 5 % of B; Rétention time = tR (min).
Method B: WATERS ZQ apparatus; lonization: electrospray in positive mode and/or négative mode (ES+/-); Chromatographie conditions: Column: XBridge C18 2.5 pm - 3 x 50 mm; Solvents: A: H2O (0.1 % formic acid) B: CH3CN (0.1 % formic acid); Column température: 70°C; Flow: 0.9 ml/min; Gradient (7 min): from 5 to 100 % of B in 5.3 min; 5.5 min: 100 % of B; 6.3 min: 5 % of B; Rétention time = tR (min).
Method C: WATERS UPLC-SQD apparatus; lonization: electrospray in positive mode and/or négative mode (ES+/-); Chromatographie conditions: Column: ACQUITY BEH C18
1.7 pm - 2.1 x 50 mm; Solvents: A: H2O (0.1 % formic acid) B: CH3CN (0.1 % formic acid); Column température: 50 °C; Flow: 0.8 ml/min; Gradient (2.5 min): from 5 to 100 % of B in
1.8 min; 2.4 min: 100 % of B; 2.45 min: 100 % of B; from 100 to 5 % of B in 0.05 min; Rétention time = tR (min).
112
Purity analysis was performed using reverse-phase HPLC using a SunFire™ C18 5 pm 4.6 x150 mm column at a flow rate of 1 mL/min under the following conditions: Condition I: Gradient from 90% of solvent A (0.1% of TFA in water) and 10% of solvent B (0.1% of TFA in methanol) to 5% of solvent A and 95% of solvent B in 85 min; and Condition II: Gradient from 80% of solvent A (0.1% of TFA in water) and 20% of solvent B (0.1% of TFA in acetonitrile) to 50% of solvent A and 50% of solvent B in 30 min.
Low resolution ESl mass spectrum analysis was performed on Thermo-Scientific LCQ Fleet mass spectrometer or similar instrument.
The chemical names of the compounds provided in this example were determined with ADCLABS version 12.0.
C027 - TFA sait
1H NMR (300 MHz, MeOH-d4): 7.50-7.36 (m, 1H), 7.24-7.10 (m, 2H), 6.88-6.76 (m, 3H), 5.12 (d, J = 10.17 Hz, 1H), 4.49 (d, J = 10.17 Hz, 1H), 4.23 (dd, J= 6.83, 2.09 Hz, 1H), 3.983.83 (m, 1H), 2.49-2.36 (m, 1H), 2.36-2.22 (m, 1H), 2.10-1.96 (m, 2H), 1.94-1.82 (m, 1H), 1.35-1.28 (m, 1H), 1.29 (s, 3H), 0.80 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 108.1, 166.0,
145.4, 136.9, 127.9, 126.1 (t, JC F = 5.6 Hz), 125.4, 123.4 118.8 (d, JC-f - 17-3 Hz), 112.0,
67.4, 64.5, 63.7, 61.6, 49.5, 45.6, 45.5, 42.4, 38.5, 30.9, 29.5, 27.6; ESI-MS calculated for CzaHas^CIFaNaOa [M+H]+: 532.2179, Found: 532.42.
C029 - TFA sait
1H NMR (300 MHz, MeOH-d4): 8.84 (d, J =6.80 Hz, 1H), 7.58 (t, J = 6.80 Hz, 1H), 7.39 (t, J = 7.11 Hz, 1H), 7.22 (t, J = 7.80 Hz, 1H), 6.88 (dd, J = 9.81, 7.80 Hz, 1H),6.78 (d, J= 10.13, 6.63 Hz, 1H), 5.11 (d, J = 10.37 Hz, 1H), 4.48 (d, J = 10.37 Hz. 1H), 4.21 (d, J = 10.37 Hz, 1H), 4.21 (dd, J = 7.32, 2.66 Hz, 1H), 3.95-3.75 (m, 1H), 2.46-2.22 (m, 2H), 2.12-1.96 (m, 2H), 1.94-1.80 (m, 1H), 1.34-1.28 (m, 1), 1.29 (s, 3H), 0.81 (s, 9H); 13C NMR (75 MHz,
113
MeOH-cL): 180.2, 169.2, 132.2, 128.7 (d, Jc*=2.2 Hz), 126.5 (d, JC-f= 4.6 Hz), 124.7 (dd, Jc-f= 33.5, 19.2 Hz), 122.6 (d, JC.F = 18.1 Hz), 101.5 (d, JC-f = 23.0 Hz), 67.4, 64.4, 63.5, 61.9, 49.8, 45.6, 45.5, 42.4, 38.6, 30.9, 29.5, 27.6; ESI-MS calculated for C28H32 35CIF3N3O3 [M+Hf: 550.2084, Found: 550.33.
C031 - TFA sait
’H NMR (300 MHz, MeOH-d4): 7.68-7.54 (m, 1H), 7.38-7.26 (m, 1H), 7.22-7.12 (m, 1H), 6.90-6.76 (m, 1H), 6.70-6.60 (m, 1H), 6.56-6.42 (m, 1H), 5.30-5.20 (m, 1H), 4.49 (d, J = 10.03 Hz. 1H), 4.25 (dd, J = 71.9, 2.39 Hz. 1H), 4.00-3.82 (m, 1H), 2.50-2.21 (m, 2H), 2.182.00 (m, 2H), 1.98-1.82 (m, 1H), 1.40-1.30 (m, 1H), 1.28 (s, 3H), 0.79 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 180.6, 165.1 (d, JC-f= 246.7 Hz), 166.1, 157.7 (d, JC-f= 247.9 Hz), 145.6 (d, JC-f= 12.0 Hz), 132.0, 128.6, 128.2 (d, JC-f= 10.2 Hz). 126.3 (d, JCF = 4.5 Hz), 125.0 (d, JC.F= 14.0 Hz), 122.4 (d, JC.F= 18.4Hz), 122.3, 109.8 (d, JC-f= 23.2 Hz), 99.9 (d, JC F= 27.8 Hz), 67.4, 64.5, 63.5, 61.5, 49.2, 45.6, 45.5, 42.3, 38.4, 30.9, 29.5, 27.5; ESI-MS calculated for C28H3335CIF2N3O3 [M+Hf : 532.2179, Found: 532.42.
C034 - TFA sait
’H NMR (300 MHz, MeOH-d4): 7.28-7.10 (m, 5H), 6.92-6.84 (m, 1H), 6.80-6.76 (m, 1H), 5.40-5.20 (m, 1 H), 5.08 (d, J = 10.96 Hz, 1H), 4.40-4.20 (m, 1H), 3.90-3.60 (m, 1 H), 2.502.30 (m, 1H), 2.30-2.15 (m, 1H), 2.15-2.00 (m, 2H), 1.90-1.75 (m, 1H), 1.57 (dd, J = 15.3, 3.71 Hz, 1H), 1.25 (s, 3H), 0.79 (s, 9H); ’3C NMR (75 MHz, MeOH-d4): 180.0, 165.9, 144.7, 136.7, 136.6, 135.8, 131.3, 130.1, 129.8, 128.1, 128.1, 126.8, 123.5, 112.0, 67.4, 64.3, 64.0,
62.2, 57.2, 45.7, 45.6, 42.7, 38.3, 31.0, 29.6, 27.5; ESI-MS calculated for C28H34 35CI2N3O3 [M+Hf: 530.1977, Found: 530.50.
C035 - TFA sait
114
1H NMR (300 MHz, MeOH-d4): 7.40-7.00 (m, 5H), 6.80-6.40 (m, 1H), 5.60-5.00 (m, 2H), 4.60-4.20 (m, 1H), 4.00-3.80 (m, 1H), 2.60-2.40 (m, 1H), 2.40-2.20 (m, 1H), 2.20-2.00 (m, 2H), 2.00-1.80 (m, 1H), 1.70-1.50 (m, 1H), 1.28 (s, 3H), 0.83 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 180.0, 165.8, 160.0-145.0 (m, 2 χ Csp2-F), 136.5, 135.9, 131.4, 130.0, 129.9, 128.0, 124.1 (d, JC-f = 6.3 Hz), 119.1, 116.7 (d, JC-f = 20.4 Hz), 101.4 (d, JC-f = 23.0 Hz),
67.4, 64.2, 63.8, 62.5, 57.4, 45.6, 45.5, 42.7, 38.3, 31.0, 29.5, 27.5; ESI-MS calculated for C28H33 35CIF2N3O3 [M+H]+: 532.2179, Found: 532.42.
MI-519-73 - TFA sait
1H NMR (300 MHz, MeOH-d4): 7.50-7.30 (m, 2H), 7.20-7.10 (m, 1H), 6.90-6.70 (m, 3H), 5.00-4.70 (m, 1H), 4.36 (d, J = 9.76 Hz, 1H), 4.05-3.96 (m, 1H), 3.70-3.50 (m, 1H), 1.94 (dd, J = 14.98, 7.30 Hz, 1H), 1.80-1.00 (m, 8H), 1.16 (s, 3H), 0.90-0.70 (m, 1H), 0.80 (s, 9H); ESI-MS calculated for C30H3735CI2FN3O3 [M+H]+: 576.2196, Found: 576.58.
Ml-519-74 - TFA sait
1H NMR (300 MHz, MeOH-d4): 7.50-7.30 (m, 2H), 7.25-7.10 (m, 1H), 6.85-6.70 (m, 3H), 5.00-4.70 (m, 1H), 4.32 (d, J = 9.69 Hz, 1H), 4.10-3.95 (m, 1H), 3.85-3.70 (m, 1H), 2.00-1.80 (m, 2H), 1.75-1.20 (m, 7H), 1.13 (s, 3H), 0.95-0.75 (m, 1H), 0.81 (s, 9H); ESI-MS calculated for C30H3735CI2FN3O3 [M+Hf: 576.2196, Found: 576.58.
MI-7102-TFA sait
115
1H NMR (300 MHz, MeOH-d4): 7.36-7.25 (m, 1H), 7.24-7.11 (m, 2H), 6.86 (d, J = 1.8 Hz, 1H), 6.80 (dd, J = 1.8, 8.1 Hz, 1H), 6.72 (d, 7 = 8.1 Hz, 1H), 4.82 (d, 7=9.6 Hz, 1H), 4.36 (d, 7 = 9.6 Hz, 1H), 4.04 (dd, 7 = 2.4, 7.4 Hz, 1H), 3.74-3.56 (m, 1H), 3.56-3.40 (m, 1H), 2.051.78 (m, 5H), 1.75-1.59 (m, 1H), 1.43-1.04 (m, 5H), 0.81 (s, 9H); ESI-MS calculated for C29H35CIF2N3O3 (M + H)+ requires 546.23, found 546.58; HPLC (Condition I) tR = 50.45 min (Purity 95.4%).
1H NMR (300 MHz, MeOH-d4): 8.38 (d, J = 7.7 Hz, 1H), 7.54 (t, J = 6.7 Hz, 1H), 7.40 (d, J = 7.1 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.93 (d, J = 6.1 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 4.45 (d, J = 10.3 Hz, 1H), 4.13 (dd, J = 2.8, 7.5 Hz, 1H), 3.77-3.55 (m, 1H), 3.55-3.42 (m, 1H), 2.09-1.71 (m, 4H), 1.70-1.56 (m, 1H), 1.45.1.02 (m, 5H). 0.82 <s, 9H); ESI-MS calculated for C29H34CI2F2N3O3 (M + H)* requires 580.19, found 580.67; HPLC (Condition I) tR = 55.01 min (Purity 88.1%).
MI-7104-TFA sait
1H NMR (300 MHz, MeOH-d4); 7.49 (t, J = 7.2 Hz, 1H), 7.45-7.38 (m, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.85-6.68 (m, 2H), 4.80 (d, J = 9.8 Hz, 1H), 4.36 (d, J = 9.9 Hz, 1H), 4.01 (dd, J =
2.4, 7.6 Hz, 1 H), 3.74-3.57 (m, 1 H), 3.55-3.39 (m, 1 H), 2.04-1.77 (m, 4H), 1.74-1.59 (m, 1 H), 1.44-1.04 (m, 5H), 0.90 (d, J = 4.5 Hz, 1H), 0.82 (s, 9H); ESI-MS calculated for
116
C29H34CIF3N3O3 (Μ + Η)+ requires 564.22, found 564.58; HPLC (Condition I) tR = 51.76 min (Purity 86.9%).
M1-7105- TFA sait
Ή NMR (300 MHz, MeOH-d4): 7.49 (t, J = 7.2 Hz, 1H), 7.45-7.38 (m, 1H), 7.22 (t, J = 8.0
Hz, 1H), 6.85-6,68 (m, 2H), 4.80 (d, J = 9.8 Hz, 1H), 4.36 (d, J = 9.9 Hz, 1H), 4.01 (dd, J =
2.4, 7.6 Hz, 1 H), 3.74-3.57 (m, 1 H), 3.55-3.39 (m, 1 H), 2.04-1.77 (m, 4H), 1.74-1.59 (m, 1 H), 1.44-1.04 (m, 5H), 0.90 (d, J = 4.5 Hz, 1H), 0,82 (s, 9H); ESI-MS calculated for C29H35CIF2N3O3 (M + H)+ requires 546.23, found 546,58; HPLC (Condition I) tR = 49.20 min (Purity 99.4%).
MI-7106-TFA sait
’H NMR (300 MHz, MeOH-d4): 8.36 (d, J = 7.0 Hz, 1 H), 7.59 (d, J = 8.1 Hz, 1 H), 7.41-7.11 (m, 4H), 7.04 (d, J= 7.6 Hz, 1H), 6.78 (d, J= 1.8 Hz, 1H), 5.19 (d, J = 11.3 Hz, 1H), 4.44 (J = 8.1 Hz. 1H), 4.07 (d, J = 11.3 Hz, 1H), 3.74-3.53 (m, 1H), 3.53-3.37 (m, ÏH), 2.08-,.83 (m, 3h), 1.83-1.e9 (m, 1H), 1.61-1.44 (m. 1H), 1.44-1.08 (m, 4H), 1.07-0.72 (m, 1H), 0.88 (s, 9H); ESI-MS calculated for CjgHaeCIzNaOa (M + H)+ requires 544.21, found 544.67; HPLC (Condition I) tR = 51.41 min (Purity 93.0%).
MI-7108-TFA sait
’H NMR (300 MHz, MeOH-d4/DMSO-d0): 10.15 (s, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.22 (s,
1H), 7.17-7.00 (m, 3H), 6.94 (d, J = 7.1 Hz, 1H), 6.81 (d, J = 6.0 Hz, 1H), 4.42 (d, J = 8.3 Hz.
117
H), 4.09 (d, J = 3.0 Hz, 1H), 3.79 (d, J = 8.3 Hz, 1H), 3.73-3.49 (m, 2H), 3.35 (d, J = 9.5 Hz,
1H), 2.10-1.84 (m, 4H), 1.52-1.11 (m, 5H), 0.87 (s, 9H); 13C NMR (75 MHz, MeOHdVDMSO-de): 177.1, 172.4, 153.6 (d, JC-F = 242.7 Hz), 138.7, 138.5 (d, JC.F = 2.4 Hz), 133.2, 129.0, 127.544, 127.541 (d, JC.F = 6.7 Hz), 126.8, 126.5, 119.7 (d, JC.F = 19.2 Hz), 111.3,
110.4 (d, JC.F = 24.1 Hz), 68.4, 66.6, 65.7, 64.0, 58.6, 46.8, 42.2, 33.26, 33.20, 30.4, 30.2, 29.7, 29.5; ESI-MS calculated for C29H35CI2FN3O3 (M + H)+ requires 562.20, found 562.67; HPLC (Condition I) tR = 55.08 min (Purity 96.1%); HPLC (Condition II) tR = 21.44 min (Purity 92.7%).
MI-7109 - TFA sait
1H NMR (300 MHz, MeOH-d4): 7.47 (t, J = 6.7 Hz, 1H), 7.42-7.33 (m, 1H), 7.18 (t, J = 7.7 Hz, 1H), 6.87 (d, J = 1.8 Hz, 1 H), 6.78 (dd, J = 1.8, 8.1 Hz, 1H), 6.70 (d, J = 8.1 Hz, ÏH), 4.40 (d, J =9.7 Hz, 1H), 4.11 (dd, J = 2.5, 7.6 Hz, 1H), 2.77-2.65 (m, 1H), 1.99 (dd, J =7.6, 15.3 Hz, 1H), 1 24 (dd, J = 2.5, 15.3 Hz, 1H), 0.92-0.62 (m, 2H), 0.81 (s, 9H), 0.56-0.30 (m, 2H); ESI-MS calculated for CZ6H29CI2FN3O2 (M + H)+ requires 504.1e, found 504.58; HPLC (Condition I) tR = 53.99 min (Purity 94.4%).
B059 - TFA sait
’H NMR (300 MHz, CD3OD): 7.45-7.34 (m, 1H), 7.26-7.12 (m, 1H), 7.04-6.93 (m, 1H), 6.90 (d, J= 1.80 Hz, 1H), 6.65 (dd, J = 8.08, 1.80 Hz, 1H), 4.41 (d, J= 9.25 Hz, 1H), 3.96 (quint, J = 8.13 Hz, 1H), 2.51-2.07 (m, 2H), 2.40-2.20 (m, 2H), 1.88 (dd, J = 14.20, 9.91 Hz, 1H), 1.32 (s, 3H), 1.20-0.80 (m, 1H), 0.88 (s, 9H); 13C NMR (75 MHz, CD3OD): 181.3, 172.9 (d, Jc-F = 266.9 Hz), 168.6, 162.7, 145.3, 135.8, 131.7,130.7 (d, JC.F = 38.6 Hz), 126.2 (d, JC-F = 4.5 Hz), 126.1, 123.6, 122.9, 122.7, 111.4, 78.4, 67.7, 63.4, 46.0, 45.8, 44.3, 38.0, 31.4,
30.2, 27.6; ESI-MS calculated for C28H31 35CI2FN3O3 [M+Hf: 546.1727, Found: 546.50.
MI-519-77 - TFA sait
U8
1H NMR (300 MHz, CD3OD): 7.50-7,40 (m, 1H), 7.40 (m, 1H), 7.20-7.10 (m, 1H), 6.85 (d, J = 1.40 Hz, 1H), 6.84-6.72 (m, 2H), 5.00-4.80 (m, 1H), 4.45 (d, J = 10.10 Hz, 1H), 4.02 (t, J =
6.61 Hz, 1H), 3.90 (quintet, J = 8.07 Hz, 1H), 2.50-2.25 (m, 2H), 2.10-1.82 (m, 3H), 1.811.31 (m, 8H), 1.30 (s, 3H), 1.10-0.91 (m, 1H), 0.91-0.81 (m 1H); ESI-MS calculated for C29H33 35CI2FN3O3 [M+Hf: 560.1883, Found: 560.50.
MI-519-78 - TFA sait
H 1H NMR (300 MHz, CD3OD): 7.45-7.31 (m, 2H), 7.20-7.11 (m, 1H), 6.86-6.82 (m, 1H), 6.816.78 (m, 2H), 4.90-4.80 (m, 1H), 4.45 (d, J = 10.33 Hz, 1H), 4.10-3.95 (m, 1H), 3.70-3.60 (m, 1H), 3.50-3.40 (m, 1H), 2.10-1.05 (m, 17 H), 1.05-0.95 (m, 1H), 0.95-0.80 (m, 1H); ESI-MS calculated for C3oH3535CI2FN303 [M+H]+: 574.2040, Found: 574.58.
MI-519-80 - TFA sait
1H NMR (300 MHz, CD3OD): 7.80-7.72 (m, 1H), 7.50-7.38 (m, 2H), 6.87 (d, J = 1.81 Hz, 1H), 6.71 (dd, J = 8.16, 1.81 Hz, 1H), 6.52-6.40 (m, 1H), 4.96-4.80 (m, 1H), 4.62 (d, J = 8.69
Hz, 1H), 4.10-3.95 (m, 1H), 3.70-3.55 (m, 1H), 3.50-3.45 (m, 1H), 2.00-1.80 (m, 3H), 1.80119
1.60 (m, 1H), 1.40-1.00 (m, 5H), 0.95-0.85 (m, 1H), 0.80 (s, 9H); ESI-MS calculated for C29H35 35CI3N3O3 [M+H]+: 578.1744, Found: 578.75.
C02701 - TFA sait (2’S,3'R,4'S,5'R)-6-Chloro-4'-(2,3-difluoro-phenyl)-2,-(2,2-dimethyl-propyl)-2-oxo-1,2dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (3-hydroxy-3-methylcyclobutyl)-amide, trifluoroacetate
1H), 7.20-7.05 (m, 3H), 6.80-6.75 (m, 1H), 5.40-5.10 (m, 1H), 4.61 (d, J = 11.39 Hz, 1H), 4.50 (d, J =7.66 Hz, 1H), 3.95-3.80 (m, 1H), 2.45-2.30 (m, 1H), 2.30-2.15 (m, 1H), 2.05-1.80 (m, 2H), 1.80-1.60 (m, 1H), 1.27 (s, 3H), 1.20-1.08 (m. 1H), 0.86 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.8, 167.0, 160.0-148.0 (m, 2 x Csp2-F), 145.2, 137.2, 126.8, 126.5-126.0 (m), 125.0, 124.1, 123.5, 122.1 (d, JC-f = 9.74 Hz), 119.1 (d, JC-f = 17.1 Hz), 112.1, 67.3, 64.5,
64.2, 62.6, 48.5, 45.6, 45.5, 43.3, 38.3, 31.0, 29.5, 27.5; ESI-MS calculated for C28H33 35CIF2N3O3 [M+H]+: 532.2179, Found: 532.50.
LC-MS: tR (min) = 0.86; [M+H]+: m/z 532; [M-H]’: m/z 530 (method A).
1H NMR (400 MHz, DMSO-de + TFA): 0.80 (s, 9 H); 1.01 (d broad, J=15.2 Hz, 1 H); 1.20 (s, 3 H); 1.60 (m, 1 H); 1.85 to 1.98 (m, 2 H); 2.08 (m, 1 H); 2.25 (m, 1 H); 3.72 (m, 1 H); 4.49 (m, 2 H); 5.30 (d, J=12.1 Hz, 1 H); 6.78 (d, J=2.0 Hz, 1 H); 7.16 (dd, J=2.0 and 8.3 Hz, 1 H); 7.23 (m, 1 H); 7.42 (m, 1 H); 7.48 (m, 1 H); 7.74 (d, J=8.3 Hz, 1 H).
C02901 - TFA sait (2'S,3,R,4'S,5’R)-4'-(3-Chloro-2-fluoro-phenyl)-2’-(2,2-dimethyl-propyl)-5,6-difluoro-2oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (3-hydroxy-3-methylcyclobutyl)-amide, trifluoroacetate
120 1H NMR (300 MHz, MeOH-d4): 7.80-7.65 (m, 1H), 7.60-7.50 (m, 1H), 7.40-7.30 (m, 1H), 7.20-7.10 (m, 1H), 6.80-6.65 (m, 1H), 5.50-5.10 (m, 1H), 4.60 (d, J = 11.39 Hz, 1H), 4.50 (d, J = 6.96 Hz, 1 H), 3.95-3.80 (m, 1H), 2.50-2.30 (m, 1H), 2.30-2.20 (m, 1H), 2.10-1.80 (m, 2H), 1.80-1.65 (m, 1H), 1.27 (s, 3H), 1.20-1.05 (m, 1H), 0.87 (s, 9H); 13C NMR (75 MHz, MeOH-di): 177.8, 167.0, 160.0-145.0 (m, 3* Csp2-F), 132.6, 128.6, 126.6, 122.5 (d, JC-f = 18.9 Hz), 121.3 (d, JC-f = 13.0 Hz), 118.8, 115.4 (d, JC.F= 21.7 Hz), 115.1, 101.8 (d, JC-f = 23.3 Hz), 67.3, 64.6, 64.3, 62.5, 48.7, 45.6, 45.5, 43.4, 38.3, 31.0, 29.5, 27.5; ESI-MS calculated for C2aH32 35CIF3N3O3 [M+H]*: 550.2084, Found: 550.33.
LC-MS: tR (min) = 0.87; [M+H]+: m/z 550; [M-H]‘: m/z 548 (method A).
1H NMR (400 MHz; DMSO-d6 + TFA): 0.80 (s, 9 H); 1.01 (d, J=15.2 Hz, 1 H); 1.20 (s, 3 H); 1.62 (m, 1 H); 1.85 to 1.98 (m, 2 H); 2.08 (m, 1 H); 2.26 (m, 1 H); 3.73 (m, 1 H); 4.52 (m, 2 H); 5.28 (d, J=12.1 Hz, 1 H); 6.79 (dd, J=6.7 and 10.1 Hz, 1 H); 7.25 (t, J=7.8 Hz, 1 H); 7.50 (m, 1 H); 7.60 (m, 1 H); 8.08 (m, 1 H).
C03001 - TFA sait
methyl-cyclobutyl)-amide, trifluoroacetate
1H NMR (300 MHz, MeOH-d4): 7.70 (d, J = 7.30 Hz, 1H), 7.60-7.50 (m, 1H), 7.45-7.35 (m, 1H), 7.25-7.15 (m, 1H), 6.88 (d, J = 6.00 Hz, 1H), 5.21 (d, J = 11.35 Hz, 1H), 4.61 (d, J = 11.37 Hz, 1H), 4.53 (d, J = 8.19 Hz, 1H), 3.95 -3.80 (m, 1H). 2.50-2.35 (m, 1H), 2.35-2.15 (m, 1H), 2.00-1.80 (m, 2H), 1.80-1.60 (m, 1H), 1.29 (s, 3H), 1.25-1,05 (m, 1H), 0.89 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.3, 166.7, 157.6 (d, JC-f= 249.5 Hz), 155.7 (d, JC-f= 243.5 Hz), 140.4 (d, JC-f= 2.8 Hz), 132.5, 128.4, 126.4 (d, JC.F = 4.9 Hz), 125.0 (d, JCF= 7.4 Hz),
123.4 (d, JC.F= 19.5 Hz), 122.3 (d, JC.F = 18.9 Hz), 121.0 (d, JC-f= 13.0 Hz), 114.5 (d, JC-f = 25.1 Hz), 104.8, 67.1, 64.6, 64.2, 62.4, 47.3, 45.4, 45.3, 43.2, 38.2, 30.8, 29.2, 27.3; ESI-MS calculated for C28H32 35CI2F2N3O3[M+H]+: 566.1789, Found: 566.50.
LC-MS: tR (min) = 0.93; [M+H]+: m/z 566 (method A).
1H NMR (400 MHz, DMSO-de + TFA): 0.81 (s, 9 H); 1.02 (d broad, J=15.2 Hz, 1 H); 1.20 (s, 3 H); 1.62 (m, 1 H); 1.87 to 1.99 (m, 2 H); 2.09 (m, 1 H); 2.27 (m, 1 H); 3.75 (m, 1 H); 4.55
121 (m, 2 H); 5.30 (d, J=12.1 Hz, 1 H); 6.89 (d, J=6.3 Hz, 1 H); 7.25 (t, J=7.8 Hz, 1 H); 7.50 (m,
H); 7.61 (m, 1 H); 8.04 (d, J=8.9 Hz, 1 H)
C031 - TFA sait
LC-MS: tR (min) = 0.84; [M+Hf: m/z 532; [M-H]’: m/z 530 (method A).
’H NMR (400 MHz, DMSO-de + TFA): 0.83 (s, 9 H); 1.11 (d broad, J=15.2 Hz, 1 H); 1.22 (s, 3 H); 1.83 (m, 1 H); 2.00 to 2.36 (m, 4 H); 3.82 (m, 1 H); 4.20 (dd, J=2.9 and 7.7 Hz, 1 H);
4.36 (d, J=10.5 Hz, 1 H); 5.00 (d, J=10.5 Hz, 1 H); 6.53 to 6.74 (m, 2 H); 6.94 (dd, J=5.6 and 8.8 Hz, 1 H); 7.21 (t, J=8.0 Hz, 1 H); 7.41 (t, J=8.0 Hz, 1 H); 7.71 (t, J=8.0 Hz, 1 H).
Cl ’H NMR (300 MHz, MeOH-d4): 7.58 (d, J = 8.07 Hz, 1H), 7.30-7.10 (m, 4H), 7.02 (d, J = 7.67 Hz, 1H), 6.77 (d, J = 1.54 Hz, 1H), 5.40-5.20 (m, 1H), 4.44 (d, J = 7.09 Hz, 1H), 4.10 (d, J = 11.25 Hz, 1H), 3.95-3.80 (m, 1H), 2.45-2.30 (m, 1H), 2.30-2.15 (m, 1H), 2.05-1.85 (m, 2H), 1.80-1.70 (m, 1H), 1.27 (s, 3H), 1.20-1.10 (m,1H), 0.86 (s, 9H); ’3C NMR (75 MHz,
MeOH-d4): 177.8, 167.3, 145.3, 137.1, 135.8, 134.4, 131.4, 130.4, 129.5, 128.3, 126.3,
124.2, 124.1, 112.2, 67.3, 64.9, 64.2, 62.8, 57.2, 45.7, 45.6, 43.4, 38.3, 31.0, 29.5, 27.5;
ESI-MS calculated for C28H3435CI2N3O3 [M+Hf: 530.1977, Found: 530.58.
LC-MS: tR (min) = 0.84; [M+Hf: m/z 530; [M-H]’: m/z 528 (method A).
’H NMR (400 MHz, DMSO-d6 + TFA): 0.80 (s, 9 H); 1.02 (d broad, J=15.5 Hz, 1 H); 1.20 (s, 3 H); 1.68 (m, 1 H); 1.82 to 2.00 (m, 2 H); 2.09 (m, 1 H); 2.27 (m, 1 H); 3.73 (m, 1 H); 4.07 (d, J=11.9 Hz, 1 H); 4.32 (dd, J=2.2 and 8.4 Hz, 1 H); 5.29 (d, J=11.9 Hz, 1 H); 6.74 (d, J=2.0 Hz, 1 H); 6.98 (d, J=7.8 Hz, 1 H); 7.15 to 7.35 (m, 4 H); 7.78 (t, J=8.3 Hz, 1 H).
C03701 - TFA sait
122 (2'S,3,R,4'R,5'R)-6-Chloro-4'-(3-chloro-phenyl)-2’-(2>2-dimethyl-propyl)-5-fluoro-2oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (3-hydroxy-3-methylcyclobutyl)-amide, trifluoroacetate
’H NMR (300 MHz, MeOH-d4): 9.00-8.80 (m, 1 H), 7.73 (d, J = 8.42 Hz, 1H), 7.40-7.20 (m, 3H), 7.15-7.05 (m, 1H), 6.89 (d, J = 6.00 Hz, 1 H), 5.32 (d, J = 11.34 Hz, 1H), 4.52 (d, J = 7.91 Hz, 1H), 4.20 (d, J = 11.28 Hz, 1H), 4.00-3.80 (m, 1H), 2.50-2.35 (m, 1H), 2.35-2.20 (m, 1H), 2.20-1.90 (m, 2H), 1.90-1.80 (m, 1H), 1.31 (s, 3H), 1.30-1.15 (m, 1H), 0.91 (s, 9H); ’3C NMR (75 MHz, MeOH-d4): 178.8, 168.2, 157.3 (d, JC-f = 255.8 Hz), 142.1 (d, JC.F= 2.6 Hz), 137.1, 135.5, 132.8, 131.7, 130.7, 129.6, 127.2 (d, JC-f= 7.2 Hz), 124.7 (d, JC F = 19 3 Hz), 115.5 (d, JC.F = 24.9 Hz), 114.8, 68.6, 66.6, 65.3, 64.0, 58.2, 47.0, 46.8, 44.7, 39.5,
32.2, 30.8, 28.8; ESI-MS calculated for C2eH33 35CI2FN3O3 [M+H]+: 548.1883, Found: 548.42. LC-MS: tR (min) = 0.87; [M+Hf: m/z 548; [M-H]‘: m/z 546 (method A).
1H NMR (400 MHz, DMSO-d0): 0.70 to 2.23 (m, 18 H); 3.68 to 5.10 (m, 4 H); 6.78 to 8.03 (m, 6 H).
C04801 - TFA sait (2’S,3'R,4’S,5'R)-6-Chloro-4'-(2,3-difluoro-phenyl)-2'-(2,2-dimethyl-propyl)-5-fluoro-2oxo-1 ^-dihydro-spirolindole-S.S'-pyrrolidinel-S’-carboxylic acid (3-hydroxy-3-methylcyclobutyl)-amide, trifluoroacetate
’H NMR (300 MHz, MeOH-d4): 9.00-8.80 (m, 1H), 7.70 (d, J = 8.35 Hz, 1H), 7.50-7.35 (m, 1H), 7.30-7.10 (m, 2H), 6.88 (d, J = 6.88 Hz, 1 H), 5.30 (d, J = 11.32 Hz, 1H), 4.66 (d, J = 11.33 Hz, 1H), 4.56 (d, J = 7.43 Hz, 1H), 4.00-3.80 (m, 1H), 2.50-2.35 (m, 1H), 2.35-2.20 (m, 1H), 2.10-1.90 (m, 2H), 1.80-1.70 (m, 1H), 1.30 (s, 3H), 1.16 (d, J = 15.34 Hz, 1H), 0.90 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.5, 166.9, 160-145 (m, 2 * Csp2-F), 155.9 (d, JCF =
243.4 Hz), 140.7 (d, JC-F = 2.69 Hz, 1H), 126.5-126.1 (m), 125.6 (d, JC F= 7.6 Hz), 125.0 (d,
123
7C.F = 3.4 Hz), 123.6 (d, 7C.F = 19.5 Hz), 122.0 (d, 7C.F = 9.8 Hz), 119.1 (d, 7C.F=17.1 Hz), 114.7 (d, JC.F = 25.0 Hz), 113.4, 67.3, 64.7, 64.3, 62.5, 48.2, 45.6, 45.6, 43.4, 38.3, 31.0, 29.5, 27.5; ESI-MS calculated for 02βΗ32 350ΙΕ3Ν303 [M+Hf: 550.2084, Found: 550.42. LC-MS: tR (min) = 0.89; [M+Hf: m/z 550; [M-H]’: m/z 548 (method A) 1H NMR (400 MHz, DMSO-d6 + TFA): 0.81 (s, 9 H); 1.02 (d broad, J=15.5 Hz, 1 H); 1.20 (s, 3 H); 1.62 (m, 1 H); 1.87 to 1.98 (m, 2 H); 2.09 (m, 1 H); 2.26 (m, 1 H); 3.73 (m, 1 H); 4.56 (m, 2 H); 5.29 (d, J=12.4 Hz, 1 H); 6.89 (d, J=6.2 Hz, 1 H); 7.20 to 7.49 (m, 3 H); 8.06 (d, J=9.3 Hz, 1 H).
MI-710201 - TFA sait (2'Sl3,R,4'S,5,R)-6-Chloro-4,-(2,3-difluoro-phenyl)-2,-(2,2-dimethyl-propyl)-2-oxo-1,2dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-hydroxy-cyclohexyl)-amîde, trifluoroacetate
1H NMR (300 MHz, MeOH-d4): 7.57 (d, J = 8.0 Hz, 1H), 7.50-7.36 (m, 1H), 7.27-7.07 (m, 3H), 6.79 (s, 1H), 5.11 (d, J = 11.1 Hz, 1H), 4.55 (d, J = 11.0 Hz, 1H), 4.39 (d, J = 7.7 Hz, 1H), 3.71-3.52 (m, 1H), 3.52-3.37 (m, 1H), 3.21 (dd, J = 7.4, 14.5 Hz, 1H), 1.92 (d, J = 9.6 Hz, 1H), 1.86-1.70 (m, 2H), 1.58 (d, 7= 11.8 Hz. 1H), 1.43-1.18 (m, 4H), 1.12 (d, 7= 15.5 Hz, 1H), 0.99 (d, 7= 13.0 Hz, 1H), 0.88 (s, 9H); ESI-MS calculated for C29H35CIF2N3O3 (M + H)+ requires 546.23, found 546.58; HPLC (Condition I) tR = 52.15 min (Purity 98.8%). LC-MS: tR (min) = 0.84; [M+Hf: m/z 546; [M-H]': m/z 544 (method A).
1H NMR (400 MHz; DMSO-d6): mixture of isomers: 0.80 (s, 9 H); 0.84 to 1.30 (m, 5 H); 1.41 to 1.87 (m, 5 H); 3.43 to 3.54 (m, 2 H); 4.03 (m broad, 1 H); 4.36 (d broad, J=10.3 Hz, 2 H); 4.83 (m broad, 1 H); 6.72 (d, J=2.0 Hz, 1 H); 7.10 (dd, J=2.0 and 8.3 Hz, 1 H); 7.14 (m, 1 H); 7.24 (m, 1 H); 7.40 (m, 1 H); 7.58 (d, J=8.3 Hz, 1 H); 7.97 (m broad, 1 H); 10.56 (m broad, 1 H).
Ml-710401 - TFA sait (2’S,3’R,4'S,5'R)-4'-(3-Chloro-2-fluoro-phenyl)-2’-(2,2-dimethyl-propyl)-5,6-difluoro-2oxo-1,2-dihydro-spiro[indole-3,3’-pyrrolidine]-5’-carboxylic acid (4-hydroxycyclohexyl)-amide, trifluoroacetate
124
’H NMR (300 MHz, MeOH-d4): 7.67 (t, J = 8.6 Hz, 1H), 7.57 (t, J = 6.8 Hz, 1H), 7.38 (t, J = 6.8 Hz, 1H), 7.15 (t, J = 7.8 Hz, 1H), 6.71 (dd, J = 6.6, 10.1 Hz, 1H), 5.01 (d, J = 10.8 Hz. 1H), 4.52 (d, J = 10.8 Hz, 1H), 4.40-4.21 (m, 1H), 3.74-3.56 (m, 1H), 3.56-3.40 (m, 1H), 2.08-1.87 (m, 2H), 1.87-1.68 (m, 2H), 1.68-1.53 (m, 1H), 1.45-1.18 (m, 3H), 1.17-0.97 (m, 2H), 0.89 (s, 9H); ESI-MS calculated for C29H34CIF3N3O3 (M + Hf requires 564.22, found 564.58; HPLC (Condition I) tR = 52.15 min (Purity 98.8%).
LC-MS: tR (min) = 0.84; [M+H]+: m/z 564; [M-H]': m/z 562 (method A) ’H NMR (400 MHz; DMSO-d6 + TFA): 0.81 (s, 9 H); 0.81 to 1.98 (m, 10 H); 3.35 (m, 1 H); 3.52 (m, 1 H); 4.53 (d, J=12.2 Hz, 1 H); 4.59 (dd, J=2.3 and 8.7 Hz, 1 H); 5.33 (d, J=12.2 Hz, 1 H); 6.78 (dd, J=6.8 and 10.3 Hz, 1 H); 7.21 (t, J=9.0 Hz, 1 H); 7.48 (m, 1 H); 7.66 (m, 1 H); 8.00 (m, 1 H).
MI-710501 - TFA sait (2,S,3’R14'S,5'R)-4'-(3-Chloro-2-fluoro-phenyl)-2’-(2,2-dimethyl-propyl)-6-fluoro-2oxo-1,2-dihydro-spiro[Îndole-3,3'-pyrrolidine]-5’-carboxylic acid (4-hydroxycyclohexyl)-amide, trifluoroacetate
’H NMR (300 MHz, MeOH-d4): 7.66-7.53 (m, 1H), 7.44-7.33 (m, 1H), 7.22-7.09 (m, 1H), 6.93-6.79 (m, 1H), 6.59-6.51 (m, 1H), 5.40-5.31 (m, 1H), 4.63-4.48 (m, 1H), 4.41-4.30 (m, 1H), 2.41-2.20 (m, 2H), 2.15-1.97 (m, 2H), 1.95-1.85 (m, 1H), 1.85-1.71 (m, 1H), 1.71-1.47 (m, 3H), 1.19-1.07 (m, 1H), 0.88 (s, 9H); ESI-MS calculated for C2gH34CIF3N3O3 (M + H)+ requires 546.23, found 546.58; HPLC (Condition I) tR= 52.05 min (Purity 98.8%); HPLC (Condition II) tR = 19.26 min (Purity 100%).
LC-MS: tR (min) = 0.80; (M+Hf: m/z 546; [M-H]': m/z 544 (method A).
’H NMR (400 MHz; DMSO-d6 + TFA): 0.81 (s, 9 H); 0.81 to 1.99 (m, 10 H); 3.35 (m, 1 H); 3.52 (m, 1 H); 4.47 (d, J=12.0 Hz, 1 H); 4.53 (d broad, J=8.3 Hz, 1 H); 5.37 (d, J=12.0 Hz, 1
125
H); 6.58 (dd, J=2.6 and 9.1 Hz, 1 H); 6.91 (m, 1 H); 7.21 (t, J=9.0 Hz, 1 H); 7.45 (m, 1 H);
7.62 to 7.72 (m, 2 H).
MI-710601 - TFA sait (2’S,3'R,4'R,5,R)-6-Chloro-4'-(3-chloro-phenyl)-2'-(2,2-dimethyl-propyl)-2-oxo-1,2dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-hydroxy-cyclohexyl)-amide, trifluoroacetate
LC-MS: tR (min) = 0.82; [M+H]+: m/z 544; [M-H]’: m/z 542 (method A).
’H NMR (400 MHz; DMSO-d6 + TFA): 0.80 (s, 9 H); 0.83 to 1.96 (m, 10 H); 3.34 (m, 1 H); 3.50 (m, 1 H); 4.02 (d, J=12.1 Hz, 1 H); 4.48 (d broad, J=8.5 Hz, 1 H); 5.32 (d, J=12.1 Hz, 1 H); 6.75 (dd, J=1.9 and 8.3 Hz, 1 H); 6.98 (d, J=7.8 Hz, 1 H); 7.18 to 7.32 (m, 4 H); 7.74 (d, J=8.3 Hz, 1 H).
MI-710801 (2,Sr3'R,4,R,5'R)-6-Chloro-4'-(3-chloro-phenyl)-2’-(2,2-dimethyl-propyl)-5-fluoro-2oxo-1 ^-dihydro-spiroOndole-S.S'-pyrrolidinel-S’-carboxylic acid (4-hydroxycyclohexyl)-amide
LC-MS: tR (min) = 0.85; [M+H]+: m/z 562; [M-H]': m/z 560 (method A).
1H NMR (400 MHz; DMSO-d6): 0.78 (m, 1 H); 0.81 (s, 9 H); 1.08 to 1.33 (m, 5 H); 1.70 to 1.90 (m, 4 H); 3.25 (m, 1 H); 3.35 to 3.58 (m, 3 H); 3.92 (d, J=9.2 Hz, 1 H); 4.43 (t, J=9.2 Hz, 1 H); 4.49 (d, J=4.8 Hz, 1 H); 6.79 (d, J=6.4 Hz, 1 H); 6.92 (d, J=7.8 Hz, 1 H); 7.09 to 7.21 (m, 3 H); 7.75 (d, J=8.5 Hz, 1 H); 7.83 (d, J=9.3 Hz, 1 H); 10.38 (s broad, 1 H).
MI-710901 - TFA sait (2’S,3'R,4,S,5’R)-6-Chloro-4’-(3-chloro-2-fluoro-phenyl)-2'-(2,2-dimethyl-propyl)-2oxo-1 ^-dihydro-spirotindole-S.S'-pyrrolidineJ-S'-carboxylic acid cyclopropylamide, trifluoroacetate
126
cf3co2h ’H NMR (300 MHz, MeOH-d4): 7.61 (d, J = 8.1 Hz, 1 H), 7.53 (t, J = 6.7 Hz, 1 H), 7.40 (t, J =
7.0 Hz, 1H), 7.21-7.08 (m, 2H), 6.79 (d, J= 1.6 Hz, 1H), 5.14 (d, J = 11.3 Hz, 1H), 4.60 (d, J = 11.3 Hz, 1 H), 4.48 (d, J = 7.0 Hz, 1 H), 2.78-2.58 (m, 1 H), 1.86 (dd, J = 8.4, 15.4 Hz, 1 H), 1.13 (d, J= 15.4 Hz, 1H), 0.88 (s, 9H), 0.78-0.60 (m, 2H), 0.47-0.16 (m, 2H); 13C NMR (75 MHz, MeOH-d4): 177.9, 169.5, 157.8 (d, JC F = 249.4 Hz), 145.2, 137.2, 132.6, 128.7, 126.8 (d, JC F = 1-6 Hz), 126.6 (d, JC-f - 4.9 Hz), 124.2, 123.6, 122.5 (d, JC.F = 18.8 Hz), 121.8 (d,
Jc-f =13.1 Hz), 64.7, 64.4, 62.9, 43.5, 31.0, 29.6, 23.9, 6.7, 6.5; ESI-MS calculated for CzeHzgC^FNgOi (M + H)+ requires 504,16, found 504.58; HPLC (Condition I) tR = 58.22 min (Purity 99.6%).
LC-MS: tR (min) = 0.98; [M+H]+: m/z 504; [M-H]': m/z 502 (method A) 1H NMR (400 MHz; DMSO-de + TFA): 0.15 (m, 1 H); 0.35 (m, 1 H); 0.54 to 0.70 (m, 2 H);
0.81 (s, 9 H);1.01 (d, J=15.2 Hz, 1 H); 1.91 (dd, J=8.4 and 15.2 Hz, 1 H); 2.66 (m, 1 H); 4.52 (m, 2 H); 5.27 (d, J=12.0 Hz. 1 H); 6.79 (d, J=2.0 Hz, 1 H); 7.18 (dd, J=2.0 and 8.3 Hz, 1 H);
7.23 (d, J=8.1 Hz, 1 H); 7.48 (m, 1 H); 7.59 (m, 1 H); 7.74 (d, J=8.3 Hz, 1 H).
C08301 - TFA sait
CF3CO2H 1H NMR (300 MHz, MeOH-d4): 7.64-7.54 (m, 1H), 7.20-7.46 (m, 1H), 7.46-7.38 (m, 1H),
7.28-7.14 (m, 2H), 5.26 (d, J= 11.34 Hz, 1H), 4.65 (d, J = 11.43 Hz, 1H), 4.55 (dd, J =8.28,
1.59 Hz. 1H), 3.95-3.80 (m, 1H), 2.46-2.33 (m, 1H), 2.30-2.20 (m, 1H), 2.40-1.84 (m, 2H),
1.76-1.64 (m,1H), 1.29 (s, 3H), 1.17 (dd, J = 15.40, 1.5 Hz, 1H), 0.88 (s, 9H); 13C NMR (75
MHz, MeOH-d4): 177.4, 166.9, 157.8 (d, JC-f = 249.9 Hz), 144.3 (d, JC.F = 248.0 Hz), 132.8,
132.5 (d, Jc-F = 12.3 Hz), 128.6, 126.7 (d, JC F = 4.87 Hz), 126.3 (d, JC-f = 3.32 Hz), 125.6,
123.9 (d, JC.F = 14.3 Hz), 122.6 (d, JC-f = 18.9 Hz), 122.1, 121.3 (d, JC-f =13.1 Hz), 67.2,
64.7, 64.5, 62.6, 48.9, 45.6, 45.5, 43.4, 38.3, 31.0, 29.5, 27.5; ESI-MS calculated for C28H3235Cl2F2N3O3 [M+H]+: 566.18, Found: 566.50.
127
C08601-TFA sait
1H NMR (300 MHz, MeOH-d4): 8.83 (d, J = 6.98 Hz, 1H), 7.54-7.38 (m, 2H), 7.30-7.14 (m, 3H), 5.26 (d, J =11.37 Hz, 1H), 4.64 (d, J = 11.37 Hz, 1H), 4.56 (dd, J = 8.35, 1.27 Hz, 1H), 3.95-3.80 (m, 1H), 2.48-2.34 (m, 1H), 2.32-2.20 (m, 1H), 2.08-1.86 (m, 2H), 1.80-1.64 (m, 1 H), 1.30 (s, 3H), 1.18 (d, J = 14.37 Hz, 1H), 0.90 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.4, 166.9, 133.9, 132.4, 130.1, 126.35 (dd, JC-f = 9.43, 2.72 Hz), 125.5, 125.0 (d, JC-f = 3.72 Hz), 124.0 (d, JC-f = 14.4 Hz), 122.1 (d, JC.F = 3.13 Hz), 121.9 (d, JC.F = 9.77 Hz), 119.3 (d, JC-f = 17.1 Hz), 119.9, 115.1, 67.3, 64.8, 64.7, 64.5, 62.6, 45.6, 45.5, 43.4, 38.4, 31.0, 29.5, 27.5; ESI-MS calculated for C2aH32 35CIF3N3O3 [M+Hf: 550.20, Found: 550.35.
C09101-TFA sait
1H NMR (300 MHz, MeOH-d4): 8.43 (d, J = 7.73 Hz, 1H), 7.66-7.54 (m, 2H), 7.39 (t, J= 7.31 Hz, 1H), 7.24-7.10 (m, 2H), 6.82 (d, J =1.43 Hz, 1H), 5.26 (d, J =12.22 Hz, 1H), 4.61 (d, J = 11.38 Hz, 1H), 4.53 (d, J = 7.73 Hz, 1H), 3.57-3.54 (m, 1H), 1.93 (dd, J = 15.41, 8.26 Hz, 1H), 1.80-1.10 (m, 9H), 1.16 (s, 3H), 0.89 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.6, 166.6, 157.7 (d, JC.F = 249.6 Hz), 144.9, 137.0, 132.4, 128.6, 126.5, 126.4 (d, JC.F = 4.9 Hz), 124.0, 123.3, 122.3 (d, JC-f= 19.2 Hz), 121.3 (d, JC.F= 13.0 Hz), 118.7, 114.9, 112.0, 68.7, 64.4, 64.0, 62.8, 50.2, 48.9, 43.2, 37.9, 37.8, 30.9, 30.8, 29.4, 28.5, 28.3; ESI-MS calculated for C30H3735CI2FN3O3 [M+H]+: 576.21, Found: 576.58.
C09601-TFA sait
CF3CO2I-I
128 ’H NMR (300 MHz, MeOH-d4): 8.84 (d, J = 6.87 Hz, 1H), 7.62 (d, J= 8.10 Hz, 1H), 7.19 (dd, J = 8.10, 1.79 Hz, 1H), 7.15 (dt, J = 8.42, 1.87 Hz, 1H), 7.01 (s, 1H), 6.94 (d, J= 9.62, 1.30 Hz, 1 H), 6.83 (d, J = 1.69 Hz, 1 H), 5.21 (d, J ~ 11.25 Hz, 1 H), 4.45 (dd, J = 8.21, 1.56 Hz, 1H), 4.15 (d, J = 11.25 Hz, 1H), 4.00-3.82 (m, 1H), 2.50-2.36 (m,1H), 2.36-2.22 (m, 1H), 2.10-1.98 (m, 1H) 1.91 (dd, J = 15.44, 8.30 Hz, 1H), 1.84-1.72 (m, 1H), 1.31 (s, 3H), 1.16 (dd, J = 15.44,1.47 Hz, 1H), 0.90 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.7,167.0, 164.0 (d, JC-f= 249.6 Hz), 145.3, 137.3, 136.6 (d, JC-f= 20.6 H), 136.6, 126.4, 126.1 (d, JC-p= 2.91 Hz), 124.3, 123.8, 117.9 (d, JC-f = 25.0 Hz), 115.4 (d, J = 23.0 Hz), 112.3, 67.3, 64.8, 64.3, 62.7, 56.7, 45.7, 45.6, 43.3, 38.4, 31.0, 29.6, 27.6; ESI-MS calculated for C28H333SCI2FN3O3 [M+H]+: 548.18 , Found: 548.67.
C09701-TFA sait
’H NMR (300 MHz, MeOH-d4): 8.21 (d, J ~ 6.81 Hz, 1H), 7.68-7.54 (m, 2H), 7.39 (td, J = 7.60, 1.36 Hz, 1H), 7.18 (t, J = 8.09 Hz, 1H), 7.13 (dd, J = 7.97, 1.92 Hz, 1H), 6.79 (d, J = 1.66 Hz, 1H), 5.30 (d, J = 11.51 Hz, 1H), 4.56 (d, J = 11.84 Hz, 1H), 4.52 (d, J - 8.26 Hz, 1H), 3.86-3.70 (m, 1H), 2.00-1.80 (m, 2H), 1.65-1.05 (m, 8H), 1.04 (s, 3H), 0.87 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.8, 167.2, 145.1, 137.2, 132.7, 128.8, 126.7 (d, JC.F = 3.6 Hz), 126.6, 124.2, 123.4, 122.6 (d, JC-f = 18.7 Hz), 121.7 (d, JC-f = 12.5 Hz), 112.1, 69.7, 64.6, 64.2, 62.9, 49.2, 43.4, 36.8, 36.4, 31.0, 29.5, 28.3, 28.3; ESI-MS calculated for C3oH3735CI2FN303 [M+H]+: 576.21, Found: 576.67.
C11701-TFA sait
’H NMR (300 MHz, MeOH-d4): 8.83 (d, J = 6.61 Hz, 1H), 7.64 (dd, J = 6.06, 2.50 Hz, 1H), 7.59 (d, J= 8.11 Hz, 1H), 7.36-7.22 (m, 1H), 7.11 (dd, J = 8.09, 1.76 Hz, 1H), 7.00-6.82 (m, 1H), 1.72 (d, J =1.72 Hz, 1H), 5.13 (d, J = 11.21 Hz, 1H), 4.58 (d, J = 11.21 Hz, 1H), 4.51 (dd, J = 8.23, 1.66 Hz, 1H), 3.98-3.80 (m, 1H), 2.44-2.32 (m, 1H), 2.32-2.20 (m, 1H), 2.101.94 (m, 1H), 1.88 (dd, J= 15.38, 8.24 Hz, 1H), 1.80-1.68 (m, 1H), 1.29 (s, 3H), 1.14 (dd, J
129 = 15,38, 1.45 Hz, 1H), 0.89 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.9, 167.1, 161.1 (d, Jc-f = 243.6 Hz), 145.2, 137.3, 136.9, 132.1 (d, JCF = 9.0 Hz), 131.2 (d, JC-f = 3.60 Hz), 130.0 (d, JC.F = 2.22 Hz), 127.0, 123.8 (d, JC-f = 57.7 Hz), 121.6 (d, JC-f = 14.8 Hz), 118.5 (d, Jc.f = 25.4 Hz), 112.1, 67.4, 64.5, 64.4, 62.7, 48.4, 45.7, 45.5, 43.3, 38.4, 31.0, 29.6, 27.6; ESI-MS calculated for CZ8H3335CI2FN3O3 [M+H]*: 548.19, Found: 548.67.
C29701-TFA sait
• CF3CO2H 1H NMR (MeOH-d4): 7.66 (d, J = 8.47 Hz, 1H), 7.56 (t, J = 6.87 Hz, 1H), 7.43 (td, J = 7.60,
1.47 Hz, 1H), 7.22 (d, J = 7.79 Hz, 1H), 7.16 (dd, J = 8.17, 1.89 Hz, 1H), 6,81 (d, J = 1.80 Hz, 1H), 5.17 (d, J- 11.92 Hz, 1H), 4.68-4.58 (m, 2H), 3.91-3.78 (m, 1H), 3.78-3.66 (m, 2H), 2.44-2.32 (m, 1H), 2.26-2.10 (m, 2H), 1.98-1.88 (m, 1H), 1.64-1.52 (m, 1H), 1.43 (t, J=7.15 Hz, 1H), 1.33-1.25 (m, 1H), 1.29 (s, 3H), 0.81 (s, 3H); ESI-MS: Calculated for C30H37CI2FN3O3 [M+H]* = 576.22, Found: 576.92.
C30201-TFA sait
1H NMR (MeOH-d4): 7.68 (dd, J = 8.16, 1.47 Hz, 1H), 7.48 (t, J= 7.09 Hz, 1H), 7.39 (td, J= 7.30, 1.29 Hz, 1H), 7.20-7.08 (m, 2H), 6.79 (d, J= 1.79 Hz, 1H), 5.19 (d, J = 11.56 Hz, 1H), 4.83 (d, J - 11.56 Hz, 1H), 4.51 (t, J = 3.96 Hz, 1H), 3.94-3.78 (m,
1H), 3.12 (s, 3H), 2.50-2.36 (m, 1H), 2.32-2.20 (m, 1H), 2.10-1.92 (m, 2H), 1.73 (dd, J = 10.67, 9.23 Hz, 1H), 1.40-1.25 (m, 1H), 1.29 (s, 3H). 0.75 (s, 9H); ESI-MS: Calculated for CZgH35ClzFN3O3 [M+H]* = 562.20, Found: 562.58.
EXAMPLE 2
Fluorescence-polarization MDM2 binding assay
The binding affinity of the MDM2 inhibitors was determined using an optimized, sensitive and quantitative fluorescence polarization-based (FP-based) binding assay using a
130 recombinant human His-tagged MDM2 protein (residues 1-118) and a fluorescently tagged p53-based peptide.
The design of the fluorescence probe was based upon a previously reported high-affrnity p53 -based peptidomimetic compound (5-FAM-pAla~pAla-Phe-Met-Aib-pTyr-(6-CI-LTrp)Glu-Ac3c-Leu-Asn-NH2 (SEQ ID NO: 1)) (Garcia-Echeverria étal., J. Med. Chem. 43: 32053208 (2000)). This tagged peptide is called PMDM6-F. The K<j value of PMDM6-F with the recombinant MDM2 protein was determined from the saturation curve. MDM2 protein was serially double diluted in a Dynex 96-well, black, round-bottom plate, and the PMDM6-F peptide was added at 1 nM concentration. The assay was performed in the buffer: 100 mM potassium phosphate, pH 7.5; 100 pg/mL bovine gamma globulin; 0.02% sodium azide, 0.01% Triton X-100) and the polarization values were measured after 3 h of incubation using an ULTRA READER (Tecan U.S. Inc., Research Triangle Park, NC). The IC50 value was obtaîned by fitting the mP values in a sigmoidal dose-response curve (variable slope) with a non-linear régression, and was determined to be 1.40 nM ± 0.25. The value was caiculated using the équation: Ka value = IC50 - L0/2. L0 is the total concentration of the fluorescent ligand; LO/2 is the total concentration of the fluorescent ligand divided by 2. Since PMDM6-F was used at a final concentration of 1 nM, LO/2 was 0.5 nM.
Dose-dependent, compétitive binding experiments were performed with serial dilutions of a tested compound in DMSO. A 5 pL sample of the tested compound and pre-incubated MDM2 protein (10 nM) and PMDM6-F peptide (1 nM) in the assay buffer (100 mM potassium phosphate, pH 7.5; 100 pg/mL bovine gamma globulin; 0.02% sodium azide, 0.01% Triton X-100), were added in a Dynex 96-well, black, round-bottom plate to produce a final volume of 125 pL. For each assay, the controls included the MDM2 protein and PMDM6-F (équivalent to 0% inhibition), PMDM6-F peptide alone (équivalent to 100% inhibition). The polarization values were measured after 3 h of incubation. The ICso values, /.e. the inhibitor concentration at which 50% of bound peptide is displaced, were determined from a plot using nonlinear least-squares analysis. Curve fitting was performed using GRAPHPAD PRISM software (GraphPad Software, Inc., San Diego, CA).
In the alternative, fluorescence polarization values were measured using the Infinité M-1000 plate reader (Tecan U.S., Research Triangle Park, NC) in Microfluor 2 96-well, black, roundbottom plates (Thermo Scientific). In the saturation experiments, 1 nM of PMDM6-F and increasing concentrations of proteins were added to each well to a final volume of 125 Cl in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 Dg/ml bovine y-globulin, 0.02% sodium azide (Invitrogen), with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room température for 30 minutes with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an
131 excitation wavelength of 485 nm and an émission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, CA).
K) values of tested compounds were determined in a dose-dependent compétitive binding experiment. Mixtures of 5 DI of the tested compound in different concentrations in DMSO and 120 Cl of preincubated protein/fluorescent probe complex with fixed concentrations in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 Dg/ml bovine y-globulin, 0.02% sodium azide, with 0.01% Triton X-100) were added into assay plates and incubated at room température for 30 minutes with gentle shaking. Final concentrations of the protein and fluorescent probe in the compétitive assays were 10nM and 1nM, respectively, and final DMSO concentration is 4%. Négative controls containing protein/fluorescent probe complex only (équivalent to 0% inhibition), and positive controls containing free fluorescent probe only (équivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. ICa, values were determined by nonlinear régression fitting of the sigmoidal dose-dependent FP decreases as a function of total compound concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, CA). Kj values of tested compounds to the MDM2 protein were calculated using the measured IC50 values, the Kd value of the fluorescent probe to the protein, and the concentrations of the protein and fluorescent probe in the compétitive assays (Nikolovska-Coleska et al., Anal. Biochem. 332:261-73 (2004)).
Compounds shown in Table 2A as the free base were tested either as the free base or as the CF3CO2H (TFA) or HCl sait. In general, comparable assay responses are expected between the free base and sait form of a compound (See, e.g., Ml-77301 (free base) and MI-77301 (TFA sait)).
Binding Kinetics of Different Isomers in Binding Media
Aliquots of freshly prepared DMSO stock solutions of compounds were diluted in FP binding assay buffer to préparé the aqueous compound incubation solutions in which compound isomerization was taking place. Final compound concentration in the incubation solution was 25μΜ, and 5% of DMSO was présent to enhance the solubility. These solutions were stored at room température for the whole time range of the experiment. 80 μΙ_ of aliquots of compound solutions were mixed with 20 μΙ_ of freshly prepared MDM2/PMDM6-F mixture in the assay plates at different time points. Final concentrations of the protein, fluorescent probe, and DMSO are same as those in the compétitive assays described above. Négative and positive controls were included in each assay plate as well. Following 15 minutes of
132 incubation at room température with gentle shaking, mP values were measured and IC50 values were determined as described above (Table 2B). Due to the plate préparation and incubation time required before measurement, it should be noticed that ail IC50 values presented below are values actually obtained 20 minutes after the labeled incubation time.
EXAMPLE 3
Fluorescence-polarization MDM2 binding assay
The binding affinity of the MDM2 inhibitors was optionally determined using a fluorescence polarization-based (FP-based) binding assay using a recombinant human MDM2 protein ÎO (residues 5-109) and PMDM6-F as follows:
MDM2 protein was serially diluted with a step of 1.8 in a Costar 96-well, black, non binding surface reference 3686 plate, and the PMDM6-F peptide was added at 5 nM concentration. The assay was performed in the buffer: 100 mM potassium phosphate, pH 7.5; 100 pg/mL bovine gamma globulin, 0.01% Triton X-100) and the anisotropy values were measured at 15 equilibrium using a Fusion reader (Packard). The fraction of ligand bound, FSb, was calculated using the following équation FSB = (Aobs -AF)/[(Ab-Aobs)Q + Aobs -AF] (ref) where Aobs= anisotropy observed, Ab= anisotropy when ail p53 is bound, AF = anisotropy when p53 is free, Q= ratio Fluorescence intensity Bound /fluorescence intensity Free (Biochemistry 43:16056-16066 (2004)). KD was determined, using the Langmuir équation 20 applied to fluorescence polarization, to be 1.8 nM.
Dose-dependent, compétitive binding experiments were performed with serial dilutions of a tested compound in DMSO. A 5 pL sample of the tested compound and PMDM6-F peptide (5 nM) and MDM2 protein (6 or 8 nM) in the assay buffer (100 mM potassium phosphate, pH 7.5; 100 pg/mL bovine gamma globulin, 0.01% Triton X-100), were added in Costar 9625 well, black, non binding surface reference 3686 to produce a final volume of 125 pL. For each assay, the contrais included the MDM2 protein and PMDM6-F (équivalent to 0% inhibition), PMDM6-F peptide alone (équivalent to 100% inhibition). The polarization values were measured at equilibrium. The ICso values, Le. the inhibitor concentration at which 50% of bound peptide is displaced, were determined from a plot using the 4-parameter logistic 30 model (Ratkowsky and Reedy, Biométries 42(3):575-82 (1986). The adjustment was obtained by non-linear régression using the Marquardt algorithm in Xlfit software (Table 3).
Table 3
Compound | IC50 (biot MDM2) | IC50 (without Tag) |
MI-710201 | 308.32 nM | 272.83 nM |
MI-710501 | 309.08 nM | 260.40 nM |
133
MI-710601 | 157.86 nM | 137.94 nM |
MI-710801 | 289.62 nM | 256.02 nM |
MI-710901 | 224.96 nM | 184.74 nM |
C02701 | 149.49 nM | 111.52 nM |
C02901 | 159.97 nM | 121.90 nM |
C03001 | 120.23 nM | 89.59 nM |
C031 | 3339.44 nM | 2742.86 nM |
C03401 | 107.66 nM | 85.61 nM |
C03701 | 270.09 nM | 220.41 nM |
C04801 | 473.01 nM | 388.72 nM |
EXAMPLE 4
Cell growth assay
Isogenic HCT-116 colon cancer cell Unes were a kind gift from Prof. Bert Vogelstein (Johns Hopkins, Baltimore, MD) and were maintained in McCoy’s 5A medium containing 10% FBS. Ail other cell lines were obtained from ATCC (Manassas, VA) and were maintained in RPMI1640 medium containing 10% FBS.
Cells were seeded in 96-well fiat bottom cell culture plates at a density of 2-3x103 cells/well with compounds and incubated for 4 days. The rate of cell growth inhibition after treatment with increasing concentrations of the tested compounds was determined by WST-8 (2-(2methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium sait (Dojindo Molecular Technologies Inc., Gaithersburg, Maryland). WST-8 was added at a final concentration of 10% to each well, and then the plates were incubated at 37°C for 2-3 hrs. The absorbance of the samples was measured at 450 nm using a TECAN ULTRA Reader. The concentration of the compounds that inhibited cell growth by 50% (ICso) was calculated by comparing absorbance in the untreated cells and the cells treated with the compounds using the GraphPad Prism software (GraphPad Software, La Jolla, CA 92037, USA). The results of this assay are presented in Tables 2A and 2C. Under conditions used in this assay, it is possible that a compound having Formula II isomerizes to a compound having Formula XII and other isomers (e.g., MI-773 isomerizes to MI-77301; MI-519-64 isomerizes to MI-519-6401). The results of this assay for MI-77301 in a variety of melanoma cell lines (Fernandez, Y., et al., Cancer Res. 65:6294-6304 and référencés cited therein) is presented in Fig. 24.
EXAMPLE 5
134
Cell death assay
Cell death assays were performed using trypan blue staining. Cells were treated in the presence and absence of indicated compounds. Both the floating and adhèrent cells were stained with trypan blue. Cells that stained blue or the morphologically unhealthy cells were 5 scored as dead cells. At least 100 cells were counted in each of three separate areas under microscope. As shown in Figs. 11 and 12, MDM2 inhibitors provided herein induce cell death in SJSA-1 and RS4;11 cancer cells with wild-type p53.
135
Table 2A
CO O Q. | (deleted | CO to CL | CO | ||||||||||||
¢- Q | to | fO | σ> CD | ||||||||||||
X | io Q. | CO | |||||||||||||
Ό | |||||||||||||||
Φ | |||||||||||||||
73 | |||||||||||||||
ω ’-ô e | 0- < | > | φ | Ή | |||||||||||
o | CO m Q. | CL | m ό | ||||||||||||
φ en | Z -I | * | |||||||||||||
? | **** | ||||||||||||||
Φ | |||||||||||||||
£ | |||||||||||||||
o | |||||||||||||||
U) | <£> | TJ | |||||||||||||
w | — | ||||||||||||||
Φ | > | Φ | CO | ||||||||||||
c □ | ¢o | > CO m | Q. >> ** | ô | |||||||||||
x | Q. | ||||||||||||||
S | |||||||||||||||
3. | |||||||||||||||
8 | |||||||||||||||
O | 1 2 | ||||||||||||||
< ω -s w | s CO io Q. | Φ CL > *-* | rCM ό | ||||||||||||
CM | s | 2 | -H | ||||||||||||
Ξ | c | c | CO | S | |||||||||||
Q S | o CO T“ | d O V“ | <çj. | CM | c | ||||||||||
I | ô « | ||||||||||||||
Φ | M | M | Λ/ | ||||||||||||
□ | O | v | |||||||||||||
*» | η | ,L | \ | ||||||||||||
o | Ύ | o^ | > | 7 | T | / O | |||||||||
« | o> | X ) o ζζΛ A | x | I Z— | o | IZ | Z- | \.Λ A zr | |||||||
3 Ë | · <A zi rX ΛΛ “· ü | ^ZI A | o LL- | <7 | |||||||||||
φ JC U | o | ü | o | LL | ô | J | M. | ||||||||
o | o | ||||||||||||||
Q. | σ> | ||||||||||||||
ra ® x LU | CM a s | 1 | o E ? CM | 1 £ | co B σ> ïn |
co 1 Ο CL | (deleted | CO LO Q. | NT | 14.7 | 14.4 | ||||
HCT- | CD T | T co io a. | o Λ | CO co | NT | ||||
Ή φ | |||||||||
8 ’ό C φ ω | ο. < ο ζ -1 | (p53 wild- | type) | CO V | 0.085 | 1.2 | |||
φ £ | |||||||||
Ο | |||||||||
ω V) φ c □ S 3. | HCT-116 | 2 i CO m Q. | type) | CO V | CO LO O O | 0.5 | |||
a | |||||||||
ü | |||||||||
Τ | 2 | ||||||||
< (0 “0 ω | S CO m Q. | Φ Q. * | CO V | <Ô O O | co b | ||||
MDM2 | V | 62.1 ± | 17.8 | S c | V | ||||
O | tr | δ | |||||||
2 | \ y | __7 \ , | |||||||
3 O 3 V) râ CJ Ë φ x: ü | IZ O LL- | X ν' O ΠΛ Χ/Ά 2X | H | ) O lA λ' zi | y/t )o “yQAx Kso | ||||
Q | KJ O | A | J | ô | U_ LL | ||||
Examp le | Ml- 519-65 | MI-773 | MI-786 |
Ό | |
*? | 0) ♦** |
ό | φ |
ο_ | φ Ό |
Η to ο ζ X
C0 ιο
Ο.
co ν
CD | τ> | |
V | S | |
Τ | > | Φ |
1 Ι- | C0 | Ο. >> |
Ο | m | 4-> |
X | Ο. |
C0 V
CM
Ξ ο
Μ to
Τ”· ό
Û&
en
Γ PC-3 I | (deleted | CO m Q. | >10 | o ΊΤ— Λ | |||||||||
.—. | |||||||||||||
H | CD | 1 | o | o | |||||||||
Q | T | CO | t” | y— | |||||||||
X | t— | in a | Λ | Λ | |||||||||
σ | |||||||||||||
φ | |||||||||||||
ra | |||||||||||||
ise indic | LNCAP | s s CO uo cl | type) | CO V | in v | ||||||||
g | |||||||||||||
φ | |||||||||||||
C | |||||||||||||
o | |||||||||||||
c/> | <D | T3 | |||||||||||
» | |||||||||||||
Φ | s | Φ | CO | tn | |||||||||
un | H U | CO LO | CL | V | v | ||||||||
T | CL | ||||||||||||
Ξ | |||||||||||||
g. | |||||||||||||
8 | |||||||||||||
O | |||||||||||||
Ξ | |||||||||||||
«4 en | S CO m | type' | CO V | m v | |||||||||
U) | Q. | ||||||||||||
CM | 00 | CM | |||||||||||
Ξ | M- | CO | 0 | ||||||||||
Q | o | V | T | ||||||||||
S | ô | ô | |||||||||||
X | |||||||||||||
X | X | O | |||||||||||
£ | < P | o | A | ||||||||||
□ | YZ -J/ | / | A | \/ | 7\ | -v | |||||||
o | <) | Ύ | v | \ | |||||||||
□ ω | xz | X Z-Y | o /< | Y Z | i- | Yo N H | Y Z XX | /< | |||||
*râ | 2 | /Ά A | zx | x | 7/ | 31 χ. | zx | ||||||
o | o | M | o | ||||||||||
Ë Φ | X7 | Λ | o | H | LL' | 0 | (7 | y. | |||||
-C o | ô | G | ô | M | ui Ù. | LL-'' | ô | ||||||
CL | xr | W) | <0 | ||||||||||
E | flk | CO | CO | 00 | |||||||||
ro ~ | o | o | 0 | ||||||||||
Λ UJ | O | O | 0 |
en m
CO I Ο 0. | (deleted ρ53) | σί r- | 16.5 | 21.3 | o T~ Λ | ||
Η | «ο > | CO | CD | b- | O | ||
ο | W— CO ν- Ο. | CD | CD | CO | T— | ||
I | CM | T”~ | Λ | ||||
Ό | |||||||
φ | |||||||
75 | |||||||
ο Έ .Ξ | 0. < Q | 2 > φ 9 ο. | m CM | O | 00 T” | CO | |
φ « | —1 | CO >, 10 *Q. | ό | Ô | ό | ||
F | |||||||
φ | |||||||
£ Μ-» | |||||||
Ο | |||||||
ν> | C0 | TJ | |||||
<λ ω | 53 wil type) | o | Γ- | 00 | CO V | ||
Ε 3 | ω | CM ô | CO ό | CM ό | |||
X | CL | ||||||
Ξ | |||||||
3. | |||||||
**** | |||||||
8 | |||||||
Ο | 1 Ό | ||||||
< <Λ ~ί ω | p53 wi type) | 0.42 | 0.9 | 0.26 | CO v | ||
CM | -H | +1 | +» | ||||
S | ID O> S | en g s | o o | CO | |||
Q | r- c | CD CO C | CM E | V | |||
Ξ | LO | ||||||
T | |||||||
£ | I | X | T | O /X | |||
P | p | o | I j | ||||
3 | L / | ||||||
•s | i \ —y | [ \ —Y | / \ —V | / ) ( | |||
Ê (0 8 | x )o A /2Λ A γγύτ | Wi )o ιΓ /ΖΛ A >/'’yGzx | Kl ? o /ΖΛ·Α | X-^ X ? ’ Z—i XZ / \ | o Tz | ||
Ê φ | ΞγΑΟ | y | |||||
E O | ô | □AJ | Ô | ||||
Examp le | Ml- 7102 | Ml- 7104 | Ml- 7105 | Ml- 791 |
Ό φ ra u 5 c φ <Λ ? φ £ ο V) ΙΛ Φ C 3 S 3: S ο | PC-3 (deleted ρ53) | 10.51 ± 3.321 | +1 - Ç & 03 ° | +l q o co co | |
Η <Ο > t > ν- co τ *2. | -H cm co cm ό | -H r-- σ> | H q co CM CM | ||
LNCAP (ρ53 wildtype) | +1 CM CO 1co o ό ό | +1 - o 1X3 o o 9 ô ° | +l CD <D co o 9 o o | ||
HCT-116 (ρ53 wildtype) | +1 - CM g g Ô C> | +1 co VCO o 9 ô o | +l rœ 5 5 ό ° | ||
SJSA-1 (p53 wildtype) | +1 ? 8 ό ° | 0.058 ± 0.0231 | co* To oo bq ° ô ô | ||
CM Ξ Q S | * 1 s | ή ™ o 03 CO | +l co to 2 CO t-M C T- | ||
Chemical Structure | ik IZ Z-f // ° ô | X ΡΛ IZ | iz /z—Ca. | ||
Q. 1 « x UJ | 1 'C· Δ ο o 5 t- in <o | Ml- 77301 (free amine ) | Ml77301 (TFA sait) |
PC-3 I | (deleted p53) | 12.9 | 15.6 | ||||||||||
I- | <o Ζξ | CM | |||||||||||
Q X | t- CO t- *O Q. | co | CD t— | ||||||||||
Ί3 | |||||||||||||
φ | |||||||||||||
cS | |||||||||||||
o ‘5 r | 0< | 2 | CO ô | CM | |||||||||
O | Q. | ||||||||||||
φ (Λ | Z _l | co > Ui +* Q. | O | ||||||||||
? | |||||||||||||
Φ | |||||||||||||
0 | |||||||||||||
<n | <0 | TJ | |||||||||||
<0 | T“ | ||||||||||||
Φ | s S | CM | CO 0 | ||||||||||
c □ | ΙΟ | Q. *2 >> m | Ô | ||||||||||
T | Q. | ||||||||||||
s | |||||||||||||
a. | |||||||||||||
'—* | |||||||||||||
3 | |||||||||||||
O | 1 Ξ | ||||||||||||
< ω ~î V) | > φ * Q, <2 > m *a. | CM O | m ό | ||||||||||
CM | C— | LO | |||||||||||
Ξ | CT> | CM | CO | ||||||||||
Q | LÛ | O | O | ||||||||||
s | 0 | 0 | |||||||||||
Φ | I | I -, P | X \P \ | ||||||||||
L. | O | ||||||||||||
3 | r | -η Ά7 | |||||||||||
« | Γ | \ J | 3 | 3 \ | |||||||||
□ | J | X | O | X > | O | ||||||||
y | X | / ° | XZ | Z—< | IZ | Z—Z | |||||||
<0 | IZ | Z— | [ IJ | ||||||||||
75 | H‘*X. | \ | 'ZT | ) | /-Fz | ^zr | )/ | /Λ F | ^ZI | ||||
8 Ê | i ur | <r | $ | O LL- | l | A | d LL- | oX / | A | ||||
Φ | \J | ||||||||||||
£ O | cf | Q | LL | \J | cT | vJ > | |||||||
O | LL | Ll | |||||||||||
Q. | 04 | O | O | ||||||||||
E Λ | 1 | O | < | r- | O | ||||||||
ra x | s | CO | LL H | (0 ω | CM o | CM ΤΟ | |||||||
LU | r. | O | Q |
PC-3 | (deleted | CO m CL | 29.8 | 17.4 | 26.7 | ||||||||||||
I- | CO | 1 | CM | CO | o | ||||||||||||
O | T“ | CO to Q. | τΓ | r< | T“ | ||||||||||||
X | CM | ||||||||||||||||
Ό | |||||||||||||||||
Φ | |||||||||||||||||
ra | |||||||||||||||||
o 'g c φ (Λ | LNCAP | T» ï CO m Q. | type) | T 0 | CO ό | ό | |||||||||||
ï | |||||||||||||||||
Φ | |||||||||||||||||
JE | |||||||||||||||||
o | |||||||||||||||||
V) | C0 | 73 | |||||||||||||||
w | |||||||||||||||||
Φ | S | Φ | CM | to | CM | ||||||||||||
c □ | H O | CO m | ê | 0 | ό | ό | |||||||||||
X | Q. | ||||||||||||||||
S | |||||||||||||||||
3. | |||||||||||||||||
s | |||||||||||||||||
o | |||||||||||||||||
Ξ | |||||||||||||||||
4 | £ | φ | 0.2 | CO | M | ||||||||||||
ω -s ω | CO m a | >; | ό | Ô | |||||||||||||
CN | 00 | ||||||||||||||||
S | Y | <D | |||||||||||||||
Q | o | o | O | ||||||||||||||
Ξ | V | ό | Ô | ||||||||||||||
'.P | */ y | r | p | ||||||||||||||
Φ | Γ | Y | Λ | ||||||||||||||
U | Γ | \ | Γ | ||||||||||||||
□ | \ | L— | 1 | \ | 1 | ||||||||||||
o s | xz | Z— | o | / xz \ | T Z— | O | IZ | H | Z— | o | |||||||
ω | /-4, | ^ZI | ), | ^ZI | > | Z1 | zx | ||||||||||
S Ë | r/ O | i | o | Λ | o | i. | |||||||||||
LL- | -τΐ=Χ. | A | A | ||||||||||||||
Φ | / H | fl | |||||||||||||||
£ o | ô | \J L | j_ | Y | !] | ô | ô | // >= li | |||||||||
o | o | ||||||||||||||||
Q. | o | o | o | ||||||||||||||
P | o | 't | M | ||||||||||||||
râ ® | CO | CO | CO | ||||||||||||||
x | o | o | o | ||||||||||||||
LU | o | O | O |
Kl
I PC-3 I | (deleted | CO in □. | ô | |||||||||||
Η | CD | 'T | ||||||||||||
ο χ | CO in a | |||||||||||||
σ | ||||||||||||||
φ | ||||||||||||||
ra | ||||||||||||||
ο Έ c | Q. < | Τ3 ϊ | ΉΓ | CO | ||||||||||
υ | Q. | ô | ||||||||||||
φ « | ζ -I | CO m ο. | > | |||||||||||
**** | ||||||||||||||
Φ | ||||||||||||||
£ ** | ||||||||||||||
ο | ||||||||||||||
<Λ | CO | ΰ | ||||||||||||
(Λ | — | |||||||||||||
Φ | V* | $ CO m | Φ | |||||||||||
C □ | Η ο | a. > | ||||||||||||
s | I | Q. | ||||||||||||
3. | ||||||||||||||
S | ||||||||||||||
ω | ||||||||||||||
< | ï | φ | CM | |||||||||||
ω -J ω | CO en Q. | Q. & | ό | |||||||||||
CM | CM | CO | ||||||||||||
S | CD | O | ||||||||||||
Q | O | V“ | O | |||||||||||
E | ό | ό | ||||||||||||
T | X | X | ||||||||||||
φ | / | P___, | O | |||||||||||
3 | Ύ - | < \/ | ||||||||||||
Ci | 3 | \ | J | Γ | ||||||||||
□ U | >x | O | }— | X Z | O | V. | ο | |||||||
ω | IZ \ | IZ \ | z\ | ^ZT | Γ IZ X | T Z | ||||||||
8 | 2 | ZI | / | /· | ZI | |||||||||
Q | O | Y | fi | |||||||||||
Ê | LU- | t^X | f | A-.. | LL- | X Z | Λ-lu | O | A | |||||
φ o | ô' | M | LL'' | j \= | LL ô | Kjl· | ΰ | |||||||
Q | Ô | |||||||||||||
Q. | O | O | O | |||||||||||
P | CO | CD | τ— | |||||||||||
râ « | CO | 00 v- | σ> ν- | |||||||||||
X | O | O | ο | |||||||||||
LU | O | O | Q |
co 1 ü Q- | φ Λ g <o J: to | 19.3 | 12.50 | 16.5 | ||||||
φ 2, | Q. | |||||||||
co | co | σ> | CD | |||||||
O X | cO tn Q. | t-.' CM | CO | |||||||
a | ||||||||||
φ | ||||||||||
8 .E | 0< O | TJ S | φ Q. | cq | O | 49 | ||||
ο ν> | Z —1 | CO IO Q. | £ | ό | ô | ô | ||||
? | ||||||||||
Φ | ||||||||||
.c | ||||||||||
ο | ||||||||||
tn | to | TJ | ||||||||
tn φ | T | ._ co tn | ΈΓ | IO | CM | h- | ||||
c □ | l·1· O | Q. | CM 0 | CD Ô | CO ό | |||||
__Γ | X | |||||||||
s | ||||||||||
3. | ||||||||||
s | ||||||||||
U | 1 5 | |||||||||
à ω -ï w | ? | “φ Q. | s. m | CO | O CD | |||||
co tn Q. | > *· | ô | ό | ό | ||||||
cm | CM | Ή | +l | |||||||
Ξ Q S | δ 6 | r- T t-: m co | s c | ΧΤ tri co | 70.2 | 14.1 nM | ||||
x | ||||||||||
Φ | '-.P \ | X O | X | X | ||||||
Z | Ύ X | p | p | |||||||
+-· | \ | \ \ | Γ \ - | • | ||||||
U | / ) | Γ \ —Y | /\ | |||||||
2 | / | X > O | \ J | / ; | ||||||
4-t | IZ | z—Z 1! | >—J X | ?° | y^x >o | v> | x /O | |||
OT | > | * 2:— rz / ' | xz F \ A | r xz | z—ζ ]| | |||||
œ υ | O | >'X | < ZI | Xf ZI | ||||||
E φ x: (_) | lir | ô ϋ | ° A | t~7 ô | üAJ/a. | °XX» Χ1Λ | ||||
Q. | O | O | O | O | ||||||
E | co | CM | ' CO | 1 | ||||||
<5 ® x | CD το | Ξ ° | i O - | 2 | O *τ | |||||
LU | ο | K | h- |
CO Q Q. | (deleted p53) | 18.4 | 11.1 | |||||||||
l·^ O | £ s | CD | CO ô | |||||||||
X | Q. | T“ | ||||||||||
TJ | ||||||||||||
Φ | ||||||||||||
eu | ||||||||||||
O C | Q. < U | p * Q. | CM | CM 0 | ||||||||
Φ V> | Z —I | CO > IO *Q. | 0 | |||||||||
Φ | ||||||||||||
O | ||||||||||||
to | to | TJ | ||||||||||
CO | T“ | 0.26 | ||||||||||
a> c □ | m ΙΟ | > Φ Z a- m +- | Ô | |||||||||
X | o. | |||||||||||
S | **** | |||||||||||
3. | ||||||||||||
s | ||||||||||||
O | ||||||||||||
T- | TJ | |||||||||||
«i ω ο V) | > Φ „ cl co ί*' IO +7 a | 0.38 | χ- Ο | |||||||||
CN | +1 | +1 | ||||||||||
2 Q | 0.1 5.0 | S c | P CN | en LO | S c | τ- Ο Ô | ||||||
Ξ | CN | co | ||||||||||
J | ||||||||||||
O | ||||||||||||
Φ | Z | 2 | £ I | |||||||||
c | p | f^· | •X | o.JL | ||||||||
3 | r' | |||||||||||
« | /À | < | J | Γ | J ' | |||||||
3 | > | |||||||||||
K* | V7! | >o | f IZ | I | O | I | I | O | ||||
to | * Z—t | IZ | Z— | |||||||||
IZ 1 ’ | \ | |||||||||||
75 | cf | <21 | )/ | ft> *·/ | ΖΣ | fl·' | ZI | |||||
O | i / | O | r \ | O | - | |||||||
Ë | O J | ΖΆ | / | A | LU- | 7^\ | f | A | ||||
φ C O | □Ό | ü | ô | LU | 5 | U | ô | |||||
O | ||||||||||||
Q. | O | O | O | |||||||||
E « | CO | 1 | CO | r~ | ||||||||
ra ® X | O | s | O | en o | ||||||||
LU | i. | h- | O |
<*> < ο 0. | (deleted ρ53) | 19.6 | ||||||||
Η | CD | CO | ||||||||
ϋ X | £ S α | r— CM | ||||||||
Ό | ||||||||||
Φ | ||||||||||
ra | ||||||||||
ο ΐ ,ç | 0_ < Q | 2 ϊ ®· Σ | tq | |||||||
φ « | 2 -1 | « >> m -·-> Ο. | ||||||||
g | *** | |||||||||
L· φ | ||||||||||
£ ** | ||||||||||
ο | ||||||||||
« | CO | •ΰ | ||||||||
V) | ||||||||||
φ | > φ | |||||||||
C □ | Α ο | * ο. Γ2 > | ||||||||
2 | X | α | ||||||||
3. | ||||||||||
* 1 * | ||||||||||
g | ||||||||||
υ | 1 | 1 2 | ||||||||
< | S 2 | |||||||||
ω -> ω | Σ °· « > m *-> tx | |||||||||
04 2 | CD m | T- | LO | |||||||
Q | ό | ό | ||||||||
5 | ô | V | V | |||||||
H | ||||||||||
X | O | |||||||||
φ | P | / | \ | |||||||
k* | < | |||||||||
3 | rT - | J | ||||||||
Ο | VJ | Γ | T | 1 J | ||||||
3 | j T | O | XZ | Z^> | O | v | £ | |||
** | XZ Z—{ \ / ' | k | 1 | x ΛΟ | ||||||
CO | xz | z—X 11 | ||||||||
Ή | //‘As | ZI | O | i | zx | (. Jr zx | ||||
ü Ë φ | 10 | Λ | LC | fA | ||||||
JC O | UÎ \ | □A | J A | |||||||
O | O | O | ||||||||
Q. | O | CO | Φ | CO | Φ | |||||
« ® X | |N | O | i E | m | O | > E CQ | ||||
X— | m | T- O | CÛ | 0 K- | ||||||
LU | O | υ | CD | O | J2 |
eo i Q Q_ | (deleted p53) | |||||||||
H | co | |||||||||
o X | v CO - u | |||||||||
T5 | ||||||||||
Φ | ||||||||||
ra | ||||||||||
O Ë | 0< | > φ * Q. | ||||||||
U | ||||||||||
Φ V> | Z -1 | *2 > m *· CL | ||||||||
--' | ||||||||||
<D | ||||||||||
.E | ||||||||||
o | ||||||||||
<A | <0 | TJ | ||||||||
en | T | |||||||||
Φ | Τ’ | > Φ „ Q*2 >» LO -w | ||||||||
c □ | ω | |||||||||
_· | x | CL | ||||||||
s | '*' | |||||||||
3. | ||||||||||
s | ||||||||||
o | ||||||||||
<t- | Ξ | |||||||||
< ω | > φ » Q. f2 m *- | |||||||||
<n | Q. | |||||||||
CN | ||||||||||
E | m | LO | Ή | |||||||
O | Λ | Λ | o | |||||||
S | V | |||||||||
’0H | X | X | ||||||||
Φ | p | *.p \ | ||||||||
□ | r | |||||||||
U □ L·. | Q | £ CL J P | ç | λ | y o | IZ | \ o Z—< E | |||
(Λ | IZ | Z* | IZ | Z — | ||||||
ra | )/· | L«..4 | zzr | J | ||||||
o Ë <D | O | c ÛQ | ff o | C CÛ | ZA | o Lir | 7) | |||
£ | \=/ | \=/ | ô | |||||||
Q | \ | ô | ||||||||
U | o | |||||||||
CL | CO | Φ | 00 | Φ | o | |||||
ra ® W | o | 1 | E m | o | 1 | E m | rσ> TCN | |||
ai | n | O u | £0 | Tt | ? «- | |||||
LU | υ | (0 | O | w | U |
GO
Table 2B
ICgo values (nM) to human MDM2 protein in FP assay | ||||
Time (hours) | MI-773 | MI-77301 | MI-519-64 | MI-519-6401 |
0.1 | 79.9 | 11.3 | 77.2 | 6.5 |
3.0 | 74.3 | 11.2 | 54.0 | 7.0 |
7.0 | 65.2 | 12.3 | 46.2 | 8.8 |
24.0 | 57.7 | 15.1 | 43.4 | 8.9 |
32.0 | 49.2 | 10.6 | 42.7 | 8.3 |
48.0 | 46.6 | 14.5 | 34.8 | 8.8 |
72.0 | 33.3 | 12.8 | 27.9 | 9.6 |
Table 2C
Example | RS4;11 (p53 wt) ICS0 (μΜ) |
MI-519-6401 | 0.13 ±0.02’ |
MI-773 (TFA sait) | 0.131 |
MI-77301 (free amine) | 0.102; 0.0811 |
MI-77301 (TFA sait) | 0.059 ± 0.0251 |
MI-7102 | 0.46 |
MI-710201 | 0.54 |
Ml-710301 | 0.16 |
MI-7104 | 0.52 |
150
MI-710401 | 0.66 |
MI-7105 | 0.37 |
MI-710601 | 0.13 |
1 Four day treatment.
EXAMPLE 6
Western blotting
For Western blot analysis, cells were lyzed in ice-cold RIPA buffer: 20 mM Tris-HCI (pH 7.5), 150 mM NaCI, 1 mM EDTA, 1 mM EGTA, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1mM sodium orthovanadate and 1 pg/ml leupeptin. The proteins in the whole cell lysâtes were detected by Western blot analysis using the following antibodies: anti-p53 (clone DO-1), anti-MDM2 (clone SMP-14), anti-p21 (clone SX118), anti-p-actin (clone AC-40) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; HRP conjugated). As shown in Figs. 8, 9, and 13-16, MDM2 inhibitors provided herein are active in this assay.
PARP cleavage was used as a biochemical marker of apoptosis. During apoptosis, caspases cleave Poly (ADP-rîbose) polymerase (PARP). Rabbit anti-PARP (Cell Signaling Cat # 9542), used in the experiment, detects cleavage of full length (116kD) Poly (ADPribose) polymerase (PARP) and larger (89kD) cleaved fragment of PARP. A total of 2 χ 106 adhèrent cells were treated in the presence or absence of MI-77301 and incubated at 37°C for 19 hr. Cells were harvested using 0.05% trypsin-EDTA (Invitrogen), washed in PBS and lysed on ice for 15min using RIPA buffer (Sigma), supplemented with protease inhibitor cocktail (Roche). Clarîfied cell lysate was obtained by centrifuging the lysed cells at 13000 x g at 4°C for 15 min. Protein in the cell lysate was estimated using commercially available Bio-Rad protein assay dye. A total of 25 pg protein was loaded on a 4-20% SDS-PAGE gel, electrophoresed, and transferred to a PVDF membrane for 3 hours at 40 V. Membrane was blocked in TBST (20 mM Tris, 0.5 M NaCI, 0.1% Tween-20, pH 7.5) containing 5 % dry milk (Bio-Rad) for 1 hr at room température. Primary antibody diluted in TBST, containing 5% dry milk, was applied to the membrane overnight in cold room at 4 °C on an orbital shaker. Membrane was washed in TBST, incubated for 1 hr at room température with either an antirabbit secondary antibody (Immunopure goat anti-rabbit antibody, Thermo Scientific) or an anti-mouse antibody (Pierce goat anti-mouse antibody, Thermo Scientific), diluted 1:2000 in TBST. Membrane was washed in TBST and developed using SuperSignal West Pico
157 reagent (Thermo Scïentific). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody conjugated to HRP (Santa Cruz) was used as a loading control for proteins. Western blot analyses for MI-77301 are provided in Figs. 25, 26, and 28.
EXAMPLE 7
In vivo efficacy studies using SJSA-1 and 22Rv1 xenograft models
SJSA-1 (osteosarcoma) tumor cells were harvested with Trypsin (0.05%)-EDTA (0.53mM) (GIBCO™, Invitrogen Corp.), growth medium added and cells placed on ice. A cell sample was mixed 1:1 with Trypan Blue (GIBCO™, Invitrogen Corp.) and counted on a hemocytometer to détermine the number of live/dead cells. Cells were washed once with 1X PBS (GIBCO™, Invitrogen Corp.) and resuspended in PBS. For Matrigel injections, after washing in PBS, cells are resuspended in an ice cold mixture of 1:1 PBS and Matrigel (BD Biosciences, Invitrogen Corp.) for a final Matrigel protein concentration of 5 mg/ml. SJSA-1 tumors were inoculated into C.B-17 SCID mice at 5 x 106 cells in 0.1ml with Matrigel. Cells were injected s.c. into the flank région of each mouse using a 27 gauge needle,
The size of tumors growing in the mice was measured in two dimensions using calipers. Tumor volume (mm3) = (AxBz)/2 where A and B are the tumor length and width (in mm), respectively. During treatment, tumor volume and body weight was measured three times a week. After the treatment was stopped, tumor volume (Figs. 17, 20, 22, and 23) and body weight (Figs. 18 and 21) was measured at least once a week. Mice were kept for an additional 60 days for further observation of tumor growth and toxicity. As shown in Fig. 22, a single 200 mg/kg dose of MI-77301 (QD1 treatment) shows comparable efficacy to a continuous dosing regimen (QD7 treatment).
Before treatment began, tumors were allowed to grow to 60-140 mm3 in volume, at which point the blood vessel supplies to the tumor should hâve been established. Mice with tumors within acceptable size range were randomized into treatment groups of 8 mice for experimental compounds and 10 mice for the Control group. Experimental compounds were given orally, once per day for 2-3 weeks, The Control group received vehicle alone (10% PEG 400:3% Cremophor:87% PBS). Other suitable vehicles for in vivo administration of the compounds provided herein include, without limitation, 98% PEG 200:2% polysorbate 80; 98% PEG 200:2% TPGS; and 0.5% polysorbate 80:0.6% methyl cellulose:98.9% water.
Using similar protocole, the antitumor activity of MI-519-6401 and MI-77301 was evaluated in the 22Rv1 prostate cancer model in mice (Fig. 19), and the antitumor activity of MI-77301 was evaluated in the HCT-116 human colorectal tumor model (Fig. 31), the LNCAP human prostate tumor model (Fig. 32), and the RS4;11 human ALL model (Fig. 33).
152.
EXAMPLE 8
Synthesis of MI-519-64 and MI-519-65
Step 1 : benzyl 3-oxocyclobutanecarboxylate (2)
Referring to Scheme 6A, BnBr was added to the mixture of compound 1 and K2CO3 in acetonitrile 150 mL. The mixture was stirred at room température over 24 h and the solid was filtered. The solvent was removed and the residue was purified by column chromatography to give compound 2.
Step 2: benzyl 3-hydroxy-3-methylcyclobutanecarboxylates (3 and 4)
MeMgCI in THF was added dropwise to the solution of compound 2 in diethyl ether at 78°C and the mixture was stirred at the same température for half an hour. After TLC monitoring showed the disappearance of the starting material, the reaction was quenched by adding aqueous NH4CI solution. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was washed with brine and dried (Na2SO4). The solid was filtered and the solvent was removed. The residue was purified by column chromatography to give compounds 3 and 4 (5:1 based on TLC analysis).
Step 3: benzyl 3-(tert-butyldimethylsilyloxy)-3-methylcyclobutane carboxylates (5 and 6)
To the mixture of compounds 3 and 4 in DMF (10 mL) was added immidazole and TBSCI, and the resulting mixture was stirred at 80°C for 30 h. After cooling to room température, water was added and the aqueous phase was extracted with ethyl acetate three times. The combined organic phase was washed with brine and dried (Na2SO4). The solid was filtered and the solvent was removed. The residue was purified by column chromatography to get compounds 5 and 6.
Step 4: 3-(tert-butyldimethylsilyloxy)-3-methylcyclobutanecarboxylic acids (7 and 8)
To the mixture of compounds 5 and 6 in îsopropanol was added Pd/C. The resulting mixture was stirred under 1 atm hydrogen for 1 h. TLC showed the disappearance of the starting material and the solid was filtered. The solvent was removed to give compounds 7 and 8.
Step 5: benzyl-3-(tert-butyldimethylsilyloxy)-3-methylcyclobutylcarbamates 9 and 10
To a 0°C stirring solution of compounds 7 and 8 and Et3N in acetone was added CICOOEt dropwise. The resulting mixture was stirred at 0°C for 30 min. A solution NaN3 in water was added, and the resulting mixture was stirred at 0°C for an additional 20 min. Water was added, and the aqueous phase was extracted with ethyl acetate three times. The combined organic phase was washed with brine and dried (Na2SO4). The solvent was removed and the residue was dissolved in toluene. Benzyl alcohol and NaHCO3 were added. The
5 resulting mixture was stirred at 80°C for 2 h. Ali the solvent was removed and the residue was purified by column chromatography to obtain two isomers 9 and 10 in a 5:1 ratio.
Step 6: 3-(tert-butyldimethylsilyloxy)-3-methylcyclobutanamine (11)
To a mixture of the major isomer 9 and NaHCO3 in isopropanol was added Pd/C and the 5 resulting mixture was stirred under 1 atm hydrogen for 1 h. The solid was filtered and the solvent was removed to give compound 11.
Step 7: 3-(tert-butyldimethylsilyloxy)-3-methylcyclobutanamine (12)
To a mixture of the minor isomer 10 and NaHCO3 in isopropanol was added Pd/C and the resulting mixture was stirred under 1 atm hydrogen for 1h. The solid was filtered and the 10 solvent was removed to give compound 12.
IS!, c m O O
O''
X +
c m O O
Scheme 6A
X
φ £ φ
Φ CO α b
£0 C
CQ
Mi ι/Ί
o ω m ίο ο
Ο CO
ra
Z ή
UJ
Z
LU O O O o
ΓΌ
O o
X o «2 o z bI a> Ο Ξ c x:
CO 0l
CN tn
Scheme 6B
>0 ο
Step 8: MI-519-64
Referring to Scheme 6B, to a solution of compound 11 in THF was added compound 13 and the resulting solution was stirred overnight. The solvent was removed and the residue thus obtained was dissolved in CH3CN/H2O (1:1). CAN was added and the reaction mixture was stirred for 30 min. Water was added and the aqueous phase was extracted with ethyl acetate three times. The combined organic layers were dried (Na2SO4), filtered, and concentrated. The residue was purified by column chromatography on siiica gel to give compound 14. Compound 14 was dissolved in methanol, 12M HCl in water was added, and the reaction mixture was stirred for 1 h at room température. The solvent was removed and the residue was purified by HPLC to give MI-519-64 as the TFA sait. 1H NMR (300 MHz, CD3OD) δ 7.54-7.52 (m, 1H), 7.42-7.38 (m, 1H), 7.23-7.18 (m, 1H), 6.88-6.75 (m, 3H), 5.04 (d, J= 9.9 Hz, 1H), 4.45 (d, J= 9.9 Hz, 1H), 4.19-4.16 (m, 1H), 3.92-3.89 (m, 1H), 2.42-2.11 (m, 2H), 2.10-1.87 (m, 3H), 1.32-1.24 (m, 4H), 0.82 (s, 9H); MS (ESI) m/z 548 [M+H]+.
Step 9: MI-519-65
To a solution of compound 12 in THF was added compound 13 and the resulting solution was stirred overnight. The solvent was removed and the residue was dissolved in CH3CN/H2O (1:1). CAN was added and the reaction mixture was stirred for 30 min. Water was added and the aqueous phase was extracted with ethyl acetate three times. The combined organic layers were dried (Na2SO4), filtered, and concentrated. The residue was purified by column chromatography on siiica gel to give compound 15. Compound 15 was dissolved in methanol, 12M HCI in water was added, and the reaction mixture was stirred for 1 h at room température. The solvent was removed and the residue was purified by HPLC to give MI-519-65 as the TFA sait. 1H NMR (300 MHz, CD3OD) □ 7.50 (m, 1H), 7.44-7.38 (m, 1H), 7.24-7.20 (m, 1H), 6.89-6.88 (m, 1H), 6.80 (m, 1H), 6.71 (m, 1H), 4.91-4.88 (m, 1H), 4.40-4.36 (m, 2H), 4.10-4.06 (m, 1H), 2.41-2.33 (m, 2H), 2.07-1.87 (m, 3H), 1.25-1.21 (m, 4H), 0.82 (s, 9H); MS (ESI) m/z 548 [M+H]*.
EXAMPLE 9
Synthesis of MI-519-6401
Scheme 7
MI-519-64 (100 mg) purified by flash chromatography on silica gel was placed in a 50 mL round-bottom-flask equipped with magnetic stirring bar. Acetonitrile (20 mL) was added to fully dissolve the compound and deionized water (7 to 10 mL) was added. NaHCO3 saturated aqueous solution (ca. 0.5 mL) was then added to adjust the pH value between 7 and 8. This solution was allowed to stir at room température for at least 12 h. TFA (0.1 mL) and another 10 mL of deionized water were added to the solution and the solution was purified by semi-preparative RP-HPLC immediately using acetonitrile and water as the eluents to give MI-519-6401 as the TFA sait. 1H NMR (300 MHz, MeOH-d4): 7.62-7.53 (m, 2H), 7.45-7.35 (m, 1H), 7.20-7.10 (m, 2H), 6.80-6.85 (m, 1H), 5.11 (d, J = 11.07 Hz, 1H), 4.57 (d, J =11.11 Hz, 1H), 4.40 (d, J = 7.39 Hz, 1H), 4.00-3.80 (m, 1H), 2.50-2.35 (m, 1H), 2.35-2.20 (m, 1H), 2.10-1.90 (m, 1H), 1.90-1.60 (m, 2H), 1.30 (s, 3H), 1.20-1.05 (m, 1H), 0.88 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.8, 168.0, 157.6 (d, JC-f - 249 Hz). 144.9, 136.8, 132.2, 128.5, 126.5, 126.3 (d, JC-f = 4.76), 123.9, 123.7, 122.3 (d, JC-f= 18.97 Hz), 122.0 (d, Jc-f =13.1 Hz), 111.8, 67.1, 64.6, 64.5, 62.9, 49.0, 45.5, 45.4, 43.3, 38.0, 30.8, 29.5, 27.3; ESI-MS calculated for C28H33 35CI2FN3O3 [M+H]+: 548.1883, Found: 548.25.
Analytical RP-HPLC spectra are presented in Figs. 1-3. Referring to Fig. 3, MI-519-6401 corresponds to the RP-HPLC peak at 31.787 minutes.
In an alternate procedure, MI-519-64 (100 mg) purified by flash chromatography on silica gel was placed in a 50 mL round-bottom-flask equipped with magnetic stirring bar. Methanol (20 mL) was added to fully dissolve the compound and deionized water (10 to 20 mL) was added. NaHCO3 saturated aqueous solution (ca. 0.5 mL) was then added to adjust the pH value between 7 and 8. This solution was allowed to stir at room température for at least 12 h. TFA (0.1 mL) and another 10 mL of deionized water were added to the solution and the solution was purified by semi-preparative RP-HPLC immediately using acetonitrile and water as the eluents to give MI-519-6401 as the TFA sait.
C02701, C02901, C03001, C03401, C03701, C03801, C04801, C08301, C08601, and C11701 of EXAMPLE 1 were prepared using procedures similar to that used to préparé MI-519-6401.
EXAMPLE 10
156
Synthesis of MI-773
Scheme 8
CAN
CH3CN/H20/acetone 2:1:1 ice bath. 5 min
MI-773
Step 1
To a stirred solution of oxindole 1 (4.19 g, 25 mmol) in methanol (50 mL) was added aldéhyde 2 (3.96 g, 25 mmol) and piperidine (2.45 mL, 25 mmol). The reaction mixture was stirred at room température for 3 h and the yellow precipitate was collected, washed successively with methanol, hexanes, and ethyl ether and dried to give compound 3 (6.25 g, 81% yield).
Step 2
To a solution of compound 3 (6.25 g, 21 mmol) in toluene (75 ml) was added compound 4 (5.43 g, 21 mmol), compound 5 (2.15 g, 21 mmol) and 4Â molecular sieves (4 g). The reaction mixture was heated at reflux overnight and filtrated. The filtrate was evaporated and the residue was purified by silica gel flash column chromatography (n-hexane/ethyl acetate = 9:1 to 5:1 ) to give compound 6 (8.78 g, 65% yield).
Step 3
The solution of compound 6 (965 mg, 1.5 mmol) and amine 7 (346 mg, 3 mmol) in 5 mL of THF was stirred at room température for 2 days and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (nhexane/ethyl acetate = 1:1 to 1:4) to give compound 8 (819 mg, 72% yield).
15θ
Step 4
To an ice-bath cooled solution of compound 8 (800 mg, 1.05 mmol) in CH3CN (8 ml), H2O (4 ml) and acetone (4 ml) was added CAN (ammonium cérium) (1.15 g, 2.1 mmol). Progress of the reaction was monitored by TLC. When ail the starting material disappeared (around 5 min), 100 mg of NaHCO3 powder was added and the reaction mixture was diluted with 50 mL of ethyl acetate. The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel flash column chromatography (methylene chloride/methanol/triethylamine = 200:1:1 to 200:10:1) to give (2'R,3S,4'S,57?)6-chloro-4'-(3-chloro-2-fluorophenyl)-N-((trans-4-hydroxycyclohexyl)-2,-neopentyl-2oxospiro[indoline-3,3’-pyrrolidine]-5’-carboxamide (MI-773) (402 mg, 68% yield, Purity (HPLC): > 95% (Fig. 35)). The absolute stereochemical configuration of MI-773 was determined by x-ray analysis.
MI-773 was dissolved in DCM, TFA was added, and the solvent was removed by évaporation. The residue was further purified by chromatography on a C18 reverse phase semi-preparative HPLC column with solvent A (0.1% of TFA In water) and solvent B (0.1% of TFA in methanol) as eluents (gradient: 45% of solvent A and 55% of solvent B to 30% of solvent A and 70% of solvent B in 30 min) to give MI-773 as the TFA sait. NMR for MI-773 (TFA sait): 1H NMR (300 MHz, CD3OD) δ 7.47 (t, J - 7.0 Hz, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.14 (t, J= 7.9 Hz, 1H), 6.83 (s, 1H), 6.80 (s, 2H), 4.39 (d, J = 10.0 Hz, 1H), 4.15-4.05 (m, 1H), 3.72-3.53 (m, 1H), 3.53-3.85 (m, 2H), 2.10-1.75 (m, 4H), 1.62 (d, J = 12.2 Hz, 1H), 1.45-1.05 (m, 5H), 0.78 (s, 9H).
Stability of MI-773 (TFA sait): MI-773 (TFA sait) was dissolved in a water/méthanol mixture: 1) water/methanol = 1:1 with 0.1% of TFA, pH 2.1; 2) water/methanol = 1:1 with 0.1% of TEA, pH 10.8; or 3) water/methanol = 1:1, pH 3.9. The solution was allowed to stand at room température. The purity was tested using a C18 reverse phase analytical HPLC column at the time points of 0, 12 h, 24 h, 48 h, and 72 h. The results showed transformation of MI-773 (corresponding to peak 3) to ΜΙ-77302 (corresponding to peak 1 ), MI-77301 (corresponding to peak 4) and another compound (corresponding to peak 2) having the same molecular weight (Figs. 6, 37, and 38). The purity of an identical sample solution stored at 4°C was also tested at 0 and 36 h. The results showed comparably slow transformation of MI-773 at 4°C.
EXAMPLE 11
Synthesis of MI-77301
Scheme 9
160 c
OH
MeOH/HjO
Ml-773
Cl
MI-77301
MI-77302
MI-773 (as the TFA sait) was dissolved in MeOH/H20 (1:1 v/v ratio) and allowed to stand at room température for 1-4 days. The solution was purified by chromatography on a C18 reverse phase semi-preparative HPLC column with solvent A (0.1% of TFA in water) and solvent B (0.1% of TFA in methanol) as eluents (gradient: 45% of solvent A and 55% of solvent B to 30% of solvent A and 70% of solvent B in 30 min). MI-77301 was isolated as the TFA sait. 1H NMR (300 MHz, MeOH-d4): 8.35 (d, J = 7.8 Hz, 1H), 7.54-7.62 (m, 2H), 7.37-7.43 (m, 1H), 7.12-7.20 (m, 2H), 6.80 (d, J = 1.5 Hz, 1H), 5.20 (d, J = 11.4 Hz, 1H), 4.58 (d, J = 11.4 Hz. 1 H), 4.51 (d, J = 7.2 Hz, 1H), 3.50-3.75 (m, 1H), 3.30-3.50 (m, 1H), 1.82-2.00 (m, 3H), 1.76 (d, J = 10.5 Hz, 1H), 1.52 (d, J = 12.3 Hz, 1H), 1.05-1.42 (m, 4H), 0.88-1.00 (m, 1H), 0.88 (s, 9H); 13C NMR (75 MHz, MeOH-d4): 177.7, 166.9, 157.6 (d, JC-F = 248.0 Hz), 145.0, 137.0, 132.4, 128.6, 126.6, 126.4 (d, JC-F = 4.9), 124.0, 123.4, 122.3 (d, JC-F = 18.8 Hz), 121.5 (d, JC-F = 12.8 Hz), 111.9, 69.9, 64.4, 64.0, 62.8, 49.7, 34.3, 34.2, 30.9, 30.82, 30.77, 29.4; ESI-MS calculated for C29H35CI2FN3O3 (M + H)+ requires 562.20, found 562.33; [a]D 25 = -27.2° (c = 0.005 g/mL in MeOH); Purity (HPLC): > 95% (See Fig. 36).
In an alternative procedure, MI-773 (77 mg) was dissolved in 15 mL MeOH/H2O (v/v =1:1). After 3 days, the needle crystals that had formed were collected, washed with cold MeOH/H2O (v/v =1:1) and dried in vacuum to give MI-77301 as the free amine (20 mg; >95% purity as determined by HPLC). ’H NMR (300 MHz, MeOH-d4): 7.49-7.55 (m, 1H), 7.25-7.31 (m, 1 H), 7.10-7.16 (m. 1H), 6.82 (d, J = 1.8 Hz, 1H), 6.50-6.71 (m, 1H), 6.49 (d, J = 8.4 Hz, 1H), 4.32 (d, J = 9.0 Hz, 1H), 4.09 (d, J = 8.7 Hz, 1H), 3.57-3.69 (m, 1H), 3.49 (d, J = 9.2 Hz, 1H), 3.46-3.57 (m, 1H), 1.83-2.07 (m, 3H), 1.68-1.80 (m, 1H), 1.54 (dd, J = 9.0, 14.3 Hz, 1H), 1.12-1.45 (m, 5H), 0.80 (s, 9H). The absolute stereochemical configuration of MI-77301 was determined by X-ray analysis.
Stability of MI-77301 (TFA sait): MI-77301 (TFA sait) was dissolved in a water/methanol mixture (water/methanol =1:1 with 0.1% of TFA). The solution was allowed to stand at room température. The purity was tested using a C18 reverse phase analytical HPLC column at the time points of 0, 12 h , 48 h, and 72 h. The results showed slow transformation of MI77301 (corresponding to peak 4) to MI-77302 (corresponding to peak 1) and two other compounds (corresponding to peaks 2, and 3) having the same molecular weight (Fig. 7). The absolute stereochemistry of MI-77302 was determined by x-ray analysis.
161
MI-710201, Ml-710401, MI-710501, MI-710601, MI-710801, and MI-710901 of EXAMPLE 1 were prepared using procedures similar to that used to préparé MI-77301.
13C CPMAS NMR spectroscopy (400 MHz) of MI-77301 (top), MI-773 (middle), and Ml77302 (bottom) is presented in Fig. 34. Chemical shift différences are observed in the 5 carbonyl région (170-185 ppm).
In an alternative procedure, MI-77301 was prepared as described in Scheme 9A.
Scheme 9A ci
toluene. 115°C 75% yield (250 g scale)
OH
2.1 eq. CAN
MeTHF/ H2O 90% (crude) yield (35 g scale)
Cl
1. Isomerization In AcOIPr ! cal/ AcOH
2. crystalllzatlon In AcOiPr
3. desolvation / drying
55% yield (15 g scale)
Cl
chemical purity > 97%
EXAMPLE 12
Synthesis of:
162 (2'S,3R,4'R,5'S)-6-chloro-4'-(3-chloro-2-fluorophenyl)-N-((trans)-4hydroxycyclohexyl)-2'-neopentyl-2-oxospiro[indoline-3,3,-pyrrolidine]-5'carboxamide; and (2‘R,3S,4'RI5'S)-6-chloro-4,-(3-chloro-2-fluorophenyl)-N-((trans)-4hydroxycyclohexyO^'-neopentyl^-oxospiroIindoline-S.S'-pyrrolidineJ-S'carboxamide
(5S,6R)-5,6-diphenylmorpholin-2-one was prepared according to J. Org. Chem. 2005, 70, 6653. mp: 139°C (Kofler); LC-MS: tR (min) = 0.96; [M+Hf: m/z 254 (method C). (3R.3,R.4'S.6'S.8,R,8a'S)-6-chloro-8l-(3-chloro-2-fluoropheny|)-6l-neopentyl-3’,4'-diphenvl 3'.4',8t.8a'-tetrahvdrospiro[indoline-3,7'-Dvrrolor2,1-cl[1.4]oxazinel -1',2(6’H)-dione
To a suspension of 496 mg (1.61 mmol) of (E)-6-chloro-3-(3-chloro-2fluorobenzylidene)indolin-2-one in toluene under argon, were added 408 mg (1.61 mmol) of (5S,6R)-5,6-diphenylmorpholin-2-one and 213 pL (1.61 mmol) of 3,3-dimethylbutyraldehyde. The reaction mixture was heated at reflux température for 6 hours, upon which it was cooled down to room température and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography on a 70 g silica cartridge (15-40 pm silica gel; eluting solvent: cyclohexane/ ethyl acetate 90/10 v/v; flow: 50 mL/min). 0.58 g of (3R,3'R14,S,6,S,8’R,8a'S)-6-chloro-8'-(3-chloro-2-fluorophenyl)-6,-neopentyl-3,,4'-diphenyl S'.^.S'.ea'-tetrahydrospirotindoline-SJ’-pyrrolo^.l-cHI ,4]oxazine] -T,2(6’H)-dione was obtained as an amorphous yellow solid. LC-MS: tR (min) = 1.81; [M+Hf: m/z 643;[M-H]': m/z 641 (WATERS UPLC-SQD apparatus; lonization: electrospray in positive mode and/or négative mode (ES+/-); Chromatographie conditions: Column: ACQUITY BEH C18 1.7 pm 2.1 x 50 mm; Solvents: A: H2O (0.1 % formic acid) B: CH3CN (0.1 % formic acid); Column température: 50 °C; Flow: 0.8 ml/min; Gradient (2.5 min): from 5 to 100 % of B in 1.8 min; 2.4 min: 100 % of B; 2.45 min: 100 % of B; from 100 to 5 % of B in 0.05 min; Rétention time = tR (min); referred to herein as Method C); 1H NMR (400 MHz, DMSO-de): 0.39 (s, 9 H); 1.30 (dd, J=4.0 and 15.2 Hz, 1 H); 1.93 (dd, J=6.3 and 15.2 Hz, 1 H); 3.49 (dd, J=4.0 and 6.3 Hz, 1 H); 4.47 (d, J=11.2 Hz, 1 H); 5.04 (d, J=4.2 Hz, 1 H); 5.08 (d, J=11.2 Hz, 1 H); 6.53 (d, J-8.1 Hz, 1 H); 6.66 to 6.76 (m, 3 H); 6.96 (m, 2 H); 7.10 to 7.26 (m, 9 H); 7.34 (t broad, J=7.9 Hz, 1 H); 7.62 (t broad, J=7.9 Hz, 1 H); 10.71 (s broad, 1 H).
163 (2,S.3R.4,R.5,S)-6-chloro-4,-(3-chloro-2-fluorophenyl)-1,-((1S.2R)-2-hvdroxv-1.2diphenvlethvl)-N-((frans)-4-hvdroxvcvclohexvl)-2'-neopentvl-2-oxospiroίindoline-3.3, pyrrolidinel-S’-carboxamide
To a mixture of 112 mg (0.97 mmol) of trans-4-aminocyclohexanol in 2 mL of tetrahydrofuran under argon, was added 0.57 g (0.89 mmol) of (3R,3'R,4'S,6'S,8’R,8a'S)-6chloro-8'-(3-chloro-2-fluorophenyl)-6'-neopentyl-3',4'-diphenyl 3',4',8',8a’tetrahydrospiro[indoline-3,7'-pyrrolo[2,1-c][1,4]oxazine] -T,2(6’H)-dtone in 8 mL of tetrahydrofuran. The resulting mixture was heated at 60°C for 17 hours, upon which 136 pL (0.97 mmol) of triethylamine was added and heating was pursued.
After 24 hours, 13.6 mg (0.12 mmol) of trans-4-aminocyclohexanol and 2.5 mL of tetrahydrofuran were added. After 41 hours, the reaction mixture was cooled down to room température and concentrated to dryness under reduced pressure. The residue was diluted with a mixture of 20 mL of ethyl acetate and 6 mL of water and decanted. The aqueous phase was extracted with 6 mL of ethyl acetate. The combined organic phases were dried over magnésium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography on a 70 g siiica cartridge (15-40 pm siiica gel; eluting solvent: cyclohexane/ ethyl acetate 50/50 v/v followed by 40/60 v/v; flow: 50 mL/min). 0.55 g of (2'S,3R,4'R,5'S)-6-chloro-4'-(3-chloro-2-fluorophenyl)-1 '-((1 S,2R)-2-hydroxy-1,2diphenylethyl)-N-((trans)-4-hydroxycyclohexyl)-2'-neopentyl-2-oxospiro[indoline-3,3' pyrrolidine]-5'-carboxamide was obtained as a white meringue, mp: 190°C (Kofler); LC-MS: tR (min) = 1.56; [M+H]+: m/z 758; [M-H]‘: m/z 756 (method C); 1H NMR (400 MHz , DMSOd6): 0.51 (s, 9 H); 0.62 (d, J=15.2 Hz, 1 H); 0.81 (m, 1 H); 1.02 to 1.35 (m, 4 H); 1.60 (m, 1 H); 1.79 (m, 2 H); 2.36 (dd, J=9.3 and 15.2 Hz, 1 H); 3.24 to 3.34 (m partially hidden, 2 H);
3.48 (m, 1 H); 3.69 (d, J=10.9 Hz, 1 H); 3.94 (d, J=7.9 Hz, 1 H); 4.13 (d, J=10.9 Hz, 1 H); 4.45 (d, J=4.4 Hz, 1 H); 5.05 (dd, J=4.4 and 7.9 Hz, 1 H); 5.14 (d, J=4.4 Hz, 1 H); 6.18 (d, J=8.2 Hz, 1 H); 6.50 (d, J=2.0 Hz, 1 H); 6.59 (t broad, J=7.9 Hz, 1 H); 6.67 (dd, J=2.0 and 8.2 Hz, 1 H); 6,73 (t broad, J=7.9 Hz, 1 H); 7.20 (t, J=7.8 Hz, 1 H); 7.24 (t broad, J=7.9 Hz, 1 H); 7.28 (t, J=7.8 Hz, 2 H); 7.35 (m, 2 H); 7.39 to 7.45 (m, 3 H); 7.49 (d, J=8.2 Hz, 1 H); 7.57 (d, J=7.8 Hz, 2 H); 10.32 (s broad, 1 H).
(2,S.3R14'R,5'S)-6-chloro-4,-(3-chloro-2-fluorophenvl)-N-((frans)-4-hydroxvcvclohexvl)-2,-neopentvl-2-oxospiro[indoline-3,3,-pyrrolidine1-5,-carboxamide
A mixture of 542 mg (0.71 mmol) of (2'S,3R,4'R,5’S)-6-chloro-4'-(3-chloro-2-fluorophenyl)-1'((1S,2R)-2-hydroxy-1,2-diphenylethyl)-N-((frans)-4-hydroxycyclohexyl)-2'-neopentyl-2oxospirolindolîne-S.S'-pyrrolidinel-S'-carboxamide in 10 mL of éthanol was cooled to 0°C and
16¼
989 mg (1.79 mmol) of ceric ammonium nitrate was added slowly via spatula in 15 min. The reaction mixture was stirred at 0°C for 1 hour, upon which it was treated with 4 mL of toluene, 2 mL of éthanol, 5 mL of saturated brine and 3 mL of ethyl acetate, and decanted. The organic phase was separated and the aqueous phase was extracted with 2x5 mL of ethyl acetate. The organic phases were combined and washed with 3 mL of 5% sodium carbonate. After décantation, the aqueous phase was diluted with water and reextracted with 10 mL of ethyl acetate. The organic phases were combined and successively washed with 2 mL of 11% sodium disulfite and 2 mL of saturated brine. It was then dried over magnésium sulfate and concentrated to dryness under reduced pressure. 222 mg of the residue was purified by flash chromatography on a 40 g silica cartridge (15 pm silica gel; eluting solvent: dichloromethane/ acetone 75/25 v/v followed by 65/35 v/v; flow: 30 mL/min). 0.183 g of an off-white meringue was obtained, taken up twice in diisopropyl oxide and dried at 25°C under reduced pressure. 157 mg of (2’S,3R,4,Rl5’S)-6-chloro-4'-(3-chloro-2fluorophenyl)-N-((frans)-4-hydroxy-cyclohexyl)-2’-neopentyl-2-oxospiro[indoline-3,3'pyrrolidineJ-S'-carboxamide were obtained as a white amorphous solid. mp: 176°C (Kofler); LC-MS: tR (min) =1.13 (91%) and 1.03 (9%); [M+H]+: m/z 562; [M-H]’: m/z 560 (method C); 1H NMR (400 MHz, DMSO-d6): 0.76 (s, 9 H); 0.85 (dd, J=1.8 and 14.3 Hz, 1 H); 0.97 to 1.28 (m, 4 H); 1.38 to 1.50 (m, 2 H); 1.67 (m, 1 H); 1.80 (m, 2 H); 2.56 (t, J=12.1 Hz, 1 H);
3.23 to 3.38 (m partially hidden, 2 H); 3.45 (m, 1 H); 3.93 (d, J=9.6 Hz, 1 H); 4.22 (dd, J=9.6 and 12.1 Hz, 1 H); 4.46 (d, J=4.4 Hz, 1 H); 6.62 (d, J=8.1 Hz, 1 H); 6.70 to 6.75 (m, 2 H); 7.13 (t broad, J=7.9 Hz, 1 H); 7.31 (t broad, J=7.9 Hz, 1 H); 7.64 (t broad, J=7.9 Hz, 1 H); 7.92 (d, J=7.7 Hz, 1 H); 10.51 (s broad, 1 H).
(2,R.3S.4,R.5,S)-6-chloro-4'-(3-chloro-2-fluorophenyl)-N-((trans)-4-hvdroxvcvclohexvl)-2,-neopentyl-2-oxospiro[indoline-3.3,-pyrrolidinel-5,-carboxamide
The rest of the crude compound (206 mg) was dissolved and stirred into 10 mL of ethyl acetate, treated with 41 pL (0.07 mmol) of glacial acetic acid and the reaction mixture was heated at 60°C for 3 hours, upon which it was cooled down to room température and stirred for 16 hours. It was then washed with 5 mL of saturated sodium hydrogencarbonate and 3 mL of water. The organic phase was dried over magnésium sulfate and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography on a 30 g silica cartridge (15-40 pm silica gel; eluting solvent: dichloromethane/ acetone 75/25 v/v; flow: 20 mL/min). The isolated product was taken up twice in diisopropyl oxide. The solid was filtered and dried at 25°C under reduced pressure. 106 mg of (2’R,3S,4'R,5’S)-6-chloro4'-(3-chloro-2-fluorophenyl)-N-((frans)-4-hydroxycyclohexyl)-2'-neopentyl-2oxospiro[indoline-3,3' pyrrolidine]-5’-carboxamide were obtained as a pinkish amorphous
16&
solid. mp: 193°C (Kofler); LC-MS: tR (min) = 1.03; [M+H]+: m/z 562; [M-H]’: m/z 560 (method C); 1H NMR (400 MHz. DMSO-d6): 0.72 (dd, J=1.5 and 14.2 Hz, 1 H); 0.80 (s, 9 H); 1.08 to 1.30 (m, 5 H); 1.68 to 1.91 (m, 4 H); 3.28 to 3.49 (m, 3 H); 3.58 (m, 1 H); 4.29 (d, J=9.0 Hz, 1 H); 4.39 (t, J=9.0 Hz, 1 H); 4.50 (d, J=4.4 Hz, 1 H); 6.68 (d, J=2.0 Hz, 1 H); 7.05 (dd, J=2.0 and 8.1 Hz, 1 H); 7.12 (t broad, J=7.9 Hz. 1 H); 7.34 (t broad, J=7.9 Hz, 1 H);
7.48 to 7.57 (m, 2 H); 7.72 (d, J=8.1 Hz, 1 H); 10.40 (s broad, 1 H); 0D = +18.4° +/- 0.9 (c = 1.525 mg/ O.ômLMeOH).
EXAMPLE 13
Synthesis of (2’8,3Ή,4'5,5,β)-Γ-3θθΙγΙ-6-οήΙθΓθ-4'-(3-οΚΙθΓθ-2-ίΙυοΓθ-ρήθηγΙ)-2'(2,2-dimethyl-propyl)-2-oxo-1,2-00170^-^^0(^016-3^^^0110^6)-5^ carboxylic acid (frans-4-hydroxy-cyclohexyl)-amide
Acetic acid 4-fl(2,S,3'R.4'S,5'R)-1,1'-diacetvl-6-chloro-4'-(3-chloro-2-fluoro-phenvn-2'f2,2-dimethvl-propvn-2-oxo-1,2-dihvdro-spirofindole-3.3l-pyrrolidinel-5’-carbonyllaminol-cyclohexvl ester
To a solution of 281 mg (0.50 mmol) of (2'S,3,R,4'S,5'R)-6-chloro-4,-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-spiro [indole-3,3'-pyrrolidine]-5'-carboxylic acid (frans-4-hydroxy-cyclohexyl)-amide in 5.0 mL of pyridine under argon, was added 178 pL (2.50 mmol) of acetyl chloride. The resulting mixture was stirred at room température for 4 days, upon which it was poured into a mixture of water and ethyl acetate. The organic phase was separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried with magnésium sulfate and then concentrated to dryness under reduced pressure. The residue was purified by flash chromatography on a 50 g silica cartridge (15-40 pm silica gel; eluting solvent: dichloromethane/ methanol 98/2 v/v; flow: 40 mL/min) followed by a second purification by flash chromatography on a 30 g silica cartridge (15-40 pm silica gel; eluting solvent: dichloromethane/ methanol 98/2 v/v; flow: 20 mL/min). 123 mg of acetic acid 4{[(2,S,3,R,4‘S,5’R)-1,T-diacetyl-6-chloro-4,-(3-chloro-2-fluoro-phenyl)-2'-(2,2-dimethyl166 propyl)-2-oxo-1,2-dihydro-spiro [indole-3,3'-pyrrolidin]e-5'-carbonyl]-amino}-cyclohexyl ester were obtained as a white powder. LC-MS: tR (min) = 1.19; [M+Hf: m/z 688; [M-H]’: m/z 686 (method A).
(2'S,3’R.4’S.5'RÎ-T-Acetvl-6-chloro-4‘-(3-chloro-2-fluoro-phenyl)-2'-(2,2-dimethvl· ΡΓθρνΠ-2-οχο-1 ^-dihvdro-spirofindole-S.S'-pvrrolidinel-S'-carboxvlic acid (trans-4hvdroxv-cyclohexvD-amide
To a solution of 117 mg (0.17 mmol) of acetic acid 4-{[(2’S,3'R,4'S,5,R)-1l1‘-diacetyl-6chloro-4'-(3-chloro-2-fluoro-phenyl)-2’-(2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-spiro[indole3,3'-pyrrolidine]-5'-carbonyl]-amino}-cyclohexyl ester in 10.0 mL of methanol under argon, was added 10 mL (81 mmol) of a saturated potassium carbonate solution. The resulting mixture was stirred at room température for 1 hour, upon which the methanol was evaporated under reduced pressure. The remaining aqueous phase was extracted 3 times with 20 mL of dichloromethane. The combined organic extracts were washed with 20 mL of brine, dried with magnésium sulfate and then concentrated to dryness under reduced pressure. 92 mg of (2,S,3'R,4,S,5,R)-T-acetyl-6-chloro-4‘-(3-chloro-2-fluoro-phenyl)-2'-(2,2dimethyl-propyl)-2-oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (trans-4hydroxy-cyclohexylfamide were obtained as a white powder. mp: 220°C (Kofler); LC-MS: tR (min) = 0.97; [M+Hf: m/z 604; [M-H]’: m/z 602 (method A); 1H NMR (60°C, CHLOROFORM-d, 400 MHz): 0.68 (s, 9 H); 0.75 to 2.62 (m partially hidden, 14 H); 3.51 (m, 1 H); 3.65 (m, 1 H); 4.28 (m broad, 1 H); 4.48 (dd, J=3.4 and 5.9 Hz, 1 H); 4.98 (d, J=10.3 Hz, 1 H); 6.65 (d, J=1.5 Hz, 1 H); 6.99 (t, J=7.8 Hz, 1 H); 7.05 to 7.48 (m, 5 H).
16T
EXAMPLE 14
Synthesis of (2'Sl3,R,4'S15’R)-6-chloro-4'-(3-chloro-2-fluoro-phenyl)-2,-(2,2» dimethyl-propyl^-oxo-l^-dihydro-spiroljndole-S.S'-pyrroliclinel-S’-carboxylic acid (frans-4-hydroxy-cyclohexylmethyl)-amîde
(2,R<31S.4'S,5'R)-6-Chloro-4l-(3-chloro-2-fluoro-phenvl)-2'-(2.2-dimethvl-propyl)-T((1 R.2S)-2-hydroxy-1,2-diphenvl-ethyl)-2-oxo-1 .Z-dihydro-spirofindole-S.S'pyrrolidinel-5'-carboxvlic acid (trans-4-hvdroxv-cyclohexylmethvO-amide
To a solution of 0.28 g (1.71 mmol) of 4-aminomethyl-cyclohexanol hydrochloride in 12.0 mL of tetrahydrofuran, was added 0.46 mL (3.26 mmol) of triethylamine. The resulting mixture was stirred at room température for 30 minutes and 1 g (1.55 mmol) of:
was added progressively via spatula, followed by 2 mL of tetrahydrofuran. The reaction mixture was heated at reflux température for 7 hours and then stirred at room température for 2.5 days, upon which it was diluted with 10 mL of water and 15 mL of ethyl acetate. The organic phase was separated and the aqueous phase was extracted with ethyl acetate. The combined organic extracts were dried with magnésium sulfate and then concentrated to dryness under reduced pressure. The residue was purified by flash chromatography on a 70 g silica cartridge (15-40 pm silica gel; eluting solvent: dichloromethane, then dichloromethane/ methanol 98/2 v/v; flow: 50 mL/min). 0.40 g of (ZR.S'S^'S.S'RJ-e-chloro-^S-chloro^-fluorophenyl)-2'-(2,2-dimethyl-propyl)-1,-((1R,2S)-2-hydroxy-1,2-diphenyl-ethyl)-2-oxo-1,2dihydro-spiro[indole-3,3'-pyrrolidine]-5’-carboxylic acid ( trans-4-h ydroxycyclohexylmethyl)-amide were obtained as a white solid. LC-MS: tR (min) = 1.16; [M+Hf: m/z 772; [M-H]’: m/z 770 (method A); Ή NMR (CHLOROFORM-d, 400 MHz): 0.74 (s large, 9 H); 0.83 (m, 2 H); 1.13 (m, 2 H); 1.20 (m, 1 H); 1.25 (d, J=15.6
16S
Hz, 1 H); 1.35 (d, J=4.9 Hz, 1 H); 1,42 (m, 1 H); 1.55 (m partially hidden, 1 H); 1.84 to 2.00 (m, 2 H); 2.29 (d, J=2.9 Hz, 1 H); 2.67 (dd, J=9.3 and 15.6 Hz, 1 H); 2.86 (m, 1 H); 3.38 (m, 1 H); 3.48 (m, 2 H); 4.11 (m, 2 H); 4.36 (d, J=8.3 Hz, 1 H); 5.20 (dd, J=2.9 and 8.3 Hz, 1 H); 5.64 (d, J=8.1 Hz, 1 H); 6.28 (m, 1 H); 6.44 (t, J=7.8 Hz, 1 H); 6.53 (d, J=2.2 Hz, 1 H); 6.62 (dd, J=2.2 and 8.1 Hz, 1 H); 6.67 (t, J=7.8 Hz, 1 H); 7.09 (t, J=7.8 Hz, 1 H); 7.25 (s, 1 H); 7.30 to 7.45 (m, 5 H); 7.54 to 7.67 (m, 5 H).
(2'S,3lR.4'S,5'R)-6-Chloro-4'-(3-chloro-2-fluoro-Dhenvl)-2'-(2,2-dimethyl-proDvl) -2oxo-1 ^-dihydro-spirofindole-S.S-pyrrolidinel-S'-carboxylic acid_ (/rafis-4-hvdroxvcvclohexylmethvD-amide
In a three-neck 50 mL flask were successively introduced 0.70 g (0.91 mmol) of (2'R,3’Sl4'S,5,R)-6-chloro-4'-(3-chloro-2-fluoro-phenyl)-2'-(2,2-dimethyl-propyl)-r-((1R,2S)-
2-hydroxy-1,2-diphenyl-ethyl)-2-oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (trans-4-hydroxy-cyclohexylmethyl)-amide, 7.0 mL of acetonitrile, 3,5 mL of distilled water and 3.5 mL of acetone. The resulting mixture was stirred and cooled to 0°C and 0.99 g (1.81 mmol) of cérium ammonium nitrate was added in small portions. The reaction mixture was stirred at 0°C for 20 minutes, upon which 89 mg (1.06 mmol) of sodium hydrogencarbonate were added and stirring was maintained for 5 minutes. The mixture was diluted with 60 mL of ethyl acetate and decanted. The organic phase was separated and the aqueous phase was extracted twice with 10 mL of ethyl acetate. The combined organic extracts were washed with 20 mL of water, dried with magnésium sulfate and then concentrated to dryness under reduced pressure. The residue was purified by flash chromatography on a 30 g silica cartridge (15-40 pm silica gel; eluting solvent:
dichloromethane; flow: 30 mL/min) followed by a second purification by flash chromatography on a 15 g silica cartridge (15-40 pm silica gel; eluting solvent:
dichloromethane/ methanol/ 28% ammonia 97/2/1 v/v/v; flow: 30 mL/min). 87 mg of (2’S,3,R,4'S,5’R)-6-chloro-4'-(3-chloro-2-fluoro-phenyl)-2,-(2,2-dimethyl-propyl)-2-oxo-1,2dihydro-spiro[indole-3,3’-pyrrolidine]-5'-carboxylic acid (trans-4-hydroxy-cyclohexylmethyl)amide were obtained as a white solid. mp: 192°C (Kofler); LC-MS: tR (min) = 0.84; [M+H]+: m/z 576; [M-H]': m/z 574 (method A); 1H NMR (CHLOROFORM-d, 400 MHz): mixture of isomers: 0.90 (s, 9 H); 0.99 to 2.09 (m partially hidden, 11 H); 3.05 to 3.27 (m, 2 H); 3.59 (m, 2 H); 4.39 (d, J=8.8 Hz, 1 H); 4.59 (m, 1 H); 6.76 (s large, 1 H); 6.99 (t, J=7.8 Hz, 1 H); 7.06 to 7.56 (m, 6 H); 7.82 (t broad, J=6.1 Hz, 1 H).
EXAMPLE 15
1«
Synthesis of (2'S,3'R,4'S,5'R)-6-Chloro-4,-(3-chloro-2-fluoro-phenyl)-2,-(2,2dimethyl-propyl)-T-methyl-2-oxo-1,2-(111^^0^^0(^016-3^^^0^106)-5^ carboxylic acid (frans-4-hydroxy-cyclohexyl)-amide
To a suspension of 0.50 g (0.89 mmol) of (2,S,3’R,4’S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-spiro [indole-3,3’-pyrrolidine]-5’-carboxylic acid (trans-4-hydroxy-cyclohexyl)-amide in 18.0 mL of acetonitrile under argon, were added 0.89 mL (0.97 mmol) of a 36.5% solution of formaldéhyde in water, followed by 65 mg (0.98 mmol) of sodium cyanoborohydride. The resulting solution was stirred at room température for 2 hours, upon which it was poured into 50 mL of ethyl acetate. The aqueous phase was separated and the organic phase was washed with a saturated solution of sodium hydrogencarbonate. The latter aqueous phase was reextracted with ethyl acetate. The combined organic extracts were washed with brine, dried with magnésium sulfate and then concentrated to dryness under reduced pressure. The residue (0.52 g) was purified by chiral HPLC chromatography on a Kromasil C18 column (1100 g batch 4680, 10 pm, 7.65 x 35 cm), eluting solvent: acetonitrile/ water 40/60 v/v + 0.1 % trifluoroacetic acid; flow: 250 mL/min. The collected solution was treated with sodium hydrogencarbonate up to pH 8 and then extracted 3 times with 200 mL of ethyl acetate. The combined organic extracts were washed twice with 100 mL of water, dried with magnésium sulfate and then concentrated to dryness under reduced pressure. The residue was then dried in a dessicator under reduced pressure for 16 hours. 0.17 g of ^’S.S'R^'S.S'RJ-S-chloro^’TS-chloro^-fluoro-phenyl)^’(2,2-dimethyl-propyl)-T-methyl-2-oxo-1,2-dihydro-spiro[indole-3l3'-pyrrolidine]-5,-carboxylic acid (4-hydroxy-cyclohexyl)-amide was obtained as a white solid. mp: 188°C (Kofler); LCMS: tR (min) = 0.85-0.97 (mixture of isomers); [M+Hf: m/z 576; [M-Hf: m/z 574 (method A); 1H NMR (400 MHz, CHLOROFORM-d): 0.73 (d, J=15.6 Hz, 1 H); 0.79 (s, 9 H); 1.15 to
1.48 (m, 4 H); 1.85 to 2.12 (m, 5 H); 2.75 (s, 3 H); 3.60 to 3.77 (m, 3 H); 4.17 (d, J=9.8 Hz, 1 H); 4.33 (d broad, J=9.8 Hz, 1 H); 6.69 (d, J=1.5 Hz, 1 H); 6.99 (t, J=7.8 Hz, 1 H); 7.05 (dd, J=1.5 and 8.3 Hz, 1 H); 7.10 to 7.25 (m, 3 H); 7.37 (m broad, 1 H); 7.56 (t, J=7.8 Hz, 1 H). Similar methodology was used to prépare C29701 and C30201.
170
EXAMPLE 16
Isomerization Studies
General Information
Expérimente involving moisture and/or air sensitive components were performed in ovendried glassware under an atmosphère of nitrogen. Commercial solvents and reagents were used without further purification with the following exception: THF was freshly distilled from sodium wire.
Flash chromatography was performed using silica gel (type H) from TM chemicals, Inc. Columns were typically packed as slurry and equilibrated with hexane prior to use. Analytical thin layer chromatography (TLC) was performed using Merck 60 F254 precoated silica gel plate (0.2 mm thickness). Subjected to elution, plates were visualized using UV radiation. Further visualization was possible by staining with basic solution of potassium permanganate or acidic solution of phosphomolybdic acid, followed by heating with heating gun.
Compounds were purified by HPLC using a Waters Sunfire C18 reverse phase semipreparative HPLC column (19 mm * 150 mm) using solvent A (water, 0.1% of TFA) and solvent B (CH3CN, 0.1% of TFA or MeOH, 0.1% of TFA) as eluents with a flow rate of 10 mL/min on a Waters Delta 600 instrument. Analytical reverse phase HPLC was conducted using Waters 2795 Séparation module.
Proton nuclear magnetic résonance (’H NMR) and carbon nuclear magnetic résonance (13C NMR) spectroscopy were performed on a Bruker Advance 300 NMR spectrometer. Chemical shifts of ’H NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe4 (δ 0.0) or relative to the signal of chloroform-d (δ = 7.26, singlet), methanol-d4 (δ = 3.31, quintuplet) and DMSO-de (δ = 2.50, quintuplet). Multiplicities were given as: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); ddd (doublet of doublets of doublets); dt (doublet of triplets); m (multiplets) and etc. The number of protons for a given résonance is indicated by nH. Coupling constants are reported as J values in Hz. Carbon nuclear magnetic résonance spectra (13C NMR) are reported as δ in units of parts per million (ppm) downfield from SiMe4 (δ 0.0) or relative to the signal of chloroform-d (δ = 77.23, triplet), MeOH-d4 (δ = 49.20, septuplet) and DMSO-de (δ = 39,52, septuplet).
Low resolution ESl mass spectrum analysis was performed on Thermo-Scientific LCQ Fleet mass spectrometer.
Compounds 1-10 were prepared according to Scheme 10 and Table 4 using methods previous described (See, e.g., Ding, K. et al., J. Am. Chem. Soc. 727:10130-10131 (2005);
172
Ding, K. et al., J. Med. Chem. 49:3432-3435 (2006); Yu, S. et al., J. Med. Chem. 52:79707973 (2009); Shangary, S., Proc. Natl. Acad. Sci. 705:3933-3938 (2008); US 7,759,383) as a mixture of isomers. Isomer A was identified as the prédominant isomer following CAN oxidation in most cases. Applicants hâve found that dissolving the mixture of isomers obtained from CAN oxidation in a solvent or a mixture of solvents and allowing the reaction mixture to mature for a period of time under various conditions provides a mixture of isomers having Isomer B as the prédominant isomer. In some cases, Isomers C and D were isolated in pure or substantially pure form. Likewise, compounds 11 and 12 were prepared according to Scheme 11 and Table 5.
The procedure for isomerization used in this study was as follows: approximately 30 mg product obtained from CAN oxidation (pre-purified by flash column chromatography) was placed in a round bottom flask equipped with magnetic stirring bar. Acetonitrile (2.4 mL) was added to dissolve the product. To the acetonitrile solution was added water (2.0 mL) and 0.5 mL NaHCO3 (saturated) solution to give a pH of approximately 8. The reaction mixture was allowed to stir at room température for approximately 3 days. The percentage of isomers was determined using analytical HPLC. Further purification was performed on semi-preparative or préparative reverse phase HPLC using MeOH (0.1% TFA) and water (0.1% TFA) as mobile phase.
Isomerization of Isomer A to Isomer B can also be carrîed out under acidic conditions, e.g., MeCN-H2O, CF3CO2H (pH <1), room température, 3 days; ethyl acetate, acetic acid, 60°C, 3 h, or neutral conditions e.g., MeOH or MeOH-H2O.
172
Scheme 10
1.0 equlv
1.1 equiv 1.1 equlv
HNRbRc
1,3 equlv THF, rt, 12 h
Oxidation
CAN 2.1 equiv
MeCN:H2O (1:1) rt. 1 h
Isomer A
Isomer B
Isomer izatlon
Isomers A-D sat. NaHCOj MeCN:H2O (1:1) rt, 3 days
173
Table 4
C P d | R 1 | R 2 | -NRbRc | Yi el da (% ) | Isomer Ratio after Oxidati on A:B:(C+ D)b | Isomer Ratio after Isomerizat ion A:B:(C+D)6 |
1 | I- | H | -NMe2 | 50 C | 95:2:3 | 6:71:24 |
2 | h | H | -NHMe | 61 | 87:5:8 | 3:71:26 |
3 | h | F | -NMe2 | 57 | 75:19:6 | 35:46:19 |
4 | H | F | NHMe | 84 | 67:2:31 | 9:79:12 |
5 | H | F | H OH | 86 | 88:2:10 | 1:80:19 |
6 | H | F | , r H | 79 | 89:10:1 | 12:61:27 |
7 | H | F | -NH2 | 56 | 0:44:56 | 0:96:4 |
8 | F | H | -NMez | 60 | 56:25:19 | 10:71:19 2:88:8 |
9 | F | H | -NHMe | 87 | 19:52:27 | 1:74:25 |
1 0 e | F | H | OH | 81 | 30:32:38 | 3:58:37 |
a Yield after oxidation;6 Ratio was determined by HPLC analysis;c Yield after HPLC séparation; ύ Ratio determined by HPLC analysis after allowing oxidation product to stand in MeOH for two hours;9 Compound 10 Isomer A and Compound 10 Isomer B are referred to as MI-219 and MI-21901, respectively, in Table 2A .
17¼
Scheme 11
CAN 2.1 equiv
MeCN-H2O1:1 rt, 1 hour
74%
lund 11 C and D
25%
Compound 12 Isomer A
Compound 12 Isomer B
Compound 12 Isomers C and D tsomerizalion
Isomers A-D sat. NaHCO3 MeCN:H2O (1:1) rt. 3 days
Table 5
C | Yield | Isomer Ratio | Isomer Ratio |
P | (%) | after Oxidation | after Equilibration |
d | a:b:(c+d)b | a:b:(c+d)1’ |
175
1 1 | 74a | 89:6:3 | 44:50:6 |
1 2 | 25e | — | 41:34:25* |
e Yield after oxidation;b Ratio was determined by HPLC analysis;c Hydrolysis yield; d Starting with pure Compound 12-lsomer A.
Analytical Data
Compound 1 - Isomer A (TFA sait): ESl: Calculated for C25H3o35CI2N302 [M+H]+= 474.17, Found: 474.50.
Compound 1 - Isomer B (TFA sait): ESl: Calculated for C25H3o35CI2N302 [M+H]+= 474.17, Found: 474.68.
Compound 1 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD): 7.72 (d, J = 8.08 Hz, 1H), 7.28-7.22 (m, 1H), 7.20-7.12 (m, 2H), 7.12-7.08 (m, 1H), 7.04 (d, J = 7.65 Hz, 1H), 6.81 (d, J = 1.79 Hz, 1H), 5.54 (d, J - 10.87 Hz, 1H), 4.37 (dd, J = 6.54, 4.52 Hz, 1H), 4.15 (d, J = 10.85 Hz, 1H), 2.98 (s, 3H), 2.81 (s, 3H), 1.70 (dd, J = 15.24, 6.67 Hz, 1H), 1.20 (dd, J = 15.26, 4.43 Hz, 1H), 0.91 (s, 9H); ESl: Calculated for C25H3035CI2N3O2 [M+H]+= 474.17, Found: 474.50.
Compound 2 - Isomer A (TFA sait): 1H NMR (300 MHz, CD3OD): 7.28-7.16 (m, 3H), 7.167.06 (m, 1H), 6.92-6.82 (m, 2H), 6.80-6.76 (m, 1H), 4.92 (d, J =10.23, 4.20-4.10 (m, 2H), 2.73 (s, 3H), 1.99 (s, J = 15.32, 6.75 Hz, 1H), 1.47 (dd, J = 15.54, 3.49 Hz, 1H), 0.80 (s, 9H); ESl: Calculated for C24H2835CI2N3O2 [M+H]+= 460.16, Found: 460.52.
Compound 2 - Isomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 7.63 (d, J = 8.06 Hz, 1H), 7.30-7.14 (m, 4H), 7.12-7.00 (m, 1H), 6.82-6.76 (m, 1H), 5.29 (d, J= 11.24 Hz, 1H), 4.47 (d, J = 6.68 Hz, 1H), 4.16 (d, J = 11.22 Hz, 1H), 2.73 (s, 3H), 1.92 (dd, J= 15.40, 8.39 Hz, 1H), 1.17 (d, J = 16.85 Hz, 1H), 0.90 (s, 9H); 13C (75 MHz, CD3OD): 177.78, 168.54, 145.38, 137.07, 135.77, 134.60, 131.40, 130.29, 129.48, 128.29, 126.32, 124.24, 124.16, 112.18, 65.11, 64.18, 62.85, 56.95, 43.42, 30.97, 29.66, 26.98; ESl: Calculated for C24H28 35CI2N3O2 [M+H]+= 460.16, Found: 460.48.
Compound 2 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD): 7.57 (d, J = 8.12 Hz, 1 H), 7.24-7.08 (m, 3H), 7.04-6.98 (m, 1 H), 6.92 (d, J = 7.62 Hz, 1H), 6.76 (d, J = 1.78 Hz, 1H), 5.02 (d, J = 12.47 Hz, 1H), 4.42 (dd, J = 7.06, 4.40 Hz, 1H), 4.13 (d, J = 12.47 Hz, 1H), 2.70 (s, 3H), 1.74 (dd, J = 15.35, 7.14 Hz, 1H). 1.17 (dd, J = 15.37, 4.38 Hz, 1H), 0.88 (s, 9H); 13C (75 MHz, CD3OD): 176.72, 167.32, 144.88, 137.13, 135.62, 133.98, 131.17, 130.24, 129.73, 128.41, 127.88, 123.91, 123.53, 112.57, 65.42, 64.33, 62.97, 59.03, 44.86, 31.01,29.57, 27.03; ESl: Calculated for C24H28 35CI2N3O2 [M+H]+= 460.16, Found: 460.50.
17ff
Compound 3 - Isomer A (TFA sait): 1H NMR (300 MHz, CD3OD): 7.80-7.70 (m, 1H), 7.507.40 (m, 1H), 7.32-7.22 (m, 1H), 6.92-6.88 (m, 1H), 6.74 (dd, J =8.15, 1.75 Hz, 1H), 6.48 (d, J = 8.11 Hz, 1H), 5.58 (d, J = 7.94 Hz, 1H), 4.38 (d, J = 7.94 Hz, 1H), 4.26 (d, J= 7.55 Hz, 1H), 2.99 (s, 3H), 2.84 (s, 3H), 2.06 (dd, J= 15.42, 7.72 Hz, 1H), 1.13 (d, J = 15.37 Hz, 1H), 0.89 (s, 9H); 13C (75 MHz, CD3OD): 180.07, 166.93, 157.51 (d, Jc-f = 243.98 Hz), 145.59, 137.11, 132.54, 128.77, 127.66, 126.74 (d, JC.F = 4.55 Hz), 125.89 (d, JC.F =13.40 Hz), 123.68, 122.85 (d, JC.F = 10.19 Hz), 123.10 (d, JC.F = 18.37 Hz), 112.07, 63.03, 62.05, 61.76, 42.09, 37.70, 36.89, 30.77, 29.34; ESl: Calculated for C25H29 35CI2FN3O2 [M+H]+= 492.16, Found: 492.44.
Compound 3 - Isomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 7.68-7.57 (m, 2H), 7.45-
7.35 (m, 1H), 7.22-7.10 (m, 2H), 6.84-6.77 (m 1H), 5.68 (d, J = 10.24 Hz, 1H), 4.64 (d, J = 10.24 Hz, 1H), 4.48 (dd, J = 8.20, 1.70 Hz, 1H), 2.98 (s, 3H), 2.80 (s, 3H), 1.89 (dd, J = 15.48, 8.26 Hz. 1 H), 1.14 (dd, J = 15.48, 1.67 Hz, 1H), 0.89 (s, 9H); 13C (75 MHz, CD3OD): 177.96, 168.37, 152.99 (d, JC.F = 253.32 Hz), 145.26, 137.39, 132.82, 128.82, 126.95, 126.70 (d, JC F = 4.79 Hz), 124.28, 122.09 (d, JC.F = 13.13 Hz), 118.90, 115.11, 112.24, 64.69, 59.97, 42.64, 37.96, 37.03, 31.03, 29.62; ESl: Calculated for C25H2935CI2FN3O2 [M+H]*= 492.16, Found: 492.46.
Compound 3 - Isomer C (TFA sait): 1H NMR (300 MHz, CD3OD) (TFA sait): 7.63 (d, J = 8.13 Hz, 1H), 7.52-7.38 (m, 2H), 7.24-7.12(m, 2H), 6.83 (d, J = 1.80 Hz, 1H), 5.47 (d, J = 11.16 Hz, 1H), 4.42 (d, J = 11.31 Hz, 1H), 4.35 (t, J = 5.66 Hz, 1H), 2.95 (s, 3H), 2.93 (s, 3H), 1.91 (dd, J= 15.39, 5.80 Hz, 1H), 1.71 (dd, J= 15.24, 5.43 Hz, 1H), 0.84 (s, 9H); ESl: Calculated for C25H2935Cl2FN3O2 [M+H]+= 492.16, Found: 494.20.
Compound 3 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD) (TFA sait): 7.60 (d, J = 8.07 Hz, 1H), 7.40-7.30 (m, 1H), 7.22-7.12 (m, 1H), 7.07 (dd, J = 8.16, 1.87 Hz, 1H), 7.046.95 (m, 1H), 6.80 (d, J = 1.87 Hz, 1H), 5.58 (d, J = 9.80 Hz, 1H), 4.51 (d, J = 9.84 Hz, 1H), 4.43 (dd, J = 6.69, 4.15 Hz. 1H), 2.99 (s, 3H), 2.80 (s, 3H), 1.68 (dd, J = 15.41, 6.81 Hz, 1 H), 1.42 (dd, J = 15.41, 4.26 Hz, 1H), 0.90 (s, 9H); ESl: Calculated for C25H2g35CI2FN3O2 [M+H]+= 492.16, Found: 492.28.
Compound 4 - Isomer A (TFA sait): 1H NMR (300 MHz, CD3OD): 7.66-7.54 (m, 1H), 7.387.28 (m, 1H), 7.22-7.10 (m, 1H), 6.87 (s, 1H), 6.82-6.72 (m, 2H), 5.21 (d, J = 10.00 Hz, 1H), 4.50 (d, J = 9.93 Hz, 1 H), 4.30-4.24 (m, 1H), 2.75 (s, 3H), 2.07 (dd, J= 15.35, 7.35 Hz, 1H), 1.8 (d, J = 14.57 Hz, 1H), 0.80 (s, 9H); 13C (75 MHz, CD3OD): 180.31, 167.24, 157.81 (d, Jq. F = 247.78 Hz), 145.44, 136.94, 132.11, 128.66, 127.94, 126.47 (d, JC.F = 4.45 Hz), 125.29, 125.01 (d, JC-f= 13.96 Hz), 123.37, 122.64 (d, JC.F = 18.03 Hz), 122.04, 64.35, 63.69, 61.74, 49.51, 42.34, 30.92, 29.55, 27.10; ESl: Calculated for C24H27 35CI2FN3O2 [M+H]+= 478.15, Found: 478.92.
177
Compound 4 - Isomer B (TFA sait): ’H NMR (300 MHz, CD3OD): 7.65-7.55 (m, 2H), 7.407.34 (m, 1H), 7.20-7.10 (m, 2H), 6.84-6.80 (m, 1H), 5.26 (d, J = 11.15 Hz, 1H), 4.64 (d, J = 11.19 Hz, 1H), 4.45 (d, J = 7.86 Hz, 1H), 2.74 (s, 3H), 1.87 (dd, J = 15.19, 8.58 Hz, 1H), 1.11 (d, J= 15.21 Hz, 1H), 0.90 (s, 9H); ’3C (75 MHz, CD3OD): 177.75, 168.20, 159.53 (d, Jc-f - 248.25 Hz), 145.22, 137.24, 132.59, 128.58, 126.63 (d, Jc* - 5.25 Hz), 124.16, 123.43, 126.66, 122.59 (d, JC-f - 4.05 Hz), 121.54 (d, JC.F = 12.75 Hz), 112.13, 64.49, 64.40, 62.73, 55.34, 43.33, 31.01, 29.58, 27.06; ESI: Calculated for C24H2735CI2FN3O2 [M+H]+= 478.15, Found: 478.25.
Compound 4 - Isomer C (TFA sait): ’H NMR (300 MHz, CD3OD): 7.62 (d, J = 8.17 Hz, 1H), 7.46-7.36 (m, 2H), 7.22 (dd, J = 8.13, 1.89 Hz, 1 H), 7.15 (t, J = 8.08 Hz, 1H), 6.80 (d, J = 1.85 Hz, 1H), 4.84 (d, J = 12.32, 1H), 4.35 (d, J = 12.32 Hz, 1H), 4.24 (t, J = 5.62 Hz, 1H), 2.67 (s, 3H), 1.87 (dd, J = 5.44, 2.53 Hz, 2H), 0.77 (s, 9H); ESI: Calculated for CZ4H27 35CI2FN3O2 [M+H]+= 478.15, Found: 478.52.
Compound 4 - Isomer D (TFA sait): ’H NMR (300 MHz, CD3OD): 7.53 (d, J = 8.11 Hz, 1 H), 7.36-7.26 (m, 1H), 7.11 (dd, J= 8.08, 1.88 Hz, 1H), 6.98-6.90 (m, 2H), 6.77 (d, J = 1.85 Hz, 1 H), 5.03 (d, J = 11.95 Hz, 1 H), 4.51 (d, J = 11.87 Hz, 1 H), 4.50-4.42 (m, 1 H), 2.72 (s, 3H), 1.72 (d, J = 15.36, 7.30 Hz, 1H), 1.16 (dd, J = 15.37, 4.09 Hz, 1H), 0.89 (s, 9H); ESI: Calculated for C24H27 35CI2FN3O2 [M+H]+= 478.15, Found: 478.38.
Compound 5 - Isomer A (TFA sait): ’H NMR (300 MHz, CD3OD): 7.63-7.53 (m, 1H), 7.407.30 (m, 1H), 7.23-7.13 (m, 1H), 6.87 (d, J = 1.36 Hz, 1H), 6.86-6.74 (m, 2H), 5.19 (d, J =
10.22 Hz, 1H), 4.49 (d, J = 10.22 Hz,1H), 4.25 (dd, J ~ 7.35, 2.71 Hz, 1H), 3.56-3.43 (m, 1H), 3.42-3.30 (m, 4H), 2.07 (dd, J = 15.43, 7.44 Hz,1 H), 1.72-1.58 (m, 1H), 1.56-1.40 (m, 1H), 1.30 (dd, J = 15.43, 2.62 Hz, 1H), 0.80 (s, 9H); ’3C (75 MHz, CD3OD): 180.26, 166.78, 157.81 (d, JC-f = 247.93 Hz), 145.43, 136.90, 132.16, 128.82, 127.96, 126.48 (d, JC-f = 4.49 Hz), 125.43, 124.94 (d, JC.F = 14.00 Hz), 123.37, 122.63 (d, JC.F = 18.23 Hz), 112.00, 71.01, 67.25, 64.38, 63.80, 61.69, 50.06, 42.36, 38.30, 33.80, 30.94, 29.55; ESI: Calculated for C27H3335CI2FN3O4 [M+H]+= 552.18, Found: 552.92.
Compound 5 - Isomer B (TFA sait): ’H NMR (300 MHz, CD3OD): 7.60 (d, J = 8.15 Hz, 1 H), 7.55 (t, J= 7.12 Hz, 1H), 7.38 (t, J = 7.57 Hz, 1H), 7.20-7.10 (m, 2H), 6.78 (d, J= 1.70 Hz, 1 H), 5.27 (d, J = 11.40 Hz, 1 H), 4.62 (d, J = 11.40 Hz, 1 H), 4.52 (dd, J = 8.33, 1.29 Hz, 1 H), 3.45-3.25 (m, 5H), 1.90 (dd, J= 15.46, 8.38 Hz, 1H), 1.64-1.48 (m, 1H), 1.46-1.32 (m, 1H), 1.14 (dd, J = 15.46, 1.34 Hz, 1H), 0.87 (s, 9H); 13C (75 MHz, CD3OD): 177.77, 167.67, 157.90 (d, Jc-F - 251.2 Hz), 145.21, 137.26, 132.67, 128.64, 126.89 (d, JC.F = 1.88 Hz), 126.65 (d, Jc-f = 4.89 Hz), 124.17, 123.43, 122.60 (d, JC.F = 19.0 Hz), 121.52 (d, JC-f = 13.0 Hz), 112.14, 79.99, 67.25, 64.45, 62.873, 48.8, 43.39, 38.26, 33.78, 31.02, 29.57; ESI: Calculated for C27H333SCI2FN3O4 [M+H]+= 552.18, Found: 552.42;
17ff
Compound 5 - Isomer C (TFA sait): Ή NMR (300 MHz, CD3OD): 8.37 (s, broad, NH), 7.62 (d, J = 8.11 Hz, 1H), 7.50-7.34 (m, 2H), 7.36-7.10 (m, 2H), 6.83 (d, J = 1.83 Hz, 1H), 4.32 (d, J = 12.09 Hz, 1H), 4.24-4.14 (m, 1H), 3.50-3.10 (m, 5H), 1.86-1.72 (m, 2H), 1.58-1.44 (m, 1H), 1.44-1.26 (m, 1H), 0.80 (s, 9H); ESI: Calculated for C27H33 35CI2FN3O4 [M+H]+= 552.18, Found: 552.42.
Compound 5 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD): 7.49 (d, J = 8.02 Hz, 1H), 7.36-7.24 (m, 1H), 7.11 (dd, J = 8.09, 1.89 Hz, 1H), 7.06-6.96 (m, 1H), 6.96-6.88 (m, 1H), 6.80 (d, J = 1.88 Hz, 1 H), 4.89 (d, J = 11.57 Hz, 1 H), 4.46 (d, J = 11.57 Hz, 1 H), 4.35-4.25 (m, 1H), 3.56-3.40 (m, 1H), 3.40-3.20 (m, 4H), 1.70-1.40 (m, 3H), 1.10 (dd, J = 14.59, 3.06 Hz, 1H), 0.91 (s, 9H); ESI: Calculated for C27H3335CI2FN3O4 [M+H]+= 552.18, Found: 552.40. Compound 6 - Isomer A (TFA sait): 1H NMR (300 MHz, CD3OD): 7.59 (t, J = 6.93 Hz, 1H), 7.41 (td, J = 7.55, 0.97 Hz, 1 H), 7.22 (t, J = 7.90 Hz, 1 H), 6.90 (d, J = 1.79 Hz, 1 H), 6.77 (dd, J =8.14, 1.79 Hz, 1H), 6.48 (d, J = 8.15 Hz, 1H), 5.21 (d, J=8.22 Hz, 1H), 4.50 (d, J = 8.19 Hz, 1 H), 4.17 (dd, J = 7.63, 2.23 Hz, 1H), 4.10-3.80 (m, 4H), 3.75-3.45 (m, 4H), 3.40-3.00 (m, 4H), 2.08-1.96 (m, 1H), 1.19 (dd, J = 15.32, 2.23 Hz, 1H), 0.81 (s, 9H); 13C (75 MHz, CD3OD): 180.28, 168.91, 157.75 (d, JC-f = 248.38 Hz), 145.50, 137.13, 132.29, 128.63, 127.67, 126.63 (d, JC F = 4.50 Hz), 125.74 (d, JC-f = 13.69 Hz), 124.72, 123.44, 122.83 (d, Jc-F = 18-25 Hz), 112.20, 65.16, 64.25, 63.84, 62.22, 58.01, 53.84, 50.05, 42.39, 35.72, 30.95, 29.52; ESI: Calculated for C29H36 35CI2FN4O3 [M+H]+= 577.21, Found: 577.48.
Compound 6 - Isomer B (TFA sait): 1H NMR (300 MHz. CD3OD): 7.66-7.48 (m, 2H), 7.427.32 (m, 1H), 7.20-7.10 (m, 2H), 6.78 (d, J = 1.68 Hz, 1H), 5.38 (d, J = 11.48 Hz, 1H), 4.65 (d, J = 11.48 Hz, 1H), 4.52 (d, J = 7.59 Hz, 1H), 4.00-3.70 (m, 4H), 3.70-3.60 (m, 2H), 3.503.40 (m, 2H), 3.40-3.10 (m, 4H), 1.97 (dd, J = 15.40, 8.62 Hz, 1H), 1.12 (d, J = 15.40 Hz, 1H), 0.88 (s, 9H); 13C (75 MHz, CD3OD): 177.73, 169.20, 145.19, 137.15, 132.54, 128.69, 126.84, 126.64 (d, JC F = 4.80 Hz), 124.11, 123.72, 122.57 (d, JC.F = 13.19 Hz), 121,77 (d, JC.F = 13.19 Hz), 112.06, 65.08, 64.59, 64.32, 62.69, 57.41, 53.70, 48.47, 43.55, 35.61, 31.06, 29.56; ESI: Calculated for C29H3e 35CI2FN4O3 [M+H]+= 577.21, Found: 577.48.
Compound 7 - Isomer B (TFA sait): ’H NMR (300 MHz, CD3OD): 7.54-7.44 (m, 2H), 7.367.26 (m, 1 H), 7.14-7.00 (m, 2H), 6.70 (d, J = 1.76 Hz, 1 H), 5.22 (d, J = 11.36 Hz, 1 H), 4.50 (d, J = 11.36 Hz, 1H), 4.41 (d, J = 8.23, 1.85 Hz, 1H), 1.81 (dd, J =15.46, 8.31 Hz, 1H), 1.06 (dd, J = 15.46, 1.90 Hz, 1H), 0.78 (s, 9H); ESI: Calculated for C23HZ5 35CI2FN3O2 [M+H]+= 464.13, Found: 464.60.
Compound 7 - Isomer D (TFA sait): ’H NMR (300 MHz, CD3OD): 7.64 (d, J = 8.01 Hz, 1H), 7.54-7.40 (m, 2H), 7.28-7.12 (m, 2H), 6.83 (d, J = 1.68 Hz, 1H), 4.96 (d, J = 12.33 Hz, 1H),
4.36 (d, J = 12.33 Hz, 1H), 4.28 (t, J = 5.60 Hz, 1H), 1.93-1.86 (m, 2H), 0.80 (s, 9H); ESI: Calculated for CZ3H25 35CIZFN3OZ [M+H]+= 464.13, Found: 464.42.
173
Compound 8 - Isomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 7.66 (d, J = 8.49 HZ, 1 H),
7.35-7.12 (m, 4H), 6.86 (d, J = 6.02 Hz, 1H), 5.67 (d, J = 10.03 Hz, 1H), 4.41 (dd, J = 8.20,
1.79 Hz, 1H), 4.13 (d, J= 10.03 Hz, 1H), 2.97 (s, 3H), 2.74 (s, 3H), 1.91 (dd, J= 15.46, 8.20 Hz, 1H) 1.17 (dd, J = 15.46, 1.82 Hz, 1H), 0.91 (s, 9H); 13C (75 MHz, CD3OD):177.80, 168.54, 156.04 (d, JC-f = 243.74 Hz), 141.04, 136,12, 135.16, 131.81, 130.66, 129.73, 128.52, 125.50 (d, JC-f =7.37 Hz), 123.70 (d, JC-f = 19.58 Hz), 114.43 (d, JC F =25.50 Hz), 113.62, 65.81, 64.45, 60.58, 57.31, 42.59, 38.04, 37.00, 31.04, 29.63; ESI: Calculated for C25H2935CI2FN3O2 [M+H]*= 492.16, Found: 492.50.
Compound 8 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD): 7.73 (d, J = 8.75 Hz, 1H), 7.30-7.18 (m, 1H), 7.18-7.12 (m, 1H), 7.12-7.06 (m, 1H), 6.89 (d, J = 6.12 Hz, 1H), 5.52 (d, J = 10.56 Hz, 1H), 4.37 (dd, J = 6.56, 4.48 Hz, 1H), 4.18 (d, J= 10.62 Hz, 1H), 2.99 (s, 3H),
2.80 (s, 3H), 1.69 (dd, J= 15.35, 6.58 Hz, 1H), 1.21 (dd, J= 15.35, 4.37 Hz, 1H), 0.93 (s, 9H); ESI: Calculated for C25H29 35CI2FN3OZ [M+H]*= 492.16, Found: 492.62.
Compound 9 - Isomer A (TFA sait): 1H NMR (300 MHz, CD3OD): 7.25-7.20 (m, 3H), 7.107.00 (m, 1H), 6.85 (d, J = 6.00 Hz, 1H), 5.13 (d, J = 11.10 Hz, 1H), 4.30-4.10 (m, 2H), 2.72 (s, 3H), 2.02 (dd, J = 15.30, 7.20 Hz, 1H), 1.52 (dd, J = 15.30, 3.90 Hz, 1H), 0.79 (s, 9H); ESI: Calculated for C24H273SCI2FN3O2 [M+H]*= 478.15, Found: 478.46.
Compound 9 - Isomer B (TFA sait):
1H NMR (300 MHz, CD3OD): 7.68 (d, J = 8.47 Hz, 1H), 7.32-7.16 (m, 3H), 7.04 (d, J = 7.63 Hz, 1 H), 6.85 (d, J = 6.01 Hz, 1 H), 5.23 (d, J = 11.21 Hz, 1 H), 4.46 (dd, J = 8.23, 1.76 Hz, 1H), 4.13 (d, 11.21 Hz, 1H), 2.71 (S, 3H), 1.90 (dd, J= 15.46, 8.23 Hz, 1H), 1.17 (dd, J =
15.48, 1.75 Hz, 1H), 0.89 (s, 9H) 13C (75 MHz, CD3OD): 177.57, 168.31, 159.98 (d, JCF = 244.73 Hz), 140.90, 135.98, 134.31, 131.59, 130.56, 129.45, 128.47, 125.84 (d, JC-f = 7.48 Hz), 123.61 (d, JCF = 19.45 Hz), 114.33 (d, JC.F = 25.29 Hz), 113.57, 65.62, 64.15, 62.93, 57.04, 63.42, 31.01, 29.60, 27.02; ESI: Calculated for C24H2735CI2FN3O2 [M+H]+= 478.15, Found: 478.46.
Compound 9 - Isomer C (TFA sait):
1H NMR (300 MHz, CD3OD): 7.66 (d, J = 8.70 Hz, 1H), 7.32 (d, J = 8.20 Hz, 1 H), 7.23 (t, J = 7.89 Hz, 1 H), 7.09 (t, J = 1.70 Hz, 1 H), 6.93 (d, J = 7.66 Hz, 1 H), 6.89 (,J = 6.13 Hz, 1 H),
4.22 (t, J = 5.73 Hz, 1 H), 3.91 (d, J = 12.36 Hz,1 H), 2.70 (s, 3H), 1.90-1.84 (m, 2H), 0.83 (s, 9H); ESI: Calculated for C24H27 35CI2FN3O2 [M+H]+= 478.15, Found: 478.58.
Compound 9 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD): 7.51 (d, J = 8.79 Hz, 1 H), 7.24-7.12 (m, 2H), 7.08 (s, 1H), 7.25 (d, J =7.13 Hz, 1H), 6.85 (d, J = 6.13 Hz, 1H), 4.80 (d, J = 11.25 Hz, 1H), 4.25-4.15 (m, 1H), 4.09 (d, J = 11.25 Hz, 1H), 2.76 (s, 3H), 1.44 (dd, J = 15.26, 7.62 Hz, 1H), 1.08 (dd, J = 15.26, 3.19 Hz, 1H), 0.92 (s, 9H); ESI: Calculated for C24H2735CI2FN3OZ [M+H]*= 478.15, Found: 478.56.
180
Compound 10 - Isomer A (TFA sait) (MI-219-TFA sait): ’H NMR (300 MHz, CD3OD): 7.32-
7.22 (m, 3H), 7.18-7.10 (m, 1H), 7.06 (d, J = 8.74 Hz, 1H), 6.88 (d, J = 6.08 Hz, 1H), 4.97 (d, J = 10.79 Hz, 1H), 4.22 (d, J = 10.79 Hz, 1 H), 4.26-4.18 (m, 1H), 3.50-3.20 (m, 5H), 2.03 (dd, J = 15.35, 6.56 Hz, 1H), 1.68-1.52 (m, 2H), 1.50-1.40 (m, 1H), 0.84 (s, 9H); ’3C (75 MHz, CD3OD): 179.64, 166.47, 140.40 (d, JP.C = 2.94 Hz), 136.54, 136.06, 131.64, 130.16, 130.02, 128.14, 127.27 (d, JP.C = 40.14 Hz). 123.05 (d, JP.C = 19.44 Hz), 115.94 (d, JP.C =
25.54 Hz), 113.09, 70.91, 67.24, 64.19, 64.10, 62.73, 57.52, 42.66, 38.14, 33.85, 30.99, 29.57; ESI: Calculated for C27H33 35CI2FN3O4 [M+Hf= 552.18, Found: 552.75; HPLC Purity = 82%.
Compound 10 - Isomer B, (TFA sait) (MI-21901 - TFA sait): Ή NMR (300 MHz, CD3OD): 7.68 (d, J = 8.47 Hz, 1H), 7.32-7.17 (m, 3H), 7.12-7.02 (m, 1H), 6.85 (d, J = 6.00 Hz, 1H),
5.23 (d, J= 11.28 Hz, 1H), 4.46 (dd, J =8.41, 1.91 Hz, 1H), 4.10 (d, J = 11.28 Hz. 1H), 3.50-
3.20 (m, 5H), 1.90 (dd, J = 15.18, 8.62 Hz. 1H), 1.65-1.47 (m, 1H), 1,47-1.33 (m,1H), 1.18 (d, J = 15.18 Hz,1 H), 0.89 (s, 9H); ’3C (75 MHz, CD3OD): 177.56, 167.81, 155.99 (d, JP.C = 243.27 Hz), 140.87, 135.98, 134.28, 131.63, 130.60, 129.51, 128.60, 125.82 (d, JP.C = 7.39 Hz), 123.58 (d, JP.C = 19.68 Hz), 114.30 (d, JP.C = 25.32 Hz), 113.55, 70.86, 67.23, 65.53, 64.16, 63.07, 57.35, 43.43, 38.15, 33.78, 31.01, 29.57; ESI: Calculated for C27H3335CI2FN3O4 [M+Hf= 552.18, Found: 552.38; HPLC Purity = 95%.
Compound 10 - Isomer D (TFA sait): ’H NMR (300 MHz, CD3OD): 7.60-7.53 (m, 1H), 7.307.10 (m, 2H), 7.08-7.02 (m, 1H), 7.00-6.92 (m. 1H), 6.84 (d, J = 6.13 Hz, 1H), 4.96 (d, J = 12.25 Hz, 1H), 4.39 (dd, J = 7.22, 4.31 Hz, 1 H), 4.10 (d, J = 12.27 Hz, 1H), 3.50-3.20 (m, 5H), 1.68 (dd, J = 15.29, 7.23 Hz, 1H), 1.62-1.48 (m, 1H), 1.48-1.32 (m, 1H), 1.17 (dd, J = 15.29, 4.16 Hz, 1H), 0.90 (s, 9H); ESI: Calculated for C27H33 35CI2FN3O4 [M+Hf= 552.18, Found: 552.40.
Compound 11 - Isomer A (TFA sait): ’H NMR (300 MHz, CD3OD): 7.50-7.40 (m, 2H), 7.28-
7.18 (m, 1H), 6.91 (d, J= 1.81 Hz, 1H), 6.78(dd, J= 8.13, 1.87 Hz, 1H), 6.46 (d, J = 8.14 Hz, 1H), 5.30 (d, J = 8.52 Hz, 1H), 4.43 (d, J = 8.52 Hz, 1H), 4,40-4.20 (m, 2H), 4.08 (dd, J = 7.47, 2.43 Hz, 1H), 2.00 (dd, J= 15.32, 7.53 Hz, 1H), 1.22 (t, J= 7.12 Hz, 3H), 1.19 (dd, J = 15.32, 2.55 Hz, 1H), 0.81 (s, 9H); 13C (75 MHz, CD3CI, note free amine): 181.33, 171.91,
156.54 (d, Jc-f = 248.02 Hz), 142.85, 134.15, 129.91, 128.37 (d, JC-f = 14.61 Hz), 127.19 (d, JC.F = 3.19 Hz), 125.94, 124.94, 124.63 (d, JC F = 4.50 Hz), 122.10, 121.69 (d, JC.F = 18.50 Hz), 110.72, 67.16, 65.70, 63.19, 61.74, 51.17, 43.45, 30.33, 29.97, 14.32; ESI: Calculated for C25H2e35CI2FN2O3 [M+Hf = 493.15, Found: 493.44.
Compound 11 - Isomer B (TFA sait): ’H NMR (300 MHz, CD3OD): 7.59 (d, J = 7.41 Hz, 1H), 7.50-7.42 (m, 1H), 7.40-7.32 (m, 1H), 7.17-7.07 (m, 2H), 6.78 (d, J= 1.65 Hz, 1H), 5.61 (d, J = 12.25 Hz, 1H), 4.56 (d, J = 12.25 Hz, 1H), 4.47 (dd, J = 8.50, 1.50 Hz, 1H), 4.25 (dq,
182
J = 10.77, 7.12 Hz, 1H), 4.13 (dq, J = 10.77, 7.12 Hz, 1H), 1.93 (dd, J = 15.39, 8.67 Hz, 1H), 1.34 (dd, J = 15.39, 1.57 Hz, 1H), 1.10 (t, J =7.12 Hz, 3H), 0.87 (s, 9H); ESl: Calculated for C25H2e 35CI2FN2O3 [M+H]+= 493.15, Found: 493.44.
Compound 12 - Isomer A (TFA sait): 1H NMR (300 MHz, CD3OD): 7.56-7.46 (m, 1H), 7.46-
7.36 (m, 1H), 7.26-7.18 (m, 1H), 6.91 (d, J =1.61 Hz, 1H), 6.76 (dd, J = 8.10, 1.50 Hz, 1H), 6.47 (d, J = 8.14 Hz, 1H), 5.29 (d, J = 8.67 Hz, 1H), 4.43 (d, J = 8.67 Hz, 1H), 4.11 (d, J = 7.47, 2.13 Hz, 1H), 2.02 (dd, J = 15.36, 7.50 Hz, 1H), 1.16 (dd, J= 15.36, 2.24 Hz, 1H), 0.81 (s, 9H); ESl: Calculated for C23H24 35CI2FN2O3 [M+H]*= 465.11, Found: 465.42.
Compound 12 - Isomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 7.58-7.42 (m, 2H), 7.367.26 (m, 1H), 7.14-7.02 (m, 1H), 6.75 (s, 1H), 5.43 (d, J = 12.00 Hz, 1H), 4.58 (d, J = 11.97 Hz, 1H), 4.35 (d, J = 8.53 Hz, 1H), 1.87 (dd, J= 15.08, 9.31 Hz, 1H), 1.09 (d, J = 15.31 Hz, 1H), 0.85 (s, 9H); ESl: Calculated for C23H2435CI2FN2O3 [M+Hf= 465.11, Found: 465.38.
Compound 12 - Isomer D (TFA sait): 1H NMR (300 MHz, CD3OD): 7.49 (d, J = 8.10 Hz, 1H), 7.36-7.26 (m, 1H), 7.13 (dd, J = 8.10, 1.85 Hz, 1H), 7.08-7.00 (m, 1H), 6.96-6.86 (m, 1H), 6.78 (d, J= 1.80 Hz, 1H), 5.32 (d, J = 12.69 Hz, 1H), 4.56 (d, J= 12.69 Hz, 1H), 4.42 (dd, J = 7.27, 3.88 Hz, 1H), 1.69 (dd, J= 15.44, 7.64 Hz, 1 H), 1.13 (dd, J= 15.44, 3.76 Hz, 1H), 0.90 (s, 9H); ESl: Calculated for C23H2435CI2FN2O3 [M+H]*= 465.11, Found: 465.54.
EXAMPLE 17
Synthesis of CB061-lsomer B (TFA sait)
Scheme 12
182
Cl | ||
o | ||
- °xY · d N Ph X H | 3 MS4A | |
ciXA-h | PhMe, reflux 12 h | |
1.0 equiv | 1.1 equiv 1.1 equiv |
OH
1.3 equiv THF. rt, 12 h
H
Oxidalion
CAN 2.1 equiv MeCN:H2O (1:1) ri. 1 h
CB061 Isomer A
CB061 Isomer B
CB061 Isomers C and D
Isomerization ________ CB061
Isomers A-D sat. NaHCO3
MeCN:H2O (1:1) ri, 3 days
CB061 was prepared according to Scheme 12 using methodology described in EXAMPLE 16 to give an A:B:(C+D) isomer ratio after oxidation of 15:67:18, an A:B:(C+D) isomer ratio after isomerization of 2:74:24, and substantially pure CB061-Isomer B (as the TFA sait) 5 after chromatography (Fig. 30).
Analytical data for CB061-lsomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 7.66 (d, J = 8.45 Hz, 1H), 7.30-7.16 (m, 3H), 7.10-7.03 (m, 1H), 6.85 (d, J = 5.98 Hz, 1H), 5.22 (d, J = 11.37 Hz, 1H), 4.46 (dd, J = 8.31, 1.68 Hz, 1H), 4.09 (d, J = 11.37 Hz, 1H), 3.70-3.50 (m, 1H), 3.50-3.39 (m, 1H), 2.00-1.84 (m, 3H), 1.82-1.70 (m, 1H), 1.58-1.46 (m, 1H), 1.40-1.12 10 (m, 4H), 1.08-0.90 (m, 1H), 0.88 (s, 9H); 13C NMR (75 MHz, CD3OD): 177.42, 166.80,
155.82 (d, Jc-F = 243.61 Hz), 140.67 (d, JC-f = 2.77 Hz), 135.73, 134.18, 131.36, 130.33, 129.44, 128.37, 125.77 (d, JC-f = 7.38 Hz), 123.38 (d, JC.F = 19.54 Hz), 114.06 (d, JC.F =
25.18 Hz), 113.39, 69.97, 65.12, 64.06, 62.94, 57.41, 49.88, 43.37, 34.38, 34.29, 30.98, 30.82, 29.39; ESI: Calculated for C29H35CI2FN3O3 [M+H]+= 562.20, Found: 562.36. The
183 absolute stereochemistry of CB061 - Isomer B was determined by single crystal x-ray crystallography.
EXAMPLE 18
Synthesis of CB087 - Isomer B (TFA sait)
Scheme 13
Oxidation
Isomerizalion
TFA(pH<1)
MeCN-H2O 3 deys
CAN 2.1 equiv MeCN :H20 (1:1) ri, 1 h
compound A 85:15 mixture of Isomers
CB087 Isomer B
CB087
Isomers A, C, and D
CB087 Isomers A-0
CB087 was prepared according to Scheme 13 using methodology described in EXAMPLE to give an (A+C+D):B isomer ratio after oxidation of 65:35, an (A+C+D):B isomer ratio after isomerization of 18:82 (in acetonitrile-water in the presence of TFA), and substantially 10 pure CB087-lsomer B (as the TFA sait) after chromatography. In this study, intermediate A was isolated as an 85:15 mixture of isomers based on 1H NMR analysis. This mixture was used in the oxidation step. The major isomer was characterized by 1H NMR and ESI. Also, little isomerization was observed in MeOH or in MeOH-water at a pH of 8 after 3 days at room température.
Analytical data for compound A major ïsomer: 1H NMR (300 MHz, CD3OD): 7.40 (s, 6H),
7.10 (s, 9H), 7.20 (t, J = 7.12 Hz, 1H), 6.74 (t, J = 7.86 Hz, 1H), 6.48 (s, 1H), 6.44 (d, J =
8.20 Hz, 1H), 6.08 (t, J = 7.02 Hz, 1H), 5.51 (d, J =8.22 Hz, 1H), 5.35 (d, J = 4.67 Hz, 1H),
4.55 (d, J = 4.45 Hz, 1H), 4.18 (s, 1H), 4.15-3.90 (m, 3H), 3.70-3.55 (m, 1 H), 2.30-2.00 (m, 4H), 1.60-1.30 (m, 4H); 13C (75 MHz, CD3OD): 179.68, 175.39, 155.86 (d, JC-p =247.63 Hz), 18<+
142.81, 134.49, 134.21, 132.34, 132.09, 129.46, 129.28 (d. JC.P = 12.91 Hz), 128.45, 128.09, 127.78, 127.16, 126.90, 126.67, 125.20, 124.90, 124.08 (d, JC-p= 3.27 Hz), 121.32 (d, JC-p= 8.18 Hz), 121.17, 110.01, 76.10, 75.35, 69.39, 67.82, 66.89, 61.60, 49.60, 48.14, 33.60, 33.48, 30.12, 29.82; ESI: Calculated for C44H41CI2FN3O4 [M+H]+= 764.25, Found: 5 764.26.
Analytical data for CB087-lsomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 8.34 (d, J =
7.70 Hz, 1H), 7.70 (d, J = 8.11 Hz, 1H), 7.70 (t, J = 7.02 Hz, 1H), 7.42 (t, J = 7.61 Hz. 1H),
7.40-7.30 (m, 5H), 7.22 (d, J = 7.90 Hz, 1H), 7.16 (dd, J= 8.17, 1.85 Hz, 1 H), 6.61 (d, J = 1.74 Hz, 1 H), 5.58 (s, 1H). 5.34 (d, J = 10.97 Hz, 1H), 4.83 (d, J = 11.04 Hz, 1H), 3.78-3.60 10 (m, 1H), 3.50-3.40 (m, 1H), 2.00-1.86 (m, 2H), 1.86-1.78 (m, 1H), 1.70-1.60 (m, 1H), 1.42-
1.20 (m, 3H), 1.02 (qd, J = 12.68, 3.30 Hz, 1H); 13C (75 MHz, CD30D): 177.29, 167.33,
154.20 (d, Jc-F = 284.04 Hz), 144.70, 136.97, 132.50, 131.26, 130.24, 130.03, 128.83,
128.70, 126.61, 126.54, 123.98, 122.91, 122.35 (d, JC-f= 18.95 Hz), 121.70 (d, JC-f= 12.66 Hz), 111.78, 70.44, 69.95, 64.89, 62.47, 49.98, 49.87, 34.33, 34.28, 30.91, 30.80; ESI: 15 Calculated for C30H29CI2FN3O3 [M+H]*= 568.16, Found: 568.54.
185
EXAMPLE 19
Synthesis of CB083 - Isomer B (TFA sait)
Scheme 14
MS 4A
1.1 equiv 1.1 equiv
PhMe, reflux 12 h
H mixture ot isomers
1.3 equiv
THF. rt. 12 h
65%
compound A tsomer Ratio: 84:16
CAN 2.1 equlv MeCN :H2O (1:1) rt, 1 h
Oxidation:
CB083
CB083 Isomers A. C, and D
Isomer B
Isomerization
TFA (pH < 1) MeCN-HîO.
days
CB083 Isomers A-D
CB083 was prepared according to Scheme 14 using methodology described in EXAMPLE 16 to give an (A+C+D):B isomer ratio after oxidation of 41:59, an (A+C+D):B isomer ratio after isomerization of 10:90 (in acetonitrile-water in the presence of TFA), and substantially pure CB083-lsomer B (as the TFA sait) after chromatography. In this study, intermediate A was isolated as an 84:16 mixture of isomers, and the major isomer was used in the oxidation step. Also, little isomerization was observed in MeOH or in MeOH-water at a pH of 8 after 3 days at room température.
Analytical data for compound A major isomer: 1H NMR (300 MHz, CD3OD): 8.42 (d, J = 7.49 Hz, NH, 1H), 7.40-7.25 (m, 5H), 7.25-7.10 (m, 9H), 7.20-6.98 (m, 3H), 6.94 (dd, J = 8.06, 1.88 Hz, 1H), 6.82 (d, J = 8.07 Hz, 1H), 6.63-6.55 (m, 2H), 6.53 (d, J = 1.84 Hz, 1H),
5.18 (d, J = 5.70 Hz, 1H), 4.32 (s, 1H), 3.97 (d, J = 5.70 Hz, 1H), 3.70 (d, J = 7.57 Hz, 1H), 3.70-3.55 (m, 2H), 3.25-3.10 (m, 1H), 2.64 (dd, J = 14.03, 6.91 Hz, 1H), 2.45 (dd, J = 13.97, 9.24 Hz, 1H), 2.15-1.90 (m, 4H), 1.55-1.30 (m, 4H); 13C (75 MHz, CD3OD): 181.03, 176.38, 144.79, 144.55, 139.09, 138.54, 135.17, 134.94, 133.16, 130.13, 130.07, 129.77,
186
129.26, 129.11, 129.03, 128.95, 128.80, 128.18, 127.66, 127.35, 122.68, 111.27, 79.40, 76.05, 72.19, 70.6, 70.56, 62.05, 53.09, 49.63, 37.84, 34.88, 34.77, 31.34, 31.07; ESI: Calculated for C45H45CIN3O4 [M+H]+= 726.31, Found: 726.44.
Analytical data for CB083-lsomer B (TFA sait): 1H NMR (300 MHz, DMSO-d6): 10.28 (s, NH, 1H), 8.51 (d, J = 6.67 Hz, NH, 1H), 7.59 (d, J = 8.03 Hz, 1H), 7.25-7.00 (m, 9H), 6.606.50 (m, 3H), 4.82 (s, 1H), 4.42 (d, J= 9.65 Hz, 1H), 3.64-3.50 (m, 1H), 3.46-3.32 (m, 1H), 3.30-3.16 (m, 1H), 2.85 (dd, J = 13.83, 4.77 Hz, 1H), 2.28 (dd, J = 13.83, 10.20 Hz, 1H), 1.90-1.66 (m, 4H), 1.38-1.10 (m, 4H); 13C (75 MHz, DMSO-d6): 178.36, 166.47, 143.95, 136.55, 133.32, 131.90, 128.69, 128.46, 128.09, 127.88, 127.18, 126.83, 126.52, 123.21, 120.72, 109.97, 70.38, 67.78, 63.18, 62.17, 52.83, 47.76, 34.54, 33.57, 29.82, 29.78; ESI: Calculated for C31H33CIN3O3 [M+H]*= 530.22, Found: 530.40.
EXAMPLE 20
Synthesis of Synthesis of CB084 - Isomer B (TFA sait)
CB084 was prepared according to Scheme 15 using methodology described in EXAMPLE 16 to give an A:B:(C+D) isomer ratio after oxidation of 97:1:2, an A:B:(C+D) isomer ratio after isomerization of 46:52:2 in acetonitrile-water in the presence of TFA after 3 days, an A:B:(C+D) isomer ratio after isomerization of 9:49:42 in acetonitrile-water at pH 8 after 3 days, and substantially pure CB084-lsomer B (as the TFA sait) after chromatography.
Analytical data for CB084-lsomer A (free amine): 1H NMR (300 MHz, DMSO-d6): 10.02 (s, NH, 1H), 7.86 (d, J = 7.60 Hz, NH, 1H), 7.31 (d, J =7.91 Hz, 1H), 7.05 (d, J = 7.91 Hz, 1H), 6.97 (s, 3H), 6.54 (s, 1H), 6.46 (d, J = 3.65 Hz, 2H), 4.50 (d, J = 4.08 Hz, NH, 1H), 3.60-3.40 (m, 2H), 3.40-3.30 (m, 1H), 3.25-3.10 (m, 1H), 2.80-2.70 (m, 2H), 2.60-2.40 (m, 1H), 1.901.60 (m, 4H), 1.34 (dd, J= 13.86, 10.33 Hz, 1H), 1.30-1.05 (m, 4H), 0.90-0.70 (m, 1H), 0.71 (s, 9H); 13C (75 MHz, DMSO-d6): 180.50, 169.86, 143.83, 138.61, 131.88, 129.53, 127.91, 127.64, 125.83, 125.55, 120.61, 108.90, 68.15, 68.08, 68.03, 61.27, 55.94, 47.20, 43.56, 34.36, 33.83, 33.77, 30.30, 30.02, 29.80, 29.67; ESI: Calculated for C30H3935CIN3O3 [M+H]+=
524.27, Found: 524.55.
Scheme 15
18716409
MS4A
PhMe, reflux 12 h
mixture of 2 isomers
OH
CB084 Isomer A
CB084 Isomer B
CB084 Isomers C, and D
Isomerization
MeCN:H20 (1:1) sat. NaHCOj 3 days; or
MeCN:H2O (1:1) TFA 3 days
CB084 Isomers A-D
Analytical data for CB084-lsomer B (TFA sait): 1H NMR (300 MHz, CD3OD): 8.54 (d, J =
7.42 Hz, NH, 1H), 7.48 (d, J = 8.06 Hz, 1H), 7.23 (d, J = 8.06 Hz, 1H), 7.20-7.08 (m, 3H), 6.90 (s, 1H), 6.67 (d, J = 6.94 Hz, 1H), 4.49 (d, J = 11.08 Hz, 1H), 4.17 (dd, J = 7.91, 1.68 Hz, 1H), 3.75-3.60 (m, 1H), 3.60-3.45 (m, 1H), 3.40-3.30 (m, 1H), 2.79 (dd, J = 14.10, 6.05 Hz, 1H), 2.36 (dd, J= 14.10, 10.21 Hz, 1H), 2.10-1.80 (m, 4H), 1.49 (dd, J = 15.58, 8.30 Hz, 1H), 1.45-1.20 (m, 4H). 1.00-0.80 (m, 1H), 0.87 (s, 9H); ’3C (75 MHz, DMSO-d6): 175.40, 144.42, 136.34, 133.82, 128.42, 127.93, 127.02, 126.60, 123.34, 121.24, 110.53, 67.72,
63.74, 63.35, 61.30, 51.75, 47.89, 42.56, 33.47, 33.44, 32.92, 29.78, 29.66, 29.52, 28.85; ESI: Calculated for C3oH39 35CIN303 [M+H]+= 524.27, Found: 524.44.
EXAMPLE 21
Synthesis of C144
Scheme 16
180
Q | |
J/ t | 3 MS4A |
PhMe. reflux 12 h | |
1.0 equiv 1.1 equiv 1.1 equiv |
BnNHj
2.0 equiv. THF, d, 12 h
C144 was prepared using methodology described above. The absolute stereochemistry of C144 determined by single crystal x-ray crystallography.
Analytical data for C144: 1H NMR (300 MHz, CD3CI): 7.70-7.40 (m, 5H), 7.50-7.00 (m, 9H), 7.00-6.80 (m, 5H), 6.80-6.60 (m, 2H), 6.43 (d, J = 7.68 Hz, 1H), 6.11 (t, J = 5.79 Hz, 1H), 5.99 (d, J = 7.56 Hz, 1H), 5.27 (d, J = 6.91 Hz, 1 H), 4.48 (dd, J = 14.79, 6.31 Hz, 1H), 4.34 (d, J =6.91 Hz, 1H), 4.21 (dd, J = 14.79, 5.41 Hz, 1H), 4.13 (d. J= 11.24 Hz, 1H), 3.80 (d, J = 11.24 Hz, 1H), 3.51 (d, J = 9.46 Hz, 1H), 2.83 (dd, J = 15.40, 9.46 Hz. 1H), 1.32 (d, J = 15.40 Hz, 1H), 0.76 (s, 9H); 13C (75 MHz, CD3CI): 178.42, 173.63, 142.12, 139.27, 137.97, 134.54, 133.23, 132.49, 131.78, 129.21, 128.88, 128.74, 128.48, 128.21, 127.92, 127.86, 127.77, 127.52, 127.29, 124.63, 122.27, 109.35, 75.06, 72.14, 70.40, 66.08, 60.65, 60.51, 43.62, 43.56, 30.11,29.91; ESI: Calculated for C44H46N3O3 [M+H]+= 664.35, Found: 664.36.
EXAMPLE 22
Cellular Activity of Ml-77301
The activity of MI-773001 in a variety of tumor cell lines is presented in Table 6. The cytotoxic concentration is the first concentration where cell death corresponding to the cytotoxic index is observed. Cytotoxicity was quantified by blue trypan exclusion at 96 h except for CCF-STTG1 at 192 hours (medium 20-50% cell death and high >50% cell death). The anti-proliferative IC5o was determined by ATP assay.
Table 6
tum or | origin | p53 | BM | Cyto tox | Cytot ox* | IC50 (nM) |
cell line | (μΜ) | |||||
H12 99 | lung | - | - | - | >10,0 00 | |
U2O S | bone | WT/W T | - | - | - | >10,0 00 |
SJS A1 | bone | WT/W T | MDM2 amplifi ed | high | 1 | 145 |
HCT 116 | colon | WT/W T | - | - | - | 229 |
RKO | colon | WT/W T | - | - | - | 480 |
22R V1 | prostat e | WT/M UT | - | medi um | 3 | 399 |
LnC ap | prostat e | WT/W T | - | high | 3 | 50 |
JAR | placent a | WT/W T | MDM2 amplifi ed | high | 3 | 169 |
CCF STT G1 | CNS | WT/W T | MDM2 amplifi ed | medi um | 1 | 162 |
Cap an2 | pancre as | -/- | - | - | - | >10,0 00 |
MCF 7 | breast | WT/W T | - | - | - | 201 |
Y79 | retinoblasto me | WT/W T | Rb mutate d | medi um | 1 | 430 |
Weri -RB1 | retinoblasto me | WT/W T | Rb mutate d | high | 0.3 | not deter mine d |
SNU | gastric | WT/W | KRAS | high | 10 | 77 |
I90
-1 | T | mut | ||||
MKN 45 | gastric | WT/W T | Met amplifi ed | - | - | >10,0 00 |
Hs7 46T | gastric | Met amplifi ed | - | - | 10,00 0 | |
SNU -5 | gastric | Met amplifi ed | - | - | >10,0 00 | |
MOL M13 | AML | WT/W T | FLT3- ITD | high | 0.1 | 14.7 |
MV4 ;11 | AML | WT/W T | FLT3- ITD | medi um | 0.3 | 45.4 |
RS4; 11 | ALL | WT/W T | - | high | 0.1 | 28 |
LY3 | ABC- DLBCL | WT/W T | - | medi um | 0.3 | 280 |
Ly10 | ABC- DLBCL | WT/W T | - | medi um/h igh | 0.3 | 90 |
Ly7 | GCB- DLBCL | WT/M UT | - | - | - | >10,0 00 |
DoH H2 | GCB- DLBCL | WT/W T | BCL2 overex pressi on | high | 0.3 | 39.3 |
Rec 1 | MOL | WT/W T | - | high | 10 | 738 |
SR | lympho ma | WT/W T | - | medi um | 0.3 | 14.9 |
H92 9 | MM | WT/W T | - | high | 1 | 114 |
Ku8 12 | CML- BC | WT/W T | - | medi um | 3 | >10,0 00 |
EHE | CLL | WT/W | - | medi | 0.3 | 70 |
191
B | T | um |
EXAMPLE 23
Cell Growth Inhibition and Cytoxic Effects on 22Rv1 Cell Lines
MI-519-6401 and MI-77301 were evaluated for their cell growth inhibition and cytotoxic effects on a prostate cancer cell line 22Rv1 (from The DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, reference DSMZ ACC438). For growth inhibition assays, cells were incubated in the presence of MI-519-6401 or MI-77301 for 96 h in 96-well format. Cell seeding conditions were adapted to get significant cell growth în this assay format. Growth inhibition assays were performed using the Celltiter-GIo Luminescent kit (Promega). The IC50 values (concentration where the growth inhibition percentage is equal to half of the maximum inhibitory effect of the tested compound) were calculated and ranged between 100 nM and 500 nM in this prostate cancer cell line for both compounds.
For cytotoxicity assays, cells were incubated with MI-519-6401 or MI-77301 for 96 h in 6well format. Cell seeding conditions were adapted to get significant cell growth in this assay format. Cytotoxic effects were measured using trypan blue staining. Both the floating and adhèrent cells were stained with trypan blue. Quantification was performed by Vi-CELL® Cell Viability Analyzer (Beckmann-Coulter) which détermines both cell concentration and percentage of viable cells. For both compounds at concentrations which were close to IC90 concentrations (concentration where the growth inhibition percentage is equal to 90 percent of the maximum inhibitory effect of the tested compound), the percentages of viable cells were sîgnîfîcantly decreased compared to untreated cells and were at best between 50 and 70 % in the 22Rv1 cell line.
EXAMPLE 24
Apoptosis Assay
Apoptosis was determined using Annexin-V-FLUOS/propidium iodide staining kit (Roche Applied Science) by modifications of the manufacturées instructions. Early stage apoptotic cells display translocation of phosphatidylserine from inner to outer surface of plasma membrane which can be detected by Annexin V fluorescein staining. Propidium iodide (PI) staining détermines the late stage apoptotic cells or necrotic cells. A total of 0.25 * 106 cells were plated overnight in a 6-well tissue culture. Next day, adhèrent cells were treated in the presence or absence of MI-77301 and incubated at 37°C for 2.5 days. Cells were harvested using 0.05% trypsin-EDTA (Invitrogen) by pooling the floating and the adhèrent cell populations, and were washed with PBS. Next, cells were stained with Annexin-V-FLUOS and PI in the incubation buffer at room température for 10 minutes in the dark. Modifications were made by using 0.5 pl each of Annexin-V-FLUOS and PI (instead of 2 μΙ each,
191 mentîoned in the instruction manuai) for staining. These modifications were found to decrease the background noise, especially of fluorescein, in the assay. Cells were acquired and analyzed in a flow cytometer. Annexin V+/PI- cells were scored as early apoptotic cells and Annexin V+/PI+ cells as late apoptotic cells. The results of this assay are presented in Fig. 27.
EXAMPLE 25
In vivo effîcacy in the SK-Mel-103 xenograft model in mice
Drug préparation
MI-77301 was dissolved in 10% PEG400 (polyethylene glycol, mol wt 400, Sigma # P3265) 3% Cremophor EL (Sigma # C5135) and 87% 1X PBS (GIBCO™, Invitrogen Corp.) at the desired concentration (prepared fresh each day and dosed orally within 1 hour). The pH of the drug solutions were checked before use and required to be between pH 3.0 and 9.0 for PO (oral gavage) and between pH 4.5 and 9.0 for IV (intravenous) administration. The pH of a solution was adjusted with 0.5N NaOH when necessary.
Cell culture
Human melanoma cells SK-MEL-103 were maintained at 37°C, 95% air, 5% carbon dioxide in HyQ® RPMI-1640 medium (with 2.05 mM L-glutamîne, 0.1 pM stérile filtered, Hyclone®, QB Perbio) supplemented with 10% FBS and penicillin/ streptomycin and passaged twice weekly.
Xenograft tumor cell injection
Tumor cells for xenografts were harvested with Trypsin (0.05%)-EDTA (0.53mM) (GIBCO™, Invitrogen Corp.), growth medium added and cells placed on ice. A cell sample was mixed 1:1 with Trypan Blue (GIBCO™, Invitrogen Corp.) and counted on a hemocytometer to détermine the number of live/dead cells. Cells were washed once with 1X PBS (GIBCO™, Invitrogen Corp.) and resuspended in PBS. Cells in 0.1 ml were injected subcutaneously (s.c.) into the flank région of each mouse using a 27 gauge needle. For Matrigel injections, after washing in PBS, cells were resuspended in an ice cold mixture of 1:1 PBS and Matrigel (BD Biosciences, Invitrogen Corp.) for a final Matrigel protein concentration of 5 mg/ml. SKMEL-103 tumors were inoculated into SCID mice (UM breeding strain:236 C.B-17 SCID, Charles River) at 5 x 10® cells in 0.1 ml with Matrigel. Treatment was started on day 4-5 after tumor injection.
Xenograft tumor growth and weight monitoring
The size of tumors growing in the mice was measured in two dimensions using calipers. Tumor volume (mm3) = (AxBz)/2 where A and B are the tumor length and width (in mm), respectively. During treatment, tumor volume and body weight were measured three times a week. After the treatment was stopped, tumor volume and body weight was measured at
193 least once a week and mice were kept for additional 60 days for further observation of tumor growth and toxicity.
Assessment of toxicity and end point
Tumors were not allowed to exceed 10% of the animal’s total body weight. If an animal had two or more tumors the total weight of ail tumors were not allowed to exceed 10% of the animal's total body weight. At the end of the experimental period or when tumor size approached 10% of the total body weight, the animal was euthanized. Animais that showed profound morbidity or a weight loss of over 20% of body weight were euthanized.
The efficacy of MI-77301 at 100 mg/kg PO in this assay is presented in Fig. 29.
Having now fully described the methods, compounds, and compositions of matter provided herein, it will be understood by those of skill in the art that the same can be performed within a wide and équivalent range of conditions, formulations, and other parameters without affecting the scope of the methods, compounds, and compositions provided herein or any embodiment thereof. Ail patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.
Claims (52)
- What Is Claimed Is:1. A compound having Formula XII:XII wherein:R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;R2 is selected from the group consisting of aralkyl and:wherein:R25a, R25b, R25c, R25d, and R25® are each independently selected from the group consisting of hydrogen, fluoro, and chloro;R3 is selected from the group consisting of optionally substituted CrC8 alkyl and optionally substituted aryl;R4 is selected from the group consisting of hydrogen and optionally substitutedCi-C8 alkyl;R5 is selected from the group consisting of:wherein:R14 is selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl;195X is selected from the group consisting of O, S, and NR ;Y is selected from the group consisting of O, S, and NR;R is selected from the group consisting of hydrogen and optionally substituted C1-C4 alkyl; andR is selected from the group consisting of hydrogen, optionally substituted CrC4 alkyl, and -COCH3, wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait thereof.
- 2. The compound of claim 1, wherein:Rz is:R3 is optionally substituted C^Ce alkyl;R5 is selected from the group consisting of:R’ is selected from the group consisting of hydrogen and optionally substituted CrC4 alkyl, or a pharmaceutically acceptable sait thereof.
- 3. The compound of claim 2, wherein R4 is hydrogen, or a pharmaceutically acceptable sait thereof.
- 4. The compound of claim 2, wherein X is NH, or a pharmaceutically acceptable sait thereof.
- 5. The compound of claim 2, wherein Y is NH, or a pharmaceutically acceptable sait thereof.
- 6 The compound of claim 2, wherein R3 is -CH2C(CH3)3, or a pharmaceutically acceptable sait thereof.196
- 7.The compound of claim 2, wherein R5 is selected from the group consisting of:or a pharmaceutically acceptable sait thereof.The compound of claim 2, wherein: is hydrogen;R1b, R1c, and R1d are each îndependently selected hydrogen, fluoro, and chloro;R3 is C4-C8 alkyl;R4 is hydrogen;R5 is selected from the group consisting of:
- 8.R1a from the group consisting ofI 'OHOHIMeMeX and Y are NH; or a pharmaceutically acceptable sait thereof,
- 9. The compound of daims 7 or 8, wherein R5 is selected from the group consisting of:'OH or a pharmaceutically acceptable sait thereof.19*
- 10. A compound having Formula XXXV:XXXV wherein:R1b and R1c are independently selected from the group consisting of hydrogen, fluoro, 5 and chloro;R3 is C4-C8 alkyl; andR25a, RZ5b, and R25c are each independently selected from the group consisting of hydrogen, fluoro, and chloro, wherein the compound is substantially free of one or more other stereoisomers,10 or a pharmaceutically acceptable sait thereof.198
- 11. The compound of claim 2 selected from the group consisting of:wherein the compound is substantially free of one or more other stereoisomers, or a pharmaceutically acceptable sait thereof.200
- 12. The compound of claim 1 selected from the group consisting of:wherein the compound is substantially free of one or more other stereoisomers, or a5 pharmaceutically acceptable sait thereof.20Î
- 13.A compound selected from the group consisting of:wherein the compound is substantially free of one or more other stereoîsomers, or a pharmaceutically acceptable sait thereof.
- 14. A compound having the structure:wherein the compound is substantially free of one or more other stereoîsomers, or a pharmaceutically acceptable sait thereof.
- 15. A compound having the structure:201 pharmaceutically acceptable sait thereof.
- 16. The compound of any one of daims 1-15, wherein the compound is a substantially pure stereoisomer, or a pharmaceutically acceptable sait thereof.
- 17. The compound of claim 16, wherein the compound is a pure stereoisomer, or a pharmaceutically acceptable sait thereof.
- 18. A pharmaceutical composition comprising the compound of any one of daims 117, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier.
- 19. A pharmaceutical composition comprising the compound of any one of daims 117, or a pharmaceutically acceptable sait thereof, for use in treating a hyperproliferative disease.
- 20. A compound of any one of daims 1-17, or a pharmaceutically acceptable sait thereof, for use in treatment of a hyperproliferative disease.
- 21. Use of a compound of any one of daims 1-17, or a pharmaceutically acceptable sait thereof, for the manufacture of a médicament for treatment of hyperproliferative disease.
- 22. The pharmaceutical composition of claim 19, wherein the hyperproliferative disease is cancer.
- 23. The compound of daim 20, or a pharmaceutically acceptable sait thereof, wherein the hyperproliferative disease is cancer.
- 24. The use of claim 21, wherein the hyperproliferative disease is cancer.203
- 25. The pharmaceutîcal composition of claim 22, wherein the cancer is selected from the group consisting of melanoma, lung cancer, sarcoma, colon cancer, prostate cancer, choriocarcinoma, breast cancer, retinoblastoma, stomach carcinoma, acute myeloid leukemia, lymphoma, multiple myeloma, and leukemia.
- 26. The compound of claim 23, wherein the cancer is selected from the group consisting of melanoma, lung cancer, sarcoma, colon cancer, prostate cancer, choriocarcinoma, breast cancer, retinoblastoma, stomach carcinoma, acute myeloid leukemia, lymphoma, multiple myeloma, and leukemia.
- 27. The use of claim 24, wherein the cancer is selected from the group consisting of melanoma, lung cancer, sarcoma, colon cancer, prostate cancer, choriocarcinoma, breast cancer, retinoblastoma, stomach carcinoma, acute myeloid leukemia, lymphoma, multiple myeloma, and leukemia.
- 28. The pharmaceutîcal composition of claim 25, wherein the cancer is selected from the group consisting of liposarcoma and melanoma.
- 29. The compound of claim 26, wherein the cancer is selected from the group consisting of liposarcoma and melanoma.
- 30. The use of claim 27, wherein the cancer is selected from the group consisting of liposarcoma and melanoma.
- 31. A kit comprising the compound of any one of daims 1-17, or a pharmaceutically acceptable sait thereof, and instructions for administering the compound, or a pharmaceutically acceptable sait thereof, to a patient having cancer.
- 32. A kit comprising the pharmaceutîcal composition of claim 18 and instructions for administering the pharmaceutîcal composition to a patient having cancer.
- 33. The kit of daims 31 or 32, wherein the cancer is selected from the group consisting of melanoma, lung cancer, sarcoma, colon cancer, prostate cancer, choriocarcinoma,204 breast cancer, retinoblastoma, stomach carcinoma, acute myeloid leukemia, lymphoma, multiple myeloma, and leukemia.
- 34. The kit of claims 31 or 32, further comprising one or more anticancer agents.
- 35. The kit of claims 31 or 32, wherein the instructions direct co-administration of the compound, or pharmaceutically acceptable sait thereof, or pharmaceutical composition together with the one or more anticancer agents.
- 36. The kit of claims 31 or 32, wherein the instructions direct pulsatile dose administration of the compound, or pharmaceutically acceptable sait thereof, or pharmaceutical composition to the patient.
- 37. A method of preparing a compound having Formula XXXVII:the method comprising allowing a compound having Formula XXXVI:to isomerize to a compound having Formula XXXVII, wherein:R32 is selected from the group consisting of-OR33and -NR34aR34b;R33 is selected from the group consisting of hydrogen, alkyl, and aralkyl;R34a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, aralkyl, optionally substituted aryl, and optionally substituted heteroaryl;R34b is selected from the group consisting of hydrogen and alkyl;R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, fluoro, and chloro;205R2 is selected from the group consisting of aralkyl and:R25bR25®R25®, R25b, R25c, R25d, and R25® are each independently selected from the group consisting of hydrogen, fluoro, and chloro; andR3 is selected from the group consisting of optionally substituted Cj-Ca alkyl and optionally substituted aryl.
- 38. The method of claim 37, wherein the solvent is selected from the group consisting of acetonitrile, methanol, ethyl acetate, and water, or a mixture thereof.
- 39. The method of claims 37 or 38, wherein the isomerization is carried out at a pH of less than 7.
- 40. The method of claims 37 or 38, wherein the isomerization is carried out at a pH of 7.
- 41. The method of claims 37 or 38, wherein the isomerization is carried out at a pH of greater than 7.
- 42. The method of any one of claims 37-39, wherein the isomerization is carried out in the presence of an acid selected from the group consisting of trifluoroacetic acid and acetic acid.
- 43. The method of any one of claims 37, 38, or 41, wherein the isomerization is carried out in the presence of NaHCO3.
- 44. The method of any one of claims 37-43, wherein the isomerization is carried out at a température of about 20°C to about 100°C.
- 45. The method of any one of claims 37-44, wherein R32 is -OR33.
- 46. The method of any one of claims 37-44, wherein R32 is -NR34aR34b.206
- 47. The method of claim 46, wherein R34b is hydrogen and R34a is selected from the group consisting of alkyl, hydroxyalkyl, hydroxycycloalkyl, optionally substituted aryJ, and optionally substituted heteroaryl.
- 48.The method of claim 47, wherein R34a is selected from the group consisting of:
- 49. The method of any one of claims 37-48, wherein the compound of Formula XXXVII is isolated as a substantially pure stereoisomer.
- 50. The method of claim 49, wherein the compound having Formula XXXVII is isolated as a pure stereoisomer.
- 51. The method of any one of claims 37-50, wherein: R32 is -NR34aR34b;R34a is:R33b is hydrogen;Rz is:; andR3 is Ci-Ca alkyl.
- 52. The method of claim 37 further comprising isolating the coFormula XXXVII substantially free from the compound having Formula XXXVI. il * I )/
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/413,094 | 2010-11-12 | ||
US61/451,958 | 2011-03-11 | ||
US61/451,968 | 2011-03-11 | ||
US61/470,992 | 2011-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16409A true OA16409A (en) | 2015-10-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011326395B2 (en) | Spiro-oxindole MDM2 antagonists | |
US9079913B2 (en) | Spiro-oxindole MDM2 antagonists | |
EP2707372B1 (en) | Spiro-oxindole mdm2 antagonists | |
CA2945527C (en) | Mdm2 inhibitors and therapeutic methods using the same | |
OA16409A (en) | Spiro-oxindole MDM2 antagonists. | |
NZ617580B2 (en) | Spiro-oxindole mdm2 antagonists |